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Biochemical :':tudies of. !luman Hyperuricaemia.. 
Trevor H. Hnrdwell. 
SummAry. 
Some of the enzymes involved in the biosynthesis of 
uric ~1cid have been i.nvestignted in two groups of patients: 
hyperuricaemic und gouty individuols. A group of normul 
controls has been uroed for comp;c,.rison. Human erythrocyte 
phosphoribosylpyrophosphate syn~hetuse (2.7.6.1 .) was found 
to be much more stable in all BHmples than has been reported. 
Hinetic paramete~·s for this enzyme,uning a modified assuy, 
were identical in individuals from the three c;linical 
groups. Inhibition studies UEint,; B rHn&e of inhibitors 
of widely differing chemical s·truc tu re showed uniformity 
in characteristics amongst gouty or f1enlthy i11dividunls. 
~ome inhibitors revealed possibJ.e Genetic variants of the 
enzyme which are linked neither to hyperuricaemia nor to 
gout. 
Statistical analyses have shown n Pignificunt 
increase in the enzymic activity of eryth~ocyte pho~pho­
ribosy]_pyrophosphate s~'nthetase in both the hyperuricaemic 
groups compared with the controln. No correlation of age 
;;i th enzymic bcti vi ty occurB in any of tl:e three clinicn.l 
groupe.. A si~::nificant decrease hnEO been found for the 
enzymic activit~· of erythroc,yte glutathione reductnse 
(1 .6.4 .2.) of thee gout group compered w:ith the other 
two ~roups. ~'l1P uctivities of theGe two enzymes do not 
appeat· to be linked. A significHnt increase :i.n serum 
adenosine deamin~se (3.5.4.4.) {1ctivitiee has been 
found in a heterogeneous hyperur·icscernic group compHred 
with controls. 
EJectrophoretic sttldies of eryth1·ocyte phospho-
ri boBylp,Yrophosplw te Rynthe te.se, ~~denoEcine deo.minRse, 
hypoxn.Jlthineguanine ])hosphoriboGyltJ·nrlRferase (2.4.2.8.) 
nnd g1u tsthione reductnse huve "htn•n prob;;ble enzyme 
polyrnOr]Jhisms which appear to be UJlreluted to hyperuricaemia 
or gout. Morlified staining techniqueH huve been developed 
for the detection of isoenzymes in Hll. ~ystems. 
'rh ere iH no evidence for urate binding to plnsmn 
protein8 in either healthy or hy]l0J"uricaemic individ•JalF 
from occluE :ion, ul trufi l tra ti on, clec trophore10is or !$P.l 
filtr·ntion experiments. Urat;e appenrf_; to be present 
in human leucocytes combined to protein 01· other com-
!'Dnent of the ceLl. '!'l1er,~ is no evicience of the preEenoe 
of urr; te in hl11nan erJ .. throc,vte6, 
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Biochemical Studies on Human Hyperuricaemia. 
Tr~~or R. Hardwell, 
Summary. 
Some of the enzymes involved in the biosynthesis .of 
uric acid have been investigated in two groups of patients: 
hyperuricaemic and gouty individuals. A' group of normal 
controls has been used for comparison. Human erythrocyte 
phosphoribosylpyrophosphate synthetase ( 2. 7. 6 .• 1 • )"was found 
to be much more stable in all samples than has been reported. 
Kinetic parameters for this enzyme,using a·modified assay, 
were identical in individuals from the three gll.in:Lcal 
groups, Inhibition studies using a range of inhibitors 
of widely differing chemical struc.ture showed uniformity 
in characteristics amongst gouty or healthy individuals. 
Some inhibitors revealed possible genetic·variants of the 
enzyme which are linked neither to hyperuricaemia nor to 
gout. 
Statistical analyses have shown a significant 
increase in the enzymic activity of eryth~ocyte phospho-
ribosylpyrophosphate synthetase in both the hyperuricaemic 
groups compared with the controls. No correlation of age 
with enzymic activity occurs in any of the three ·clinical 
groups. A significant decrease has been. found for the 
enzymic activity of erythrocyte glutathione reductase 
(1.6.4.2.'f of the gout group compared with the other 
two groups. The activities of these two enzymes do hot 
appear to be linked. A significant increase in serum 
adenosine deaminase (3,5,4.4.j activities has been 
found in a heterogeneous hyperuricaemic group compared 
with controls, 
Electrophoretic studies of erythrocyte phospho-
ribosylpyrophosphate synthetase, adenosine deaminase, ,. 
hypoxanthineguanine phosphoribosyltransferase (2.4.2.8.) 
and glutathione reductase have shown probuble enzyme 
polymorphisms which appear to be unrelated to hyperuricaemia 
or gout, Modified staining techniques he~e been developed 
for the detection of isoenzymes in all systems. 
There is no evidence for urate binding to plasma 
proteins in either healthy or hyperuricaemic individuals 
from occlusion, ultrafiltration, electrophoresis or gel 
filtrat~on experiments. Urate appears to be present 
in human leucocytes combined to protein or other com-
ponent of the cell. There is no evidence of the presence 
of urate in human erythrocytes. 
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Introduction. 
Uric acid is the principal. end product of nucleic acid 
and purine metabolism in men and women a nd the anthropoid 
apes. Other mammals are able to oxidise uric acid to 
allantoin by the action of the hepatic enzyme uricase 
which is absent in man. The normal uric acid level in 
plasma throughout adult life lies in the range 1.5-6.0 
mg/100ml (90-359 pmol/l) and in most individuals the level 
increases slightly with age. On average plasma uric acid 
levels are higher in males than in females. An increase in 
plasma uric acid level, or hyperuricaemia, occurs in many 
pathological conditions arising from an increase in the 
rate of purine catabolism de novo or a decrease in renal 
clearance of uric acid or a combinat i on of both processes. 
The clinical conditions associated with hyperuricaemia 
will be discussed later. 
Chemistry of Uric Acid. 
Uric acid was first synthesised by Emil Fischer and 
Ach in 1895. The Fischer school demonstrated t he chemical 
interconversions of the purines and thereby establishec 
the correct structural formula of uric a cid. 
0 H HN~N/O o'~.J--N 
H H 
a ) } urine ring b ) Uric a cid 
Diag. 1 Structural formula of a) purine ring b ) Uric Acid. 
The hydroxyl structure · of uric acid or lactim is formed 
by enolization of the tautomeric l a ctam or keto structure. 
(Diag . 2) The tautomeric forms are in an equilibrium 
which is pH dependent and for example in aqueous solution 
at pH"-'7, the lactim is the predominant tautomer. 
H H 
Lactam Lactim 
2,6 , 8 Trioxypurine 2 ,6, 8 Trihydroxypurine 
Diag.2 Tautomeric structures of Uric Acid. 
It h as been shown by spectrophotometric evidence 
that the lactam form p redominat es in aqueous s olut i on 
at pH < 7. 
Uric acid i s a weak dibasic acid cha racterised by 
two dissociation constants at pKa : 5. 75 and 1 0. 3 which 
\"iyngaardan and Kelley ( 1976 ) explained by the ionisation 
of hydrogen a toms from positions 9 a nd 3 respectivelY 
(Di ag .1 ) . There is no significant ionisat ion of t hs 
hydrogen ions from position 1 or 7. Uric acid readily 
forms salts such as mono-or di - sodium or pota ssium urates. 
The crystals found in synovial fluid or tophi of gouty 
patia nts are monosodium urate monohydrate and these are 
deposited when the solubility is exceeded. Ur a te a nd 
uric acid show strong negative birefringence when viewed 
2 
I 
I 
I 
under polarised light . \Vith a red compensator, urate 
crystaills are yellow when orientrated parallel to the axis 
of pollarisation and blue when perpendicular. These ,prop-
erti:es are diagnostic for the identification of urate crys-
tale in synovial fluid and tissue deposits. 
J.'olonosodium urate is much more soluble than uric acid in 
aqueous solution but bo.th are pH dependent. .Monosodium 
urate solubility is dependent on sodium ion concentration 
in particular but it also increases with ionic strength. 
The solubility of monosodium urate in plasma is 7 mg/100 ml 
(4t9 p.mol/1) and this exceeds the expected saturation value 
of 6·4mg/100ml (383 p.mol/1) as calcul:ated from the solubility 
product of the urate in the presence of the accepted sodium 
:i:on content of plasma (130 xto3J-Ullol/1). The increased 
solubility of the urate in plasma ·has been attributed to 
urate binding to proteins and other plasma components. 
Indeed supersaturated solutions of 400mg/100ml (23~92 x 103 
J-UliOl/1) can be prepared in vitro by dissolving uric acid in 
plasma and stable supersaturated solutions of urate in the 
range 40-90 mg/100 ml (2•392 x to3-5·382 x 103 pmol/1) 
plasma have been reported in patients with leukaemia (Gold 
and Fritz 1957) and lymphoma (Kjellstrand et al. 1974) after 
extensive chemotherapy with cytotoxic drugs~ 
The pH of urine decreases as it passes along the renal 
tubule and in consequence a proportion of urinary urate is 
converted into uric acid. Urine is saturat.ed· with urates 
at 15mg/100ml (897 )Jll!Ol/1) at pH5 whereas pH7 urine can 
accomcdate 158-200mg/100ml (9•448x10 3 -11 •960x103;=ol/l). 
Fatients with gou·t tend to excrete unusually acid urine and 
the limited sol.ubili,ty of ~.;rate at pH5 becomes clinically 
significant. (Wyngaarden and Kelley 1976 b). 
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Biosynthesis de novo of uric acid. 
Uric acid is formed from the oxypurine bases, xanthine 
and hypoxanthine, in reactions catalysed by the enzyme 
xanthine oxidase. The catabolism of dietary nucleic acids 
and of endogenous purine ribonucleotides are the principal 
sources of the two purine bases. The whole process is 
represented in the following diagram:-
Endogenous purine 
A ribonucleotides 
' 
' ........ 
........ 
' 
' 
' 
' 
........ 
' 
' 
Hypoxanthine 
' 
' 
" ' 
' 
xanth~ 
xanthine 
oxidase 
/ 
/ 
/ 
/ 
/ 
/ 
/ 
( 
/ 
/ 
/ 
/ 
/ / 
/ / 
/ 
/ 
/ 
/ 
/ 
/ / 
/ / 
/ / 
/ 
/ 
,/ 
Dietary nucleic acids 
/ 
/ 
xanth=;>e 
Uric acid 
oxidas e 
Diag.3 Formation of uric acid from oxypurine bases. 
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Endogenous purine ribonucleotides are formed by catabolism 
of nucleic acids and by de novosynthesis from phosphoribosyl 
pyrophosphate. Adenine and guanine are the two purine 
bases found in all nucleic acids and these undergo 
deamination to the corresponding oxypurines, hypoxanthine 
and xanthine, in reactions catalysed by the deaminase~ 
shown in F ig. 1. 
Biosynthesis de novo of Purines. 
Nearly all living matter, including humansJ are able 
to synthesise the purine ring de novo. The use of l a belled 
i s otop es provided the first major contribution toward t he 
determination of the metabolic pathway by which purine 
biosynthesis is accomplished. Radioactive labels in-
dicated the origin of each of the atoms of the purine 
ring. Buchanan et al (1948 a and b) demonstrated that 
carbons 2 and 8 a re derived from formate, carbon 6 is 
derived from C02 and that carbons 4 and 5 come from 
the carbonyl and methylene carbons of glycine respectively. 
Additionally, nitrogen 7 is also derived from glycine . 
Thi s information is Ehown schematically below:-
Carbon dioxide 
Glyc ine 
Aspar t a te 
------ Formate 
.Format e 
Amide nitrog en of glutamine 
Diag. 4 The precursors of the atoms of the purine ring. 
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Subsequent studies showed that nitrogen '1 is derived 
fro~ as~artic acid and that nitrogen at positions 3 
and 9 come from the amide ni tro·gen of glutamine. 
(Sonne. 1953-1956). 
A major contributioh to the resolution of the 
biosy.nthesis of purine nucleotides was the recognition 
by Greenberg (1951) that the nucleotide, inosinic acid, 
was the first product with a complete purine ring formed 
in the pathway. 
It is now accepted that the initial step in purine 
biosynthesis is the ATP dependent pyrophosphorylat~on 
of ribose-5-phosphate by the enzyme phosphoribosylpyrophos-
phate synthetase. ATP labelled with 32P indicated that 
the formation of 5-phosphoribosyl-1-pyrophosphate (PRFP) 
involves one of the few reactions in which a pyrophosphate 
group is transferred intact from ATP (Khorana et al 1958), 
The second step in this pathway involves a glutamine 
dependent amination of PRPP which yield 5 phosphoribosyl-
1-amine (:FRA) by the action of enzyme pyrophosphoribosyl 
phosphoamid'otransfera.se. The subsequent steps in the 
biosynthesis of inosinic acid are shown in Fig.2. The 
conversion of inosinic acid to either adenylic acid or 
guanylic acid involves the two stage processes illustrated 
in Fig.2. · 
It has been suggested that IRA formation is the 
rate limiting stage for the regulation of purine 
biosynthesis. 8upport for such an hypothesis has grown 
from the observations presented below:-
1) FRA is the product of the first reaction unique to 
purine biosynthesis and there are no branch points 
in the pathway between Pll and inosinic acid ( Ir-1P). 
6 
The reaction which controls the formation of PR:A is 
therefore ideal to contr.ol the complete biosynthetic 
pathway. 
2) Brockman and Anderson (1963) ha••e reported that there 
is no: accumul:ation of intermedia te.s between FRA and 
IMP provided that there is neither chemical inhibition 
nor genetic variants of any of the enzymic reactions. 
In support of this evidence Rosenbloom et al (1968) 
have shown that in the absence of formylglycinamide 
ribonucleotide amidotransferase inhibitors there is 
no. increase of formylglycinamide ribonucleotide 
(FGAR) in human cells. 
3) In cells with an increased demand for purine 
metabolism euch as erythroleukaemic cells, the 
activity of glutamine PRI'F amidotransferase, which 
catalyses FRA formation, is increased (Reem and 
Friend l975). It has been demonstrated ty Nierlich 
and. Magasanick (1963),albeit in bacteria, that 
PRIP amidotransferase is derepressed when cells 
are grown in media with a limited availability 
of purines. 
4) FRPF, the substrate for FR~F amidotransferase appears 
to control purine biosynthesis (Fig. 2). 
5) Purine biosynthesis is dependent on glutamine 
I 
I availability and this is a cofactor for PRFF 
amidotransferase (Fig 2). 
6) PRA synthesis is controlled by the end products, 
purine ribonucleotides e .• g. GMP, IMP and AMP, of 
the biosynthetic pathway. 
The above evidence provides convincing support 
of -che hypothesis that PRA synthesis .is regulated and 
7 
) 
that its rate of formation is important in purine bio-
synthesis. But aii increase in concentration o-f _:FRP:P 
do_es boost the format±on of IRA and consequently the 
rate of purine bipsynthesis. It would therefore seem 
worthwhile, in a s-tudy of human hyperuricaemia to 
investigate the enzyme responsibJ:e for the biosynthesi·s 
of IRPP in vivo. 
8 
Measurement Of Uric Acid. 
The 'uric acid thread test' devised by Sir Alfred 
Garrod (1819-1907) is probably the first qualitative 
test reported £or the detection of uric acid. It was 
performed by addition of acetic acid to serum into which 
were placed one or two threads from linen fabrics. The 
container was left in a cool room for 36-60 hours. 
Crystals of uric acid were deposited on the threads from 
sera containing large amounts of uric acid. 
·rhe murexide test depends on the oxidation of uric 
acid in acid solution to form alloxan. The latter 
on addition of ammonia forms ammonium purpurate, a 
purplish red substance. The test is not specific for 
uric acid and gives a positive result, albeit more 
brownish in colour, with xanthine (~yngaarden, 1960). 
The qualitative murexide test has been superseded by 
quantitative calorimetric, enzymatic, fluorimetric., 
coulometric as well as· by chromatographic :nethod·s. 
Assay methods currently in use for the measurement 
of uric acid depend either on the chemical or enzymic 
oxidation of uric acid to allantoin .. (Diag 5). 
Uric Acid Hydrox~acetylene Allantoin 
diureide carboxylic acid 
Diag. 5 Formation of allantoin from uric acid. 
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For chemical ·anal!ysis a chromogen is reduced concurrently 
with the oxidation process and the resulting chromophore 
measured spectrophoto~etrically. Uricase is used to catalyse 
the enzymic reaction which can be followed by measurement 
either of the oxygen cons.umed or of the. hydrogen peroxide 
formed. Measurement of the latter involves a coupled 
peroxidase or catalase reaction. Alternatively the enzymic 
reaction can be assayed· using chemical oxidising agents and 
calorimetric measurements made before and after treatment 
with ur:i:case. 
The reduction of sodium tun_gstate by uric acid in 
alkaline solution is the most commonly used calorimetric 
method of assay, (Folin 1933). The reaction is subject 
to iriterference by 6ther reducing agents commonly present 
in either urine or plasma and these include ascorbic acid, 
------. free thiols, salicylates, homoeentisi~ acid, caffeine, 
theophyline, theobromine, L..,dopa and high concentrations 
of glucose ( Lum and Gambino 1973) •· Archi bald ( 1957) has 
modified the phosphotungstate method. (Kern and Straneky 1937) 
by replacement of the cyanide reagent by polyanethol 
sodium sulphonate to eliminate the turbidity which often 
develops with cyanide reagent. The use of diagnostic 
kits has been investigated by Logan et al (1970) but it is 
a sobering thought to find that many kits were found to be 
unacceptable with no correlation between cost and p:;rform-
ance (Kim et al 1971 ). 
Uric acid, an oxy-purine base, is capable of ligand 
formation with metallic ions and the reduction of the 
metallic complexes provide a more specific assay for 
uric acid than the reduction of phosphototungstate. (Bittner 
et al(1963) used a cupric sulphate-neocuproine indicator 
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in which ,the cu:s;;ric ion is reduced by uric acl:d j!n a 
weakly acid medium. i<Iorin and Frox ( 1973) investigated 
s•v•ral ~eactions ca~able of reducing Fe3 + to Fe 2+ over 
a wide range of pH and finally sele.cted 1 , 10-phenanthroline 
for its solubility, molar absorption, optimum wavelength 
and stability. ll'iorin ( 1 974) re.placed 1 , 1'0 phenanthroline 
by 2,4,6-tripyridyl s-triazine and found that the sensitivity 
was doubled and interference by bilirubin was decreased 
fourfold. The reaction is calorimetric and does not 
require deproteinisation. 
Automated colorimetriG methods usually require 
dialysates and they depend on either the reduction of 
phosphotungstate or arsenotungstate or on the reduction 
of a metal coaiplex (e.g.cupric phenanthroline, neocuproine 
or bathocuproine). All appear to overestimate urate by 
0•4-1 ·0 mg/100 ml (Logan et al, 1970 Lum and Gambrino 1973). 
Uric acid shows a maximum at 292 nm with a molar 
absorption coefficient of 12.,500 cm~)mol-1 at pH 9•4 in its 
~ 
ultra violet absorption spectrum (Cavalieri and Bendich, 
1950 Bergmann and Dikstein, 1955) whereas allantoin 
has no ultra-violet absorption at 292nm. In the presence 
o=: uricase, the decrease in optical density at 292 nm 
indicates the amount of uric acid present in a buffered 
assay mixture (Praetorius 1949) but Haeckel (1979) reports 
that albumin can interfere at this wavelength. Other 
substances present in biological fluids absorb u.v. in 
this region and such absorbance can be eliminated by the 
introduction of a suitable blank (Liddle et al 1959) or 
by differential spectrophotometry. The high purity and 
epecificity of uricase now available make this potentially 
one of the most reliable ::Jethods currently in use. 
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Kageyama .( 1971) coupled catalase to the uricase reaction, 
oxidised' methanol to formaldehyde and measure.d colorimetrically 
the deh;ydrolutidine formed by condensation of formaldehyde 
with acetylacetone and· ammonia. The reactions are as follows:-
Uricase Uric Acid + 2H20 + 0 2 Allantoin + C0 2 + H2o2 
H
2
o
2 
+ CH
3
0H catalase HCHO + 2H
2
0 
HCHO + Acetylacetone + NH4'3---31o> 3, 5·-diacetyl-l, 4-dehydro-
lutidine. + 3H2 0 
The uricase reaction has also been coupled with the 
hydrogen peroxide-peroxidase oxidation of a chromogen 
such as e.g. 0-dianisidine hydrochloride (Lorenz and 
Berndt 1967) or tribromophenol-e~inoantipyrine (Kabaeakal.ian 
et al. 1973), Serwn ·can be used without deproteinisation 
and there is no significant interference by haemolysis, 
bilirubin ( < 10mg/100ml.) ascorbic acid or glucose. 
Block and Lata ( 1.970 ). have developed. a fl.uorescent 
method using scopol.etin (7-hydroxy-6-methoxycowna.rin) 
capable. of de.tecting uric acid in the picomole range • 
.Pl.uorescence o·f scopoletin (.e:icci tat ion max 3'48nm; emission 
max •. 465nm) is abolished by oxidation with hydrogen 
peroxide catalysed by horseradish peroxidase. The method 
combines the specificity of the uricase method with the 
simplicit~ o~ fluorimetric detection. 
A coulometric determination of uric acid in serum 
and urine has been reported by Tray ~nd Iurdy (1970). 
This ~ethod gives comparable values tc the uricase methods 
for plasma but higher values for uric acid in urine. 
eeparation of uric acid from protein can be accomplished 
by pa~£age of serum or other biological fluid through a 
str:.:;ng anion-exchange rssin ir. the acetate form (Carr and 
Pressman 1962). Extraneous U.V. absorbing material can be 
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removed by washing with water and the uric acid elu.ted from 
the col.u:nn with NaC·1• in buffer and estimated by enzymic assay. 
An alternative chromatographic method involves the use of 
.high pressure liquid 6hromatography. The uric acid is 
separated from the purine bases ·by a Etrong anion exchange resin 
with an acetat~ mobile ph*se. The uric acid in the 
eluant may be measured directly by monitoring spectrophoto-
metrically at 293nm or by electrochemical detection. 
(Kissinger et al 1975). 
During the past few years many modifications -usually 
minor- of the accepted ·methods of assay for uric acid have 
appeared and immobilised enzyme systems are being used 
for routine determination of serum uric acid (Sundaram 
et al 1978). It is not practical to consider all 
modifications in detail in the current work but some 
of the relevant informacion concerning the different 
methods is shown in Table 1 
Several comparisons .have been made in attempts to 
recommend an assay of choice •. Itiaba et al ( 1975) found 
that the uricase -U.V. method gave significantly lower 
values of serum uric acid than the autoanalyser calorimetric 
phosphotungstate method using hydroxyl•mine for colour 
intensification. Slaunwhi te e·t al ( 1975) have compared 
the calorimetric, enzymatic and liquid chromatographic 
methods and claim that the latter technique is more 
accurate than the other two .. Three quantitative clinical 
chemical routine methods have been evaluated using as 
reference a mass fragmentation method (Ohman 1979). 
The latter involves the addition of (1 ,3-15N2 ) uric 
acid to serum followed by ion exchange chromatography. 
Afcer conversion to the tetra-trimethylsilyl derivative 
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the ~urified mixtu~e is ~nalysed by combined gas chroma-
togra~hy-mass spectrometry using a multiple ion detector. 
A significant difference was obs.erved with the reference 
only when using a uricase-oxygen consumption method. 
The Kageyama (1971) u~icase/catalase method as wel:l as 
the uricase/U V spectrophotometric method gave linear 
correlations. 
Immobilised enzyme reactors will certainly become 
the method ·of choice for routine determination of serum 
uric acid in clinical la·bora tories. Analysis costs 
can be dramatically ~educed ten fold as compared to the 
corresponding solution methods. Sundaram et al (19'78) 
have immobilised uricase onto the inside surface ·of a 
thin nylon tube and have found the reactors are stab::Le 
for rv 3 months .or 4,000 tests. Similar stability of 
the enzyme electrode has been found using. immobilised 
columns (Ehdo et al 1979) and membrane sandwich reactors 
(Kamoun and Donay 1978), The immobilised enzymes are 
readily prepared ~nd some are commercially available. 
In a Technical Bulletin, Watts (1974) revues the 
assay of uric acid but no firm recommendation is reported 
and although the use of uricase is most widely favoured, 
the final selection is a personal choice dependent on 
laboratory facilities. 
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Distribution of Uric Acid. 
In heal thy individuals under c.ondi tions of normal 
production and removal, the body contains a read~ly 
miscible uric acid pool of about 1 .:2g. ·and between 
50-75% of this is turned over daily.· This fraction 
represents the rate of formation and excretion of 
uric acid in normal subjects but it is independent 
of the amount entering the lumen of the intestine 
and undergoing bec-terial destruction. The distribution 
of uric acid amongst different body fluids for a 
healthy individual is given below as quoted in Geigy. (1962) 
Body fluid 
Whole blood 
Serum 
Gastric juice 
Breast milk 
Pancreatic juice 
Urine 
Saliva Male 
Saliva Female 
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Normal Value 
1 .0-3.0mg/100ml 
3.0-6.0mg/100ml 
0.8-2.0mg/100ml 
1. 3-4.1 mg/1 OOml 
0,2mg/100ml 
80-976 mg/24hr 
0.3-0.6mg/100ml 
3. 1 mg/ 1 OOml 
1.9mg/100ml 
Urate binding to plas~a proteins. 
The subj ec,t of urate binding by plasma proteins has 
remained controversial over many years. A lo_ose binding 
of urate bo.th to albumin (Campion et al 1973) and to .a 
specific o< 2 globulin has been reported and such 
interactions have been postulated to be of importance 
in the pathogenesis. of gout (Alvsaker 1965; Alvsaker 
and-~eegmiller, 1972). Many investigators he.ve claimed 
substantial binding of urate to nondiffusable elements 
of plasma whilst others have concluded that all urate 
·is in true solution because it is readily fil terab:l.e 
and'dialysable. Even electrophoretic studies of urate 
localisation in serum have yielded conflicting data_. 
Yu and Gutman (1953) used ultrafiltration and found 
no difference in urate content with the corresponding 
sera. Their data indicated that the plasma urate in 
man is virtually tOO%· filtrable at the glomeruli and 
that ..v 90;~ of the filtered urate is normally res or bed 
in ~he tubules. They also postulated that some urate 
may be present in plasma in aggregates which are filtrable 
or readily depolymerised. It seems probable that such 
polyQers would be more likely to occur at the higher 
plasma urate levels found in gout or nephritis. 
Alvsaker (1965, 1966 and 1968) has studied urate 
binding by several methods which include a) equilibrium 
gel filtration b) i~munoelectrophoresis and c) radio-
autography. From these studies Alvsaker quotes binding 
levels o-f 30% in normal sera and reduced binding -v 1 3-
30~t in gouty patients. However, Klinenberg and Kipper 
( 1 970) using equilibrium dialysis experiments found 
I 
that the urate bound to plasma proteins was related to 
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free urate concentration, protein concantrations, ionic 
strength,, pH and temperature. They also reported a 
decreased binding in their patients wi.th severe tophaceous 
gout and in p&t~ents taking large doses of aspirin. 
Sheikh and Moller ( 1 9.68 examined urate binding 
to plasma proteins in human and rabbit by equilibrium 
dialysis, ultrafiltration and gel filtration at - 40° 
and 20° and found that urate binding decreases as the 
temperature increases. In contrast to AJ.:vsaker they 
found only 5% bind'ing at 20° and these findings support 
the hypoth~eis that the binding of tirate in vivo i~ 
very &mall and consequently will have only minor 
physiological imp~ications. 
The work of Farrell et al (1971) indicated that 
the addition of lithium urate to plasma artificially 
increases the apparent binding of urate. Other extensive 
studies by Farrell et al (1971 and 1975) by ultrafiltration 
showed only negligible bindi~g of urate to plasma protein 
under physiological conditions of temperature and medium 
composition. Conflicting results have been reported 
by Campion et al (1973 and 1974) who showed that 10% 
of urate in solution could bind to albumin at physio-
logical temperatures. The experiments were done in an 
ultrafiltration cell that included a magnetic stirre~ 
and ~teele (1976) reinvestigated urate ultrafiltration 
using a similar app~ratus. Hie result not only showed 
a disparity in urate ultrafiltrability between stirred 
and unstirred samples but other hazards in t:he complex 
nature of urate ultrafiltration. 
A relationship between free urate, protein bound 
urate, hyperuricaemia and gout in Caucasians and Maoris 
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has been reported (Kl.inenberg et al. 1 977), Although 
Maoris have high serum uric acid• concentrations and 
show an increased incidence of gout as compared to 
Caucasians living in the same environment. (Frior et al. 
1964) it has been found that Maoris living on a remote 
island show a l.ow incidence of gout in spite of hyper-
uricaemia. Free and protein bound urate has been 
measured in• gou.ty patients, subjects with asymptomatic 
hyperuricaemia and normal: control. subjects in both 
Caucasian and Maori popul:ations. The studies of urate 
binding to serum proteins showed no difference between 
gouty and asymptomatic hyperur:i:caemia subjects, thus 
both have similar free urate concentrations. This suggests 
that the clinical manifestations of gout are not directly 
related to the free urate concentration. The Maoris 
have not onl.y markedly increased binding of urate to 
protein as compared to Caucasians·but a urate binding 
gl.obul.in has been demonstrated which is not found in 
Caucasians,, (Kl.inenberg et al. 1 977) , 
Further work on urate binding not onl.y in healthy 
individuals but in patients with hyperuricaemia and 
especially gout is clearly desirable:, 
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CJ.:inica:L conditions of hyperuricaemia. 
Hyperuricaemia is difficu~t to define and rec~nt 
progress in the understanding of purine metabolism and 
urate deposition h~s revealed the necessity for some 
modifications of the traditiona!L classification of 
hyperuricaemia and gout. Boss and Seegmiller (1979) 
have suggested that a rational definltion of hyperuric-
aemia should be based on the physicochemical saturation 
of serum with urate, which at 37° is a·bout 7mg/100ml 
(419 pmol/1). 
Distribution curves of sodium urate in the population 
are not Gaussian but are slightly ske.wed toward the higher 
values. The absence of a bimodal distribution indicates 
the probable abcence of two distinct groups,, normal and 
hyperuricaemic individuals in t}le community. Hyperuric-
aemia has therefore been d·efined as a serum urate level 
in excess of the mean population value by at least two 
standard deviations. It would be. clinically convenient 
if one could define the upper limit of normal as that 
sodium urate level above which complications are bound 
to occur and below which they never occur but in praotic~ 
there is no critical cut-off value. Although the patient 
with a serum urate level of 9mg/100ml (53Bpmol/l) is 
at much greater risk to an attack of gout than one with 
a level of 7mg/1 OOml ( 419p.mol/l) _ only 10% of gouty 
patients have serum urate levels exceeding 9mg/100ml 
(538Fol/l) and by no means all individuals with high 
uric acid levels present a clinical picture of gout. 
~lthough hyperuricaemia is a prerequisite for the 
development of gout, it may not be present at the time 
of diagnosis, [ome degree of elevation usually persists 
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between attacks of gout but it can be intermittent and 
therefore missed. Asymptomatic hyper.uricaemia has been 
found in blood relatives of gouty patients and female 
relatives tend to have lower serum urate levels than 
male relatives. 
Increase in serum uric acid may be theoret-ically 
due to either overproduction or decreased destruction 
or decrea~ed renal excretion of uric acid. Decreased 
destruction is not really relevant because uric, acid is 
not metabolised by human tissues although an appreciable 
amount is degraded by intestinal bacteria in the digest±ve 
tract. In practice it is usually a combination o-f the 
other two factors which operate in many clinical conditions, 
but for simplification the clinical conditions associated 
with hyperuricaemia have been segregated into three 
categories which are summarised in Table2. Some of these 
maladies will now be discussed. 
Decreased Renal Excretion. 
:::erum uric acid is freely filtered across the glomerulus 
and in the early part of the proximal tubule 98-100% of the 
filtered urate is resorbed (Steele 1971). A variable 
amount of the filtered load is secreted back into the 
proximal lumen in a more distal part of the proximal 
tubule. This classical three component hypothesis of 
filtration, resorption and secretion for renal handling 
of urate proposed by Gutman and Yu (1961) has been confirmed 
and· extended by the introduction of a post secretar;.,-
absorption component (Diamond and Paolino, 1973) which 
occurs in the late part of the·proximal tubule or the 
distal tubule (RieeElbach and Steele 1974). The final 
concentration of uric acid in the urine is a function 
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of ~he relative amounts of tubular secretion and post 
secretary resorption since uric acid is almost completely 
resorbed in the proximal tubule. In healthy individuals 
the tubular secretary capacity for uric acid is high 
( >50%) and because only rv 10% of t he filtered urate 
load appears in urine, i~ follows that the post secretary 
resorption of uric acid must also be high, Normal renal 
handling of urate has been depicted by Rieselbach and 
Steele (1974) as shown in Diag. 6. 
Diag. 6 
Filtration 
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Diag. 6. Urate t rans f er in the human kidney 
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An impairment of the ability of the kidneys to 
handle any of •:he f.our component system for urate 
c:Learance will alter serum uric acid l!evels in an 
individual. Fatients wi.th chronic renal failure due 
to diseases other t:~an gout initial.J:y show an enhanced 
clearance of urate as compared with creatinine but 
progrssive deterioration in renal function eventually 
gives rise to hyperuricaemia. Increased s~r.um uric acid 
may occur in eclampsia in the absence of retention of 
urea. In this condition there m~y be a decrease in 
uric acid clearance with no associated abnormality of 
other function of the kidney. On this basis the 
simultaneous presence of decreased uric acid clearance 
and usual urea clearance msy aid. in differentiating 
eclampsia from glomerulonephritis complicating pregnancy. 
Hyperuricaemia may occur, in association with retention 
of other urinary constituents, in conditions associated 
with urinary abstruction (prostatic, bi~ateral, uretheral 
calculus etc), urinary suppression (acute tubular necrosis, 
shock, intestinal obstruction etc), destructive renal 
lesions (tuberculosis, pyelonephritis, polycystic kidney 
etc), congestive heart failure and adreno-cortical 
insufficiency (Addieons disease). 
Renal disease is the most serious extra-articular 
consequence of hyperuricaemia and three types of renal 
disease have been reported by Klinenberg et al (1975), 
gouty nephropathy, acute intratubular crystal deposition 
and nephrolithiasis. The presence of monosodium urate 
monohydrate crystals in renal parenchyma is definitive 
for gouty nephropathy. Barlow and Beilin (1968) have 
found that diagnosie·by means of renal biopsy is difficult 
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since crystals rarely form in the cortex but are usually 
present in the medulla. The high sodium concentration 
present in the medulla, which is higher than that of 
plasma, lowers the solubilfty of monosodium urate and 
thus favours deposit·:i:on of urate crystals. Decreasing 
the medullary codium concentration by generous hydration 
will decrease the tendency for intramedullary deposition 
of monosodium urate. Urate crystals are fairly soluble 
in formalin which is commorily used for fixation in histo-
chemical investigations of renal autopsy and biopsy 
specimens and thii fact is probably responsible for 
many reports of the absence of intrarenal urate crystals 
in patients with gout., However Tal bott and Terplan ( 1 960) 
reported that 176 of 191 gouty patients had urate crystals 
in renal parenchyma. The precise pathophysiological 
consequences, if any, of intramedullary deposition of 
urate crystals are unknown but Klinenberg et al (1975) 
report the decline in the kidney's ability to form 
concentrated .urine as the earliest physiological 
disturbance. Renal insufficiency is certainly common 
in gout, Barlow and Beilin,(1963), but .it appears to 
correlate better with the age of the patient than with 
the extent of the. gout. Long-standing hperuricaemia 
does not inevitably produce gouty nephropathy and chronic 
renal insufficiency. Berger and Yu (1975) reported that 
after a 12 year study, no appreciable loss of renal 
function was found in 112 patients with gout as compared 
to normo uricaemia subjects. Additionally Ro~enfeld 
(1974) found that the drug allopurinol, an inhibitor 
of the enzyme xanthine oxidase, had-no value in the 
prevention or development of renal insufficiency in 
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asymptomatic hyperuricaemia subjects. 
Nephrolithiasis associated with hyperuridaemia 
may be of three ty,::es: pure uric acid stones, mixed' uric 
acid-calcium oxalate stones and. calcium oxalate stones. 
The cause of mixed uric·· acid-calcium oxalate stones and 
pure calcium oxalate stones in the presence of hperuricosuria 
is unknown but the incidence of calcium oxalate stones is 
·decreased by treatment of hyperuricosuric patients with 
allopurinol (Coe, 1977). 
The Framingham Heart Study (Hall et al 1967), in 
1949, represents an in-depth epidemiological survey of 
5127 men and women aged 30-62 in Framingham, fiJassachusetts,. 
The study showed that all ca6es of renal failure secondary 
to hyperuricaemia were preceeded by multiple attacks of 
arthritis or stones. 
Hyperuricaemia may also be associated with an 
incre·a.sed incidence of arterioeelerotic cardia vascular 
disease. The Framine;ham studyshowed that the incidence 
of coronary arte~y disease in patients with gout is twice 
as high as those individuals without gout. Other studies 
by Viozzi et al (1972) and by Bluhm and Riddle (1973) 
have demonstrated a statistically significant correlation 
between hiperuricaemia and arteriosclerosis but the 
Tec.umseh Community Health Study showed no relationship 
·between hyperuricaemia and coronary heart disease. 
(Myers et al 1968). The oversight of factors such as 
ethnic considerations, diet etc may cause erroneous 
interpretations in population studies. It must be 
remembered that the contribution of two major risk 
factors for coronary artery disease-hypertension and 
obesity- is difficult to eli~inate since both appear to 
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be inde~endent1y associated ,with hyperuricaem-ia (Ha.ll 
1965; Hall et al 1967). In vi,tro studies by Ginsberg 
e.t al ( 1977) have indicated that urate crystal:s may play 
a part in atherogenesis. Incubation of monosodium urate 
crystals with platelets results in the rapid release of 
serotonin, .ATP and ADP. The latter is a potent stimulator 
of platelet aggregation and effects a further release 
reaction-and aggregation. A local interaction of platelets 
and urate crystals at the blood vessel wall could result 
in platelet aggregation .and consequent endothelial-cell 
damage (Nustard et al 1·963). Such a p:cogress c_ould be 
an important initiating event in atherosclerosis. 
Pathological conditions associated with increased 
cellular turnover lead to marked overproduction of uric 
acid. Hyperuricaemia: is common in patients with 
myeloproliferation (such as polycythemia vera and myeloid 
me-taplasia) or lymphoprolifera ti ve disorders. ( Kj ellstrand 
et al 1974). Acute intratubular precipitation of free 
uric acid leading to renal failure is an acknowledged 
complication in these patients undergoing cytotoxic 
treatment in the form of chemotherapy or radiotherapy 
(Talbott and Yu 1976 a) 
Gout. 
The acute gouty attack and crippling effects of 
chronic gouty arthritis have been described as early 
as the fifth century B.C. An updated version of the 
acute attack was described by 3ydenham in 1683 as follows:-
'The victim goes to bed and sleeps in good health. 
About two o'clock in the morning he is awakened by a 
severe pain in the great toe: more rarely in the heel, 
ankle or instep. ':'he pain is like that of a dislocation, 
and yet the parts feel a.e i:f cold water was .poured over them. 
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Then follows bhills and shivers and little fever. ~he 
pain, which was first moderate., becomes more intense, 
f'iith its intensity the chills and shivers increase. 
After a time this comes to its height, accqmodating 
itself to·the bones and ligaments of the tarsus and 
metatarsus. Now it is a violent stretching and tearing 
of the ligaments, n<;:>w it is a gnawing pain and now a 
pressure and tightening, So exquisite and lively 
meanwhile is the feeling of the part affected that it 
cannot bear the weight of bedclothes nor the jar of a 
person walking in the room. The night is passed in 
torture, sleeplessness, an:d turning of the part affected 
and perpetual change of pocture' ( Sydenham, 11850). 
However it was not until the 19th century that 
elevated uric acid was demonstrated in gouty patients 
and not until the 20th century that urate crystals were 
definately imp~icated as the inciting cause of gout. 
Hyperuricaemia and gout can either ~e primarY 
disorders o~ secondary to other clinical conditions or 
occasionally to drug therapy, In fatients with primary 
gout, elevated uric acid levels are caused by increased 
production of uric acid, i:npaired renal clearance of 
uric acid or a combination of both. Although the clinical 
expres~ion of primary gout appears to be genetically 
controlled, specific metabolic defects have been identified 
in only a small proportion of :.;atients and these will 
be discussed later. Epidemiological studies (e.g. Healy, 
1975; Talbott and Yu 197tb) suggest that a number of 
environmental and social factors m,:_~· not only contribute 
to the cliriical manifestations of primary gout but may 
mask the underlying genetic defects in uric acid metabolism 
and/or excretion ( \'iyngaarden and KelJ:ey 1 976 ~'), 
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Frevalence and i:ncid'ence of th-:1 C.iagnosis .of gout. 
ll. study of the prevalence, of gout and of the incidence 
of diagnosis frpm 1971-1975 was carried out in a 
representative general practice sample comprising 64 
practices and a population numbering 1 in 14'5 of the 
total population of Great Britain has been reported by 
Currie (1979). The results show an annual incidence of 
0.25 ~o 0.35 per 1000 and an overall prevalence at 25th. 
December 1975 of 2.6 per 1000. The prevalence in England 
was greater than that in Wales which was greater than 
that in Scotland. 'In Scotland gout is much less frequently 
met with than in England ......• and when it does occur 
is generally in the upper classes ....... '(Garrod 1876). 
In 10% of all the cases the gout was believed to be 
secondary, with induction by diuretics ·being the most 
frequent cause.. The prevalence of primary gout was 
estimated as 2. 3 per 1000, which. ·is': in keeping with 
estimates covering Europe and North America (Lawrence 
1 960, i·iyngaarden and Fr.edrickson 1 960 Kellgren 1 964) . 
Scott et al (1976) showed that serum uric acid levels 
in England and Glasgow had the same frequency distribution 
and mean levels. It is as yet not po~sible to ascertain 
the effect of dietary alcohol on plasma uric acid levels. 
The average dietary consumption of alcohol in Europe 
amounts to between 1 0 and 1 5~~; of the total calorie 
intake and in the past women have not taken as much 
alcohol as men, However in this age of sex equality 
women are drinking more and so it will be of intere:=t 
to observe whether the incidence of gout remains higher 
in males than in females. It should be noted that the 
consumption of alcohol in some countries is very low and 
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yet gout is no.t uncommon. Gout is not associated with 
alcoholics but it could be that high alcohol. intake is 
a contributary factor in gout. 
The clinical course of primary gout can be divided 
into three phases:-a) the asymptomatic stage b) the 
acute intermittent stage and c) the chronic stage. 
The main objective of treatment for al.l. o~ these stages 
is prompt treatment and prevention of symptomatic gout, 
avoidance or reversal. of any of the possible complications 
of hJ·peruricaemia and treatment of any associated 
conditions such as hypertension. 
Drug induced hyperur~caemia. 
Several. drugs may induce.hyperuricaemia by increasing 
production and/or decreasing excretion of uric acid. 
Diuretic induced hyperuricaemia is of some concern. 
About 50% of the patients with essential. hypertension 
treated with diuretics become hyperur~caemic although 
fortunately many of them remain asymptomatic. Faul.us 
et al. (1970) routinely screened blood urate in ~aiients 
in a large hospital in the U.S.A. and found that diuretics 
could be implicated as the cause of 20~ of the cases 
of hyperuricaemia found in this survey. The mechanism 
of diuretic induced hyperuricaemia, although not resolved, 
possibly involves. an increase in resorpcion of uric acid 
in the proximal. tubule (Hol.mes et al. 1972). 
The popular concept between overingestion of alcohol. 
and acute gout maybe due to lactic acidosis ind~ced by 
ethanol. but Luber et al. (1962) have reported that there 
is a high purine content in wine and beer. Lactic acid, 
l.ike other weak organic acids, interferes with the tubular 
secretons of urat~. Alcohol. ingestion may raise the serum 
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urate concentratioh as much as 1 to 3mg per 100ml.(60-
179;unol/ l). 
The antituberculous agent pyrazinamide a nd its deamina : ed 
form pyrazinoic acid are potent inhibi~ors of renal-tubula r 
urate secretion ( Meis el and Diamond, 1 977). Et hambutol, 
an extensively u s ed antituberculous drug also decreases renal 
clearance o f uric acid ( Postlethwaite et al 1 972). Nicot i nic 
a cid also decreases rena l excre t ion of uric acid (Gaut et a l 
19 71) Nicotinic and pyrazinoic acids are s t ructarally simila r. 
COOH 
Nico t i nic a c id Fyrazinoic a cid 
Di ag . 7 ~truc ture Nicotinic a nd r y r azino ic acids . 
Aspi r in e xhibits a d ual a c tion in the excr et ion o f 
uric a c i d. There is a " thr eshold" l e vel whe r e by doses of 
lees than 2 g . dail y i n creases ser um ._.rat e c oncentre.tion due 
t o inhibitors o f tubular sec retion; h i gher doces a re generally 
u r icos uric s i n ce resor ption of ~ric a cid i s preferentially 
i nhi bi ;, e d ( Gra~· zel et a l 1 961 ) • The drugs known to b e 
i n d u c e r s o f hy perurica e mi a are s h own in Table3 whi c h 
include& their known mechanism of a ction. 
2 9 
Hyper~ipidaemia in Gout, 
Elevations of plasma triglyceride and free fatty acid 
levels have been reported in patients with primary gout 
but the mechanism of this hyperlipidaemia is by no means 
established. A positive cbrrelation (r= 0.249 F( 0.05) 
has been found between plasma trig~ycerides and free fatty 
acid levels in gouty ~atients by Nishida et al. (1975). 
Hypertriglyceridaemia and normal serum cholesterol levels 
have been reported by Feldman et al. (1964) and by Berkowitz 
(1964) in patients.with gout. It has been suggested that 
the high levels of serum triglyceride found in association 
with ~out may be explained on the basis of high alcohol 
consumption and the body weight problem in many countries. 
It would appear worthwhile to investigate hyperuricaemia 
and hyperlipidaemia using Fredrick~on's classification for 
the latter condition (see Ap~endix I). 
Despite thEi rather consistent presence of hyper:.:ricaemia 
in acute gout it is important to realise that this is 
apparently not the cause of the acute symptoms. No such 
attacks occur in patients with renal failure with high 
blood uric acid concentrations. Moreover there is. no 
consistent quantitative correlation between the clinical 
response to such agents as ACTH, cortisone, cinchophen, 
salicylates, probenecid etc. and their uricosuric or 
blo~d urate-lowering effects. Administration of uric 
acid, orally or intravenously, does not precipitate an 
attack even in gouty patients. Observations such as 
these have led to the hypo~hesis that some purine. 
metabolite, probably a precursor of uric acid is the agent 
directly responsible for the acute attack. However attacks 
of acute gout,accompanied by hyperuricaemia,have been 
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pr.ecipi tated by administration of chl!orothiazide and other 
benzothiol comp·ounds for purposes of inducing diuresis. 
The mechanism of this process has yet to be completely 
resolved. It does however become apparent that any 
systematic study of hyperuricaemia should include two 
groups of patients, additional to a group of healthy 
controls, one group with the diagnosis of gout and the 
other to have asymptomatie h~peruricaemia and absence 
of gout in their family history .. 
Enzymology of .Hy.peruricaemia and Gout. 
The excessive production of uric acid may be primary, 
that is due to a pathological or a .genetically determined 
abnormality or secondary as a complication of an acquired 
di,s;order. A number of specific enzyme defects presented' in 
Table 4 have been reported and such mutations can account 
for some of the genetic basis of primary gout. 
Phosphoribosylpyrophosphate synthetase (E.C.2.7.6.1 .) 
PRPP is an essential substrata for several pathways 
involved in the biosynthesis of pyrimidines, purines and 
nucleotides and in the salvage of purines. In fact PRPP 
serves as a phosphoribosyl donor in many reactions which 
are listed· in Table 5. Any of these reactions are capable 
of competing with the reaction of the pathway for purine. 
biosynthesis de novo for available FRPF. 
The synthesis of PRPP from ATP and ribose-5-phosphate 
is catalysed by FRPP synthetase and the reaction involves 
direc.t transfer of the termina 1 pyrophosphate of ATP 
to the 1-carbon of ribose-5-phosphate (Khorana et al 1958). 
The enzyme is stereospecific for a pentose sugar with a 
hydroxyl group at position 2 and a phosphate at position 
5 (Fox and Kelley 1972). Magnesium ATP is ano-ther 
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substrata for the enzyme and d-ATP can be substituted for 
ATP. But the lack of enzymic activity with ADP and nucleoside 
triphosphates other than ATP and d-ATP suggest that a 
triphosphate structure, the purine ring and the 6-amino-
purine (Fox an.d Kelley 1 971 a) are necessary for any 
compound to be an effective substrata. The enzyme has 
an absolute requirement for inorganic phosphate and the 
enzyme is inactive in the absence of phosphate (Fox 
and Kelley 1'972) • 
The kinetic mechanism of the enzyme from human 
erythrocytes has been studied in detail and appears to be 
an ordered bi-bi mechanism. Fox and Kelley ( 1972:) 
indicated by product inhibition studies that ribose-5-
phosphate is bound fi:rst to the enzyme and PRFP released 
last. The regulation of PRPP synthetase activity is 
quite complex and there appears to be three different 
active sites for the binding of such diverse inhibitors 
of the enzyme as .e. g_. ADP which competes with .Mg ATP 
and FRFP a.nd 2_, 3_ diphosphoglycerate which compete with 
R-5-P (Fox and Kelley 1'912). There is no evidence that 
FRPI inhibits the enzyme under normal conditions ·(Fox 
and Kelley 1971 b) since the Ki for I'R:PP is 0.05 mM 
which is about 10 times its intracellular concentration 
in human cells. ·rn marked contrast the Ki value of the 
enzyme for 2,3 diphosphoglycerate is 5.3mM which 
approximates to its concentration in human erythrocytes. 
A large number of compounds have been found to inhibit 
PRFI synthetase by a third mechanism which is non-
competitive with respect to both ribose-5-phosphate and 
magnesium ATF. These include A."'lP,GDP,GTP,IDP,ITP,TDP, 
NAD+, NADP+ and FAD (Switzer 1971, Fox and Kelley 1972, 
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Green and Martin 1974). In general the di- and tri-
phosphates are -more potent inhibitors than the mono-
phosphates (Fox and Kelley 1972) and it has been proposed 
that the enzyme is regulated by heterogeneous metabolic 
pool inhibitors with binding at a third site on the 
enzyme (Fox and Kelley l972, Switzer 1971). This group 
of inhibitors have a low affinity for the regulatory 
active site. 
Human PRFP synthetase is composed of a repeated 
single subuni t of _.. 60,000 dal tons (Fox and Kelley 
1·971 a; Beaker et al 1977). The enzyme :t~eversibly 
assume aggregated forms of molecular weights varying 
from"""' 60,000 to greater than 106 • ~:naller aggregates 
of the enzyme appear to be inactive whereas aggregates 
composed of 16 and 32 subunits are active (Fox and 
Kelley 1971 a). The effect of small molecule activators 
and inhibitors appears to be correlated with their. effect 
on the state of aggregation of the enzyme (Becker et al 
1977). _ It is now accepted that the subunit measured by 
Fox and Kelley (1971 a) is a dimer a.nd the evidence 
for a subuni t of molecular weight 33,-000 is summarised 
in Table6-. The properties of the aggregated forme 
of FRP? s~nthetase are presented in Table?•', Structural 
alterations in PRPF synthetase coul~ alter either the 
affinities of the binding sites for different inhibitors 
or the subunit aggregation, Such changes could alter 
activity with subsequent overproduction of FRPP, purine 
and uric acid. 
Specific genetic alterations of FRPP synthetase 
appeared to be important in gout when Jones et al (1962) 
reported an increased turnover of PRPP with overproduction 
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of uric acid in three gouty patients. An increased· 
rate of FRrF formation in erythrocytes in several gout 
patients was reported by Hershko et a:l ( 1 968) and' 
although the mechanism was not established this observation 
was confirmed by Sperling et al ( 1971 ) . A marked'ly 
accelerated rate of PRPP cynthesis with overproduction 
of urate was demonstrated in two brothers with gou~ 
(Sperling et al ,1972) and this was later shown to be 
consequential to altered .kinetic properties of PRFF 
synthetase ( Sperling et al 1'973). Two additional families 
have been reported in which excessive rates Of FRFF 
synthesis can be attributed to abnormalities of the 
enzyme but the enzyme defect appears to be different 
in each of the three families (De Vries et al 1 973., 
Becker et al 1974). The enzyme from a patient of the 
gouty family reported by Sperling et al (1972) was 
partially purified and kinetic analysis showed that 
although i.ts affinities for ribose-5-phosphate, ATP 
and inorganic phosphate were normal, its sensitivity 
to inhibition by nucleotides and 2.3 diphosphoglycerate 
was markedly reduced (Sperling et al 1973). The results 
indicated that the gouty patient had a mutant enzyme 
structually altered in some way which rendered it 
relatively resistant to control by nucleotides .• 
The second variant form of FRPF synthetase was found 
in two brothers with gout in whom the rate of purine 
synthesis de novo as assessed by 14c glycine incorporation 
into urinary uric acid was 3-5 fold greater than normal 
(Becker et al 1973}. The enzymic activity was threefold 
the normal activit~· in erythrocytes over a range of 
inorganic phosphate concentrations. Increased thermal lability 
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and altered electrophoretic mobility (i.e. a lower 
isoe:lectric point) was found in the enzyme purified 
from gout patients in this family {Becker et al 1975). 
By .means of antibody inactivation and immunodiffusion 
using rabbit anti•serum developed to purified normal 
FRPF synthetase, the increased catalytic ac.tivity per 
molecule was shown by Becker et al (1975 and 1980) to 
account for the increased activity of the mutant enzyme, 
Another structural variant of FRPP synthetase 
associated with excessive intracellular FRFP concentration 
was identified by Becker (1976) in the erythrocytes 
of two affected brothers. Although FRPP synthetase 
from these individuals wa:s normal at ·saturating substrate 
concentration partially purified preparations of the 
erythrocyte enzyme had a three or four fold higher 
affinity for ribose-5-phosphate than did comparable 
preparations from healthy controls. This variant enzyme 
had a slo.wer electrophoretic mobility than the usual 
enzyme. 
Lejeune e.t al (1979) report abnormalities of FRPF 
synthetase in two cases of gout beginning at an early 
age. The kine-tic abnormalities are manifest in an 
inc-rease affinity for inorganic phosphate in the absence 
of inhibitors and a decrease inhibition by low concentrations 
of ADP in the presence of phosphate. No other abnormality 
wa:s apparent. 'i'he t·lio cases of gout were characterised 
clinically by their early occurence (one patient a 
premenopausal woman), their family character and their 
nor~al sensitivity to allopurinol. 
The differences in th~ enzyme defects described ~bove 
exemplify the heterogeneity found in some patients with 
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gout and suggest that additional mutations of FRPF 
synthetase may well account for purine overproduction 
in primary gout'" The abnormalities in some of the enzyme 
variants are subtle and would be missed by routine mass 
screening of enzymic actiyities. The application of more 
refined techniques and the use of i·soelectric focusing 
could more readily expose other enzyme variants present 
in gouty individuals. Kelley and \·/yngaarden ( 1 97 4) 
report that 'there is no question now that increased 
FRFF synthetase act~vity represents a specific genetic 
type of gout' but that the relative frequency of the 
disease within the gouty population remaihs to be 
determined but 'it would appear "o be a relativily unusual, 
if not a rare, cause of dOut'. This problem to our 
.knowledge, has yet to be resolved. 
Phosphoribosylpyrophosphate-amidotransferase. (E.C.2.4.2.14) 
Although this enzyme domina"es the regulation of 
de novo biosynthesis of purines there is meagre evidenc-e 
to date of its role in the pathogenesis of gout. Fibroblasts 
cultured from two patients with gout, who showed an 
increased p~·oduction of url.c acid, were found to be 
relatively insensitive to the effect of adenine and 
hypoxanchine on the early s"ages of purine biosynthesis. 
Henderson et al (1968) sugges"ed that this insensitivi"y 
could be due to a mutation of one of the regulatory 
subunits of I'RPP amidotransferase.· ~ubsequently it was 
found that one of the patients had an increased IRF:F 
synthetase activity (Becker et e.l 1973) which accounted 
for the increased ?RIP in the fibroblasts. The second 
subject had normal FRIP synthetase and her lack of 
response "o feedback inhibition has yet to be evaluated. 
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(Kelley and Vlyngaarden 19:74). 
Hypoxanthine-guanine phosphoribosyl.transferase HGPRT(E.C.2.4.2.8) 
'HGPRT catalysis the transfer of th·e J;:hOsJ;:horibosyl 
moiety of I'RPP to the 9 position of hy.poxanthine and guanine 
to form H'!P or Gfo<..F respecti vily. Its af.fini ty for different 
substrates has been reported by Krenetsky et al (1969). 
Xanthine as well as several purine analo·gues such as 
6-mercaptopurinol and allopurinol act as substra.tes but 
PRPF is the only compound to serve as a donor of the 
phosphoribosyl. moiety for HGl-'R.T (McDonald and Kelley 1971). 
A deficiency of.the enzyme in man was found i:n patients 
with an unusual neurological disorder ( Seegmiiler e.t al 
1967). Each of the pati2nts had Lesch-Nyhan syndrome, 
an X linked disorder characterised by self-mutilation, 
spasticity, mentala~d growth retardation and hyperuricaemia 
due to an excessive production of uric acid (Leech and 
Nyhan 1964). Shortly after (Kelley et al 1967) found 
some patients with gout also had a deficiency of this 
enzyme. But. these gouty patients do no.t have the 
devastating neurol·ogical and behavioral features 
characteristic of Lesch-Nyhan syndrome. They generally 
had partitil deficiency of the enzyme. The deficiency 
has been demonstrated in all tissues from affected subjects 
obtained at autopsy (Rosenbloom et al 1967), in fibroblasts 
and amniotic cells cultured at the time of amniocentesis. 
(Fujinoto e~ al 1968). From a consideration of enzymic 
activities alone, there is no clear cut off which will 
segreeate the Lesch-Nyhan syndrome from gout. A partial 
deficiency of HGPRT has be~n reported in five members 
of two families having gout associated with overproduction 
of uric acid. The mutant en~~mes of the two families 
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differ in their relative activity for the purine substrates 
hypoxart"thine, guanine and adenine as we.ll as in their heat 
stability (Kelley et al 1967}. Other families with gout 
associated with a partial deficiency of HGFRT have been 
reported (e.g. Yu e.t al 1972, Fox et al 1975 Gutensohn 
and John 1979 and Edwards et al 1979) but the kinetic 
properties of the mutant enzyme indicates many variante 
of the enzyme with no single specific characteristic 
for· the clinical condition. Edwards et al ·( 1 979) eug.;;;est 
that purine salvage is a major contributor to increased 
purine excretion and that the purine catabolic pathway 
responds differently to an increased substrate load in 
HGFRT deficiency. The purine salvage pathway is normally 
an i:npor"tant mechanism of the reutilization of hypoxanthine 
in 2an (Murray 1971). A deficj.ency of HGIRT WHS the 
first specific genetic variant demonstrated with primary 
gout and to date has been the most exteneively studied. 
Adenosine monophosphate-p;yrophosphate phosphoribosyl transferase 
( APRT I E., c. 2. 4. 2. 7) . 
The activities of several enzymes are elevated in 
erythrocytes from pe.tients with a deficiency of HGFRT. 
Many patients with a partial deficiency of HGTRT show 
increased activity of APRT (Kelley et al 1969). AFRT 
defic~ency has been reported in two families presenting 
with supposed 'uric acid' stones (Dean et al 1978, cimmonde 
et al 1978), The 'uric acid' stones were found to be 
2,8-dehydroxyadenine and not associated with hyperuricaemia. 
Glucose-6-phosphataee (E.C.3.1 .3.9). 
Fatients with'Type 1 glycogen storage disease or Von 
Gierke's disease cannot metabolise glucose-6-phos~hate to 
glucose and inorganic pho~phate because of glucose-6-
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phosphatase deficiency. An associated comp!l!ica:tion of 
this disease is hyperuricaemia which frequentJ.ly results 
in gout. The acidosis of serum lactate and ketone bodies 
resulting from hy.poglycaemia interfere with ·renal secretion 
of uric acid (Yu et al 1957, Goldfinger et al 1965). 
Furthermore Aiepa et al 1967 and. Jacoveic and Sorensen 
1:96.7 have demonstrate.d an increased ra.-ce of ur.;i;c acid 
synthesis de novo in these patients. Gout becomes 
significant in early adult life. The FRPF content of 
erythrocytes of the patients is normal (Greene and 
Seegmiller 1969) but this is not surprising since 
gl:ucose-6-phosphatase is normally restricted to liver, 
kidneys and gastrointestinal tract. 
Glutathione Reductase. (E,C,1 .6.4.2.) 
Glutathione reductase catalyses the reduction of 
+ + . glutathione with NADPH+H or NADH + H serv~ng as hydrogen 
donors. Long (1967) has reported an increased activity 
of the enzyme in erythrocytes from 23/28 negro patients 
with gout and also in a group of Caucasians with untreated 
gout (Long 196~). Control screening of a large negro 
population showed that 3~.% had an increased enzymic 
activity and moreover the mean serum urate concentration 
was higher in the individuals with the increased glutathione 
reductase activity then in others with a ''normal'' enzymic 
activity (Long 1970). Beutler (1969) has reported that 
this enzyme activity is dependent on diet and i-c is accepted 
that not only pathology e.g. diabetes mellitus but the 
vitamins nicotinamide and riboflavin increase the activity 
of glutathione reductase (Beutler 1966), Changes in 
enzymic activity must be interpreted with reservation 
and not; automatically be attributed to a pathological 
condition. 
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Increased glutathione reducta£e activity would 
increase N~DP+ p roduction from the reduced coenzyme and 
an increased NiiDF + /NADFH ratio would accelerate the 
pentose mono~hosphate shunt pathway with increased pro-
duction of ribose-5-phosphate and subsequently PRFP 
by the following reactions. 
GS~G+ NADl'H+H+-~) 2GSH + NADP+ 
G-6-F + NADP~D glucone-5-lactone-6-phosphate + NADPH 
~20 
6-phospho-D-g luconate 
~ NADP+ 
D-ribulose-5-phospha te 
~ 
D-ribose-5-phophate /+ ATI' 
PRFP + AMP 
The increased availability of FRFP would again increase 
purine biosynthesis de novo which may be a ~artial cause 
of the hyperuricaemia observed in gout. 
Adenosine deeminase (E.C. 3 .5.4.4.) 
This is a widely distributed enzyme which catalyses 
the d_ea.m·tna.t ion of adenosine to inosine and ammonia. 
Adenos ine Inosine 
Diag.8 P ea.lf'l•flo.tio tl of adenosine . 
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Ni·shizawa et al 1(1975) studied ADA in patients with 
hyperuricaemia in· primary gout and found increased enzymic 
activity in untreated cases. They did not indicate 
whether the increased enzymic activity was associated with 
primary or secondary gout, 
Isoenzymes. 
It is of historical interest that medical applications 
of multiple forms of an enzyme preceeded any biological 
understanding and the routine inveE:tigations of LDH 
isoenzymes in the clinical chemis~ry labor•tory reflects 
the important role that these isoenzymes have assumed· 
as an ancillary aid to diagnosis. 
There is no particular isoenzyme that has been 
associated with either hyperuricaemia or gout but several 
electrophoretic variants have been reported in a few 
patients. These are summarised in Table 8, 
Drug Therapy. 
Agents currently used in the treatment of hyperuricaemia 
and gout can be conveniently divided into those used to 
treat an acute attack of gout by alleviating pain and 
inflauunation and those used to control hyperuricaemia.· 
Treatment of an acute gouty attack. 
Anti-inflammatory drug treatment should be started 
as soon as possible following the diagnosis of acute gout 
for the most effe~tive r~sponse (Smyth 1972). Colchicine 
is the traditional drug of choice and it is relatively 
specific for acute gout (e.i.Wallace, 1977, Yu 1974) 
although Tabatabai (1978) reports that ·the drug is 
effective in pseudo gout (characterized by deposit of 
calcium pyrophosphate crystals in synovial fluid). 
~allace (1972) has found that ~ore than 90% of the 
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patien~s wittt gouty arthritis respond if ~olchicine 
~~ given orally within a few hours following the onset 
of an attack. There are however unpleasant side effects 
associated with colchicine: these are primarily gastro 
intes-tinal and include nausea, vomiting, cramps and 
diarrhoea. Gastrointestinai toxicity occurs in nearii:y 
80% of patients having oral colchicine (Primer Rheumatic 
Diseases 1973). Sometimes these adverse effects occur 
bafore the beneficial effect of colchicine. Otherwiee 
adverse effects include alopeQia, neurotoxicity, myopathy, 
transient bone marrow depression and hepatotoxicity 
but these effects are usually assoc~ated with exceesive 
parenteral colchicine or reduced hepatic and/or renal 
clearance of colchicine. ( Golfinger, 1 971, ';iallace, 
1974, ··tiyngaarden and Kelley, 1 976.). 
Fhenylbutazone is as effec.tive as colchic.ine (Freyberg 
1 962, Gutman 1 965) and untoward reac'tions occuring during 
'the treatment of acute gout are rare (Smyth and ::'ercy 1973) 
although gastro intestinal intolerance and fluid.retention 
dominate the side effects that sometimes limit its usefulness. 
Relief is usually apparent within 6-24 hours and complete 
resolution of inflammation uEually takes three to five days 
( 'o'lyngaarden and Kelles 1976). Indomethacin has been shown 
to be as effective as phenylbutazone (Emyth and Fercy 1973) 
but unpleasant side effects are not infrequent (Boardman 
and Hart 1965). A multi centre trial of naproxen and 
phenylbutazone in acute gou~ by Sturge et al (1977) 
snowed that naproxen is a useful alternative agent to 
phenylbutazone for the treatment of acute gout and is 
of real value to patients with gastro intestinal intolerance 
to aspirin or indomethacin (Hill et al 1973; Kogstad 1973). 
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The mechanism of the intensely painful inf:J.:ammation 
of the acute gouty joint is unknown.. Activation of the 
Hagemann. factor, complemen·t and the kinin system have 
been implemented but subsequent~y rejected (Spilberg 
1974, Phelps and McCarty 1969 Phel:ps et al 1966), The 
drugs are all po.tent inhibitors of prostaglandin synthetase 
(Taheguchi and Sih 1'972, Fllower et al 1973) suggesting 
that prostaglandins p:lay a major part in the inflammation 
of acute gout. Col!ch:i:cine does not inhibit prostaglandin 
synthesis and presumably acts by a different mechanisl!l, 
cdchicine therapy does appear to control serum glyco-
saminoglycan levels and the patient becomes asymptomatic 
when serum glycosaminoglycans fall to approximately 
normal val:ues (Katz 1979). An inspection of the chemical 
formulae of these drugs would concur with different 
mechanistic action of colchicine and the other anti 
inflammatory agents. (Diag 9 shows the chemical structure 
of these drugs and allopurinol). 
Fenoprofen and ibuprofen, recently marketed anti-inflammatory 
drugs, also appear to be effective. in relieving the 
inflammation of acute gout with minimal adverse reactions 
(vlanasukapunt 1976, 8chweitz et al 1978). 
ACTH and corticosteroids may be used to treat ·acute 
gout but are primarily reeerved for the 5% resistant 
cases (ivyngaarden and Kelley 1976). Rebound of attack 
may occur on steroid withdrawal but this can be overcome 
by colchicine therapy (Viyngaarden and Kelley 1976). 
Smyth (1972) reports that prophylactic colchic1ne 
is useful in reducing the number of gouty attacks and that 
daily administration of 0·5-1 ·5 mg of the drug decreases 
the incidence of gouty attacks in as many as 75% of patients. 
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Allo p uri n o l 
Di ag . 9 . Chemical fo rmulae of ~ome ant i - i n f lammatory 
drugs a nd all opur i nol . 
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Concrol of hYperuricaemia. 
Hyperuricaemia can be controlled with e±ther uricosuric 
drugs or with- the xanthine oxidase inhibitor all!opurinol. 
:Patients with moderate hyperuricaemia and serum urate 
concentration~ :less than 9.0mg r.er 100ml with just aches 
and pains or low back pain or other ill defined symptoms 
but without evidence of gout do not require treatment 
(Kelley 1977). In support of this, Fessel et al (1973) 
reported th~t in a group of 124 asymptomatic hyperuricaemic 
subjects followed over a four year period, the risk of 
gouty arthritis or nephrolithiasis was not higher than 
in 211 normouricaemic individuals. 
The indications for urate lowering therapy according 
to 11langini ( 1979) are: a) frequent gouty a_ttacks despi-te 
conservative treatment; b) _chronic joint change with or 
without tophaceous deposits; c) uric acid nephrolithiasis; 
d) evidence o~~urate-induced renal damage e) uric acid 
level above 9me/1 OCml C".nd f) overproduction and hypoexcretion 
of uric acid. The aim being to maintain the serum uric 
acid level below 5.0-5.5mg/100ml. 
Drug selection depends pri1narily on the mechanism of 
hyperuricaemia. In the overproducer/hypoexcreter allopu~irt61 
is the drug of choice _while in the patient with nor~al 
renal excretion who excretes less than 6COmg/day of uric 
acid on a purine restricted diet eicher class of drug 
can be used (Smyth, 1972). ura~e lowering therar.y 
should not be ini tilj_ted until a.fter an a.cu-:e gout~· a,ttack 
hus complecely subsided ( 'tiyngaarden and i{elley 1 976). : c-
Uricosuric Agents. 
Uricosuric drugs inhibit both the presecretory and 
poet secretary components of renal tubular resorption and 
increase the renal clearance of uric acid (Diamond and 
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i aoline 1 973, l~e!l:ly 1 975, Yu 1 974, Fox 1 977, Fanelli 1 97.5). 
The pharmacological action of uricosurics is impaired in 
patients with .renal insufficiency: inc·reasing, doses are 
required as renal function diminishes. ';:hen creatinine 
clearance fall:s below 25ml/min uricosurics ar·e essentially 
ineffec.tive regardlest of the doses (Yu 1 974, F~x 197.7). 
Drug in tolerance, ·impaired renal failure and aspirin therapy 
are the .most common causes of treatment failure (Fox 1977). 
Ii.educ.tion of serum uric acid by uri.cosuric· s not only 
decreases the number of gouty attacks but prevents further 
tophaceous deposits. Preexisting tbphi may be partially 
or completely resorbed (Smyth 1972, Fox 1977, Fanelli 1975). 
The uricosuric agent of choice is probenecid. (Diag 10). 
It is readily absorbed from the gastrointe~tinal tract 
and becomes 90% protein bound. I.t is metabolised in the 
liver to active hydroxylated and carboxylated metabolites 
as well as inac~ive glucuronides (Fox 1977, Wyngaarden 
and Kelley, 1 976) . Probenecid and its metaboli tes are 
excreted by the kidney bu·t renal clearance can be markedly 
effected oy urinary pH since the drug is a weak acid' 
(Fox 1 977, ;::yngaarden and Kelley 1 976) • Excessive dosage 
mus~ be avoided on commencing therapy to prevent marked 
uricosuria and the posEibility of renal calculus formation 
(Fox 1977, Goldfinger 1971 ). 
Approximately 60% of patients respond to probenecid 
(~yngaarden and Kelley 1976), In p~tients allergic 
to probenecid, sulphinpyrazone is an effective alternative. 
It has a relatively short half life of three hours compared 
to probenecid (six to twelve hours). 
Stone formation is a major complication of uricosuric 
treatment with about 10% of patients EO treated likely 
to develop uric acid stones (Kelley 1975). :tatients 
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should be well hydrated and al:d;:ali'ne urine should be 
maintained duririg initiation of th~ therapy (~myth 1972, 
Fox 1977). Other minor adverse effaces to probenecid 
·include gastrointestinal irritation (8-18~ of recipients) 
and hypersensitivity reactions such as fever and rash 
(5%) but the dru~ has no cumulative toxicit;y and for 
this reason is often prefe~rea to allopurinol for patients 
in whom either drug can be used (Fox 1977, Wyngaarden 
and Kelley 1976). Gastrointestinal comphiints and 
hypersensitivity reaations are the major side effects 
of sulphinpyrazone but additionally the drug has antiplatelet 
activity and sho~ld be used with caution for patients with 
bleeding disorders or receiving anticoagulants (Kelley 
1975). 
A new class of uricosuric compounds, the benzofurans, 
have been discovered and tested, and benzbromarone has 
been found usefl.d in the clinical control of hyperuricaemia 
([inclair and Fox 1975). This drug significantly increases 
the clearance of uric acid by a renal tubular effect and 
it has only a minor inhibi tcry effect on urate bind'ing 
protein and xanthine oxidase. Only the renal tubular 
activity of the drug is relevant to its hyperuricaemia 
effects in ma.n under normal circumstances. 
Sinclair, 1977, Sorenson and Levison 1976). 
Allopurinol 
(Fox and 
Allopurinol is the most effective drug for lowering 
seru~ uric acid. Both allopurinol and its long-acting 
metaboli te, o}(J.'pu:!'inol are xan1:hine oxidase inhibi tore 
(Kelley 1975) 1:hus preventing the for~ation of uric acid 
from xanthine. (Diag 11 .) Inhibition of xanthine oxidase 
also reduces uric acid production by decreasing de novo 
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purine synthesis aEi is evidenced by an overall reduc.tion in the 
24· hour excretion o£ uric acid., xanthine and hypoxanthine 
(Hitchings 1975). Allopurinol lowers the intracellular conG:en-
tration o£ FRFF. It is a s.tructural anologue o£ hypoxanthine 
and is converted· to the ribonucleotide £orm by the action o£ 
HGPRT with the consumtion o£ PRPP (Fox et al 1970). Allo-
purinol has a relatively short hal£ life o£ two or three 
hours but its metabolite oxypurinol has a ha!l:f life o£ 28 hours 
and is slowly excreted by the kidney (Fox 1977). 
Allopurinol is useful in treating all forms of 
hyperuricaemia and is the drug of choice when a) urinary 
uric acid exceeds 600 mg per day on a purine restricted 
diet where uricosurics may be hazardous because of the 
danger of uric acid stone formation b) there is a history of 
uric acid stones or calculi and c) hyperuricaemia is .due to 
or is complicated by renal insufficiency (Kelley 1975, Fox 1977). 
Reduction in serum uric acid: is dose dependent but low 
doses must be given in renal failure since elimination 
of oxypurinol depends on renal clearance. 
Uric acid levels usually fall one or two days after 
treatment starts (Fox 1977) and the frequency of acute 
gouty attacks generally d·ecreases within 3-6 months of 
allopurinol-induced normouricaemia. Tophi, if present, 
begin to resolve in size by six months (Fox 1977). 
~ide effects are usually minimal but initiation of 
treatment may induce exacerbations of acute gouty arthritis 
in 10% of the patients Kelley (1975). Gastrointestinal 
disturbances or minor skin rashes are common complaints in 
patients receiving allopurinol (Wyngaarden and Kelley 1976). 
However serious toxicity can occur and includes granulomatous 
hepatitis, vasculitis, agranulocytosis and toxic epidermal 
necrolysis (Jayobski et al 1970, Simmons. et al 1972, Ulsinger 
and Yount 1976). 
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Nature of the problem undertaken. 
The study of hyperuricaemia requires a rigid definition 
of the lev:el of serUm. urate above which any patient will 
be classified as hyperuricaemic. In order to do this one 
must have confidence in the ability to measure uric acid 
in serum and do so accurately wi-ch reproduceable results. 
The large variety of assay methods at present available 
presents problems of selection. It therefore seems desirable 
to assess 3 or 4 different methods before deciding on our 
standard assay for uric acid measurement. 
We have seen that there is much confusion regarding 
the nature, if any, of urate binding in ·Plasma and it would 
seem profitable to ascertain whether we can find any evidence 
for urate binding no·t onl:y in healthy control individuals 
but in hyperuricaemic individuals. 
An analysis of previous work which has been .condensed 
into the p~eceeding pages appears to indicate that it would 
be advisable to separate the known cases of gou·t from other 
hyperuricaemic individuals. Fur.thermore one must be prepared 
if neGessary to subdivide the heterogenous collection of 
hyperuricaemics into tur-cher subgroups (see Table4 ). 
i,.t this s-cage it seems desirable to confine our investigations 
to 3 main groups of individuals. The normal controls will 
consist of > 20 heal thy individuals with serum uric levels 
( 7 .Omg/108ml (420 }·l:nol/1). Gout patients who have been 
refered to us with this clinical diagnosis will comprise 
the second group to be investigated. It may be necessary 
to subdivide this group into subclasses. e.g. those with 
tophi and "those without tophi or to segregate the patien"ts 
according to their drug therapy etc. The third group 
will be individuals who are hyperuricaemic according 
5 I 
to ou~ defiriit~on, Heparinised blood samples will be 
collected from the thre_e groups of indiv±duals. 
When one is considering overproducti'on states of a 
metaboli te it is sensible t.o. have regard to the biosynthetic 
pathways for the production or destruction of the ma ta·b-oli te. 
Uric acid is the end product of purine biosynthesis de novo 
and'so we must investigate the production of uric acid. 
PRPP synthetase is not only required for purine biosynthesis 
de novo but it appears to be for rate limiting for purine 
synthesis and this pinpoin-ts the enzyme for .being of 
particular interest in purine overproduction states. 
But PRP:F synthetase is reported to be an unstable enzyme 
which requires appropriate buffer conditions to maintain 
its activity during storage and manipulati-on and moreover 
the human enzyme is far less stable than that of rodent 
enzymes (Lebo and Martin 1976.). Iri consequence little 
work has been done with this enzyme from human cells 
or tissues and most enzyme work. on gout or hyperuricaemia. 
has centred on HGPRT and other enzymes in the purine 
biosynthetic pathway. '1ie have found in preliminary 
experiments that the human erythrocyte enzyme is more 
~table than we deduced from previous reports. '1ie there-
fore decided to investigate the enzyme fr.om erythrocytes 
of our three groups of individuals. It was proposed 
to study the enzyme kineticully and to examine the effect 
of ihhibi~ors on all blood samples. Bs such means we 
hope to establiEh tests which would be useful in a 
clinical laboratory to not only differentiate between the 
three groups of individuals but to further segregate 
the ap:_:arent genetic he.terogeneity which apparently 
occurs in gouty arthritis (Seegmiller 1975). Other 
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enzymes will be. investigated as time per~its so that 
each sample from patients with gout can be used to 
maximum effect. 
Analysis of isoenz;ymes confers a greater specificity 
in diagnosis in the search for pathogenesis of various 
disease states than does analysis of total unseparated 
serum activity of the .enzyme. Diagnostic specificity 
can be further increased by analysing several different 
isoenzyme systems especially when studied under a wide 
variety of different conditions no~ too remote to those 
prevailing in vivo. It is therefore proposed to invest-
igate several isoenzymic systems. FRPP synthetase, 
HGPRT, glutathione reductase and ADA in the first instance 
to ascertain the frequency of any variants in our blood 
saniples from the three groups of individuals. The 
genetic nature of such variants will be established 
by family studies. 
It is hoped that the integration of our studies will 
shed some.light on the complex·nature of hyperuricaemia 
and gout and indicate the direction that future work 
should take. 
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Experimen·tal rl[ethods and Materia]£ 
1) Collection of blood samples. 
10 ml venepunc.ture samples were colle.cted in li.th:i.:um 
heparin and were processed, in most cases, within 
4 hours of the blood being taken. The samples were 
centrifuged at 3000 rpm for 10 minutes, the plasma 
separated, divided into small aliquots and kept frozen 
until required. The padked cells were washed three 
times with physiological saline and centrifuged at 
3000 rpm for tO minutes. At each separation care was 
taken to remove al:l: traces of the buffy layer of cells. 
After the final wash, the saline was removed and the 
original volume of blood was restored by addition of 
physiological saline. A 1ml aliquot of the homogenous 
suspension of red cells in saline was added to 10~1 ice 
cold water and mixed for 10 minutes on a rotor mixer. 
Bml of phosphate buffer, (90 mmol/1, pH 7·4 containing 
4 mmol/1 EDTA) w:ere added to the 'laked' cells and again 
mixed for .1.0 minutes on the rotor mixer prior to cent-
rifugation at 3000 rpm for 10 minutes. The supernatant 
was aliquoted into plaEtic tubes and stored frozen until 
required; the remaining reconstituted cells were also 
stored frozen. 
Preliminary experiments, over a period of time, 
had indicated that the activities of several enzymes, 
-in particular FRPF synthetase, were beEt maintained in 
the presence of EDTA and high phosphate concentration. 
The presence of mercaptoethanol, reduced glutathione 
or no additive were unsatisfactory for maintaining 
the enzymic activity of PRFF synthetase. 
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a) Control samples. 
Healthy volunteers from the technical staff were 
bled. Other controls were selected initially from O.P. 
samples af.ter consultation of the relevant clinical 
summaries and ultimateJ:y by their plasma uric acid 
analysis. Any sample having ,e, uric acid level greater 
than 420 p. mols/1 was automatically transferred to the 
hyperuricaemic group of patients. 
b) Hyperuricaemic samples. 
This group of individuals consisted of two sub-
groups: people with e. me.tabolic high serum uric acid 
and hospital patients with uremie.. All samples were 
checked for plasma uric acid content in excess of 420 
p mols/l. This criterion was breached by one individual. 
This was e. lady with a long history of hyperuricaemia 
but whose serum uric acid was currently controlled 
chemotherapeutically with allopurinol, It seemed sensible 
to include this sample in this group in order to ascertain 
whether an unusual finding in. her case might be attributed 
to the drug therapy and thereby justify furt~1er study 
with other individuals having similar chemotherapy. 
c)Gout samples. 
The letter shown in Diagram 12 was sent out to 
the G.Ps in the Torbay Hospital District, relevant O.P. 
clinics and hospital wards. The diagnosis of gout was 
the decision, based on clinical symptoms, of the patient's 
doctor. All specimens received from G. Es were processed 
on arrival at the laboratory and it was assumed that 
they were despatched to Torbay Hospital within the 4 
hours specified above. Our sample includes one case 
of secondary gout. 
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2) Measurement of Ur:i!c Acid. 
It was dec:i!ded to compare several different assays 
for plasma uric acid and from a compurison of the results 
obtained, the method of choice would be selected for 
future analyses. 
Assays were performed with a Technicon Autoanalyser I 
or a Gilford Etasar III spectrophotometer. 
The four methods selec-ted were ( i) Technic on AAI 
phosphotungstate' method_monitored at 664 nm incorporating 
Crowley's modification with the addition of sodium 
carbonate; (Crowley,1964) (ii) an .acid ferric reduction 
of urate with 2,4,6-tripyridyl-s-triazine measured at 
593 nm (Morin, 1974); (iii) absorbance at 293 nm following 
uricase action (Haeckel 1979) and (iv) the Boehringer 
Mannheim Diagnostics Urica-quant enzymic calorimetric 
method involving a linked reaction of uricase with cat-
alase in the presence of methanoi and acetylacetone, 
monitored at 410 nm. Standard calibration curves from 
fixed concentrations of uric acid have been used through-
out the analysis together with suitable 'blank' reac~ions 
in all cases. 
It is appropriate at this stage to consider the 
outcome of these preliminary experiments in order to 
justify our ultimate method of assay. Sera analysed 
for uric acid content by the four methods gave a mean 
value per method as follows:-
Phosphotungstate 
2,4,6-Tripyridyl-s-triazine 
Uricase 
Urica Quant 
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398•8 JlliiOl/1 
285 · 7 pmol/1 
333·3 pmol/1 
327•4 ,umol/1 
C.orrelation diagrams of these results for ab.out 
30 different sera are shown· in figures 3 1 4, and 5 
It is apparent that the phosphotungstate method over-
estimates the uric acid present by inclusion of mise-
ellaneous nonurate reducing agents present in sera. 
Interference by such nonurate reducing agents may 
account for the random error found in the T P T Z method. 
By far the best corre~ation and precision was found 
with U V monitoring following the action of uricase 
and the colorimetric uricase assays. The· colorimetric 
uricase me·thod was adopted as the method of choice 
since it not only correlates closely with the uricase 
differential spectrophotometric method but it can be 
modified for the analysis of smaller aliquots of sera 
(0•2 ml instead of 1 ml) and is more convenient for 
batch analysis. 
Urica-guant method for assay of serum uric s.cid. 
This :assay is ba£ed on the method of Kageyama 
(1971) and involves the following reactions:-
HCHO + 2 acetylacetone + Nn3 -3, 5-diacetyl-1, 4-dihydro-
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Reagents, 
Solution 1 Ammonium phosphate buffer 0··.6 mol/1 pH 7·0, 
methanol 1 •7 mol/1, catalase 700 u/ml:. 
Solution 2 Acetylacetone Q,•42 mol/1, methanol 2·5 mol/1. 
:Standard uric acid. 357 p. mol/1. 
Uricase 5 u/ml in 50% aqueous glycerol, 
Uric acid reagent prepared by adding 5ml solution 2 
to 100ml of solution 1. This reagent is stable for 
1 month when stored at+ 4°. 
Procedure. 
The sample blank is prepared by adding 0•2 ml 
plasma or serum to 2 ml of the uric acid reagent and 
mixed. 1 ml of this solution is added to 10 pl of uricase 
and mixed. The two sol:utions are incubated for 1 hour 
at 37° in the absence of sunlight. The absorbance of 
the sample is meast<red against the sample blank at 
410 nm. A uric acid standard is read against a reagent 
blank in the absence of serum. All assays were at least 
duplicated. 
A sample 
Uric acid content of plasma = 357 . · ------
- -A standard 
where A is absorbance of sample against sample 
sample 
)l mol/1 
blank at 410 nm and A is absorbance of standard 
standard 
against reagent blank at 4'1 0 nm. A reference sera is a:lso 
included in each batch as a routine precaution. 
3) Measurement of Protein content of haemolysates. 
Biure.t reagent. 
Sodium potassium tartrate 14g, cupric sulphate 3g, 
potassium iodide 5g, sodium hydroxide 8g, surfactant in 
1 litre aqueous solution. 
Total protein blank solution. 
Potassium iodide 4 • Og, sodium hyd.roxide 6 • 4g, 
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surfactant in l litre aqueous solution. 
Instrument- Gilford Etaser III with. manual cuvette. 
Method- 1 ml Biuret reagent is added to 20 pl haemolysate 
and allowed to stand for 15 minutes at room temperature 
after mixing. The blank solution is treated similarly 
after the addition of 1 ml of the protein blank solution 
to 20 ~1 of haemolysate. The absorbance of the test 
solution is read at 550 nm against a human pro.tein 
standard solution using the blank reaction. Technicon 
human reference serum diluted to contain 14'4 g/1 is 
used to prepare the standard which is treated as des-
cribed above after the addition of 1 ml of biuret reagent 
to 20 pl of reference serum. 
4) Urate binding to plasma proteins. 
(a) Occlusion at diastolic pressure. 
Haemos.tasis was produced in heal thy ''volunteers" 
by means of a sph~omanometer cuff applied to the upper 
arm and maintained at diastolic pressure for 1:0 minutes. 
Blood samples were obtained after timed intervals by 
vene,::uncture from a canula with a tap. .All samples 
were left to retract at room temperature for 2 hours, 
unless otherwise stated, prior to centrifugation at 
3000 rpm for 10 minutes. The serum was collected and 
either stored at 4° for not more than 6 hours before 
analysis or incubated to 37° prior to assay. ~ - globulins, 
uric acid and T4 estimations were performed manually 
whilst other assays were automated. These methods 
together with the appropriate flow diagra~6 are included 
in the Appendix I. 
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(b) Ultrafiltration 
r>Iembrane ultrafiltration has been used to prepare 
}>rDtein-free filtrates of serum for the assay of free 
uric acid and protein-bound uric acid in the residiU!n, 
5 ml serum was placed in a Centriflo C F 25 cohe 
(preeoak&d in distilled water for 1 hour) inserted in 
a centrifuge tube and spun for 20 minutes at 3.000 r p m 
at room temperature. The uric acid content of the 
filtrate and untreated serum was estimated by the. uricase 
:nethod. All samples were analysed on the day of collection. 
(c) Electrophoresis 
A Shandon electrophoresis tank U77 was used with 
a Vokam power pack, 
Gel buffer: Barbitone 0•07 M, pH 7•6, Prepared by 
dissolving 1 •66g. barbitone and 12•76 sodium diethyl 
barbitone-in distilled water to 1 litre, 
Bridge buffer: Barbitone 0 • 058111, pH 7 • 6.. Prepared by 
diluting 100 ml gel buffer with 20 ml distilled water. 
Cellogel cellulose acetate blocks (0.•25 x 6 x 17 erne) 
were i=ersed in gel buffer for 2 hours prior to 
electrophoresis at 140 volta, 25-30 milliamps for 4i hours 
at room temperature. The gels were subsequently stained 
for uric acid and counter stained for protein. 
The visual detection of uric acid was a modification 
of the method of Haeckel (1976) involving the following 
reactions:-
uricase Uric acid H202 + allantoin 
catalase H202 + ethanol acetaldehyde 
± aldehyde ± 
ace.taldehyde + NAD.t: ~ acetate + NADFH + H dehydrogen se 
NADFH + ~ + NBT _P_M_s _ --::.NKDF + ?orma:<;an 
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The reagent was prepared by reconstituting lyophilized 
reagent obtained from Smith Kline Instruments Ltd with 
a supplied d'ilu.3rit. Each gel was immersed in 20 ml: 
of the reconstittited reagent, containing 150 ul uricase, 
3 mg NBT and 3 mg PMS, for 30 minu·tes.. The fortified 
reagent was used within 10 minutes of preparation. 
The cellulose acetate block wae, cciunterstained .·for 
protein by soaking in 3% aqueous trichloracetic acid 
containing 0 • 2% Ponceau S for 30 minutes. 5% aque·ous 
acetic acid was used to remove exce~s stain and after 
wae,hing, the aellulose acetate was dried between sheets 
of blotting paper. 
d) Column chromatography, 
0•2 ml serum was applied to a 50 x 2 cm diameter 
column packed with Sephadex G200 to separate the serum. into 
molecular size fractions. Fhy.siological saline was 
used· as eluant and 0 • 5 ml fractions were collected 
throughout the elution. The protein content of the 
eluant was monitored continuously by recording the 
absorbance at 280 nm on a LKB Uvicord 254. Each 
fraction was evaporated to dryness in order to 
concentrate the amount of uric acid preEent prior 
The presence of uric acid was measured 
colorimetrically at 664 nm using phosphotungstate 
in the presence of sodium carbonate. 
5) Hyperlipidaemia 
10 ml venepuncture samples were taken from patients 
after a 10 hour period of fasting. No anticoagulant 
was added to the samples which were allowed to retract 
for 1 hour prior to centrifugation at 3000 rpm for 
10 minutes. The serum was separated and kept at 4° 
6 1 
until analysed for cholesterol ,and triglyceride content. 
Abnormal levels o-f either constituent indicated further 
/ 
analysis by lipid electrophoresis and nephelome.try. All 
patients showing a chy~omicron fraction after lipid electro-
phoresis had the rigidity of the_ fasting period queried but 
if a repeat specimen showed the same distribution of lipid 
electrophoretic bands the sample was designated Type I. 
The anal:ytical methods for these investigations, which 
are routine procedure in a clinical laboratory, are 
ou:tlined in the Appendix I. 
All sera showing hyperlipidaemia were segregated 
into their Frederickson type and assayed for their 
uric acid content. The sera from a control group of 
individuals with normal cholesterol and triglyceride 
content following a 10 hour fasting period were also 
investiga,ted for their uric acid content. 
(6)Distribution.of uric acid. 
a) Erythrocytes 
Ion exchange resin: Dowex 2XS (l00-200 mesh) in the 
acetate form using a 2cm x 0•4 cm diameter column. 
Eluant 500 ml M HCl and 500 ml M NaCl 
10 ml fresh venepuncture blood collected in lithium 
heparin was centrifuged at 3000 rpm and the plasma 
and buffy coat removed. The cells were washed twice 
with physiological saline. 1 ml of the packed cells 
were diluted 1:10 with distilled water and haemolysed 
by freeze thawing twice. 0•5 ml of the haemolysate 
was passed through the ion exchange column. The column 
was washed twice with 10 ml distilled water and the 
washings discarded prior to elution with 5 ml of the 
HCl-NaCl eluant. 
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The eluant was. moni:tored at 293 nm in a Ferkin 
Elmer 402 scanning spectrophotometer. r;jany haemolysates 
were examined by this technique which is a modification 
of that used by Carr and Pressman (1962). 
b) Leucocytes 
Stock phosphate buffer pH 7·0 
Na2HP04 
KH2P04 
8 "52g 
5•44g 
made up to 1 litre with H20 
Glucose oxidase/peroxidase so~ution: Fermcozyme 952DM, 
supplied by Hughes and Hughes Ltd. 
Working colciur reagent 
Stock phosphate buffer, pH7•0, 295ml; Fermcozyme 952 DM, 
5ml; sodiWII azide, 300 mg; phenol, 300 mg; 
4-aminophenazone, 100 mg; 
Uric acid standard = 120 pmol/1 
Uricase = 5 u/ml 
Preparation of leucocytes 
Reagent Lomodex 70 (Leuconostoc mesenteroides N.C.T.C) 
obtained from Fisons Ltd. (Dextran "(,0 is a 6% w/v starch 
solution in 0•9% saline. The average molecular weight 
of the dextrans is ;'"<../ 70., 000). 
BTL Intermediate centrifuge (1600 rpm s 600g) 
Method 
2 ml dextran was added to 1'0 ml heparinised plasma, 
gently mixed and the sample allowed to separate into 
two layers at room temperature (approx. 45 minutes). 
The upper layer was separated from the red cells prior 
to centrifugation for 10 minutes at 1:600 rpm. The 
supernatant was discarded, the pellet washed with 4 ml 
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1) 
0·9~ saline and centrifuged at 1600 r.p.m. The supernant 
was discarded and 2 ml water added to the pellet followed 
by 2 ml 1 •8% sodium chloride, Following centrifugation 
at 1600 r.p.m. the supernant was discarded and ~he pellet 
was freeze thawed thrice in isopropanol. The leucocyte 
preparation was diluted with distilled water to cgntain 
12 g/1 protein immediately prior to use. 
1•0 ml of colour reagent and 0·1 ml uricase were 
added to 0•1 ml leucocytes in a test tube. A blank 
and a control tube were also prepared by substituting 
0•1 ml water and 0•1 ml uric acid standard for the 0·1 ml 
leucocyte. The tubes were examined during the course 
of the day and at 48 hours. The experiment was repeated 
but with liquid paraffin covering the ~elution in th• 
three tubes to exclude atmospheric oxidation. ~everal 
leucocyte preparations were examined by this technique, 
En zymology 
a) FRJ·P eynthetase 
The assay involves the measurement of AI•!F production 
and is essentially a modif.ication of that reported by 
Valentine and Kurschner (1972) which uses the following 
linked indicator system:-
R- 5-P + ATP :PRPP synthetase 
AMP + ATP adenylic kinase(AK). 
Pyruvic kinase(?K) PEl' + ADP 
FRFF + Al\lF 
2ADF 
pyruvate + ATP 
pyruvate + NADH + ~ lactic dehydrogenaee(LDH) + lactate + NAD 
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Buff'er Stock solutions Na2 HP042H20 16•02 g/l Solution A 
~2·25 g/l ~elution B 
iiorking solution 276 ml.3..;olution A and 24 ml S'olution B 
yield a buffer 90 mM phosphate which is 
routinely checked for pH 7 • 88 s-olution C. 
Stock reagent • rvlgCl2 81 :3 mg; KF 38·6 mg; PEP (mono-
cy.clohexyl ammonium salts) 1'06 • 9 mg; 
ATP (disodium salt) 161 mg contained in 
150 ml phosphate buffer C. The pH, 7•4,is 
checked before use. Eolution is stabl_e 
for 1• week at 4°. 
Working reagent :NADH 13•2 mg, AK 200 pl, PK 80 ~l, 
LDH 60 fl are added to 60 ml of stock 
reagent and the volume is .. :nade. up to 
80 ml with water. This solution is stable 
for 4 hours at room temperature. 
R-5-P (disodiuin salt) stock solution. 19 mg R-5-P per ml 
water. 0 Etable for 1 week at 4 • 
(i) Assay of enzymic activity. 
2 ml working reagent and 200 pl haemolysate are 
added to a test and blank cuvette and incubated at 37° 
for 30 minutes. The reaction is ~nitiated by addition 
of 20 ~l of stock R-5-P to the test cuvette and 20 pl 
water to the blank. The change in absorbance at 340 nm 
at 37° is meacured at 5 minute intervals for 30 minutes 
on a MSE Vitatron or monitored continuouslY on a Gilford 
3500 rate analyser linked to a recorder. The final 
concentration in m mol/l of reagents in the assay cuvette 
are l'llgCl2 1·8; ATP 1 "2, PEP 1•8, KF 3•0, NADH 0•21, 
R-5-P 0•60 in 61 ~Yt phosphate buffer pH 7·4. 
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Calculations for PRPP •ynthetase. 
Molar extinction NADH = 6220 
Enzymic activity as f mol/mg/ml protein/hr 
= ~·A X 2•22 X 106 
2 X 6220 X 0•2 
= 892' 3 A A 
where ~ A = change in absorbance/hour 
The effect of variation in concentr•tion of the 
substrates, magnesium and phosphate was studied by 
preparing the reagents at the above concentrations but 
omitting the substance being inves.tigated. Varying 
amounts of the later were then diluted and the effect 
on enzymic activity at each concentration measured. 
({i)Yariation of R-5-P 
Stock solution of R-5-P: 274 mg R-5-P was dissolved 
in 5 ml aqueous solution (200 mmol/1) 
A range of concentrations of R-5-P from 0•002 
to 2•0 mmol/1 was prepared in water and 20·rll aliquots 
added to a series of reaction cuvettes pre.pared as 
indicated above. The assay was monitored on a 1\tSE 
Vitatron and were at least duplicated. 
(iii) Effec·t of ~H 
The pH of the buffer s.olution was varied by 
altering the relative amounts of phoephate solutions 
A and B. A pH greater than 8 could not be obtained 
since complex magnesium phosphates are precipitated 
on addition of the standard reagents. A range of pH 
values from 6'0 to 8•0 was studied using the procedure 
for the usual assay. 
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(iv) i'lagnesium concen:tration .c.urve. 
A Gilford 3500 enzyme rate analyser was progra.mmed 
for a preincubation time of zero, an incubation time 
o:f 3 minutes and a read time of 2G seconds to study 
the variation of magnesium concentration at constant 
R-5-P (0 ··60 mmol/l) and' ATF ( 1 • 2 mmol/l) concentrations. 
This instrument was used for these investigations to 
enable a. result to be obtained. before the reagents complex 
to form an ammonium magnesium phosphide· precipitate. 
Double strength reagents·, containing no magnesium, 
and a sui ta.ole dilu·tion of magnesium were placed on 
the two dispenser towers of the instrument. This 
procedure was repeated for various. concentrations of 
magnesium and the ratio Mg2 +: ATP in the final reaction 
mixture were 1 ·OO, 1•33, 3'33 and 13•33. 
(v) ATP concentration curve. 
Stock solution of disodium ATF 
110 mmol/1 solution was prepared by dissolving 
121 •04 mg disodium ATI in 20 ml a<±ueous solution. 
Other reagents, except for R-5-P and ATF were 
prepared in 4/3 times the 6oncentration used for assay 
of PRPP synthetase. 0.5 ml aliquots of the different 
concentrations of ATP were adcied to 1·5 ml of the working 
reagents in a ceries of cuvettes. A blank cuvette 
contained 0•5 ml water and 1•5 ml of the reagents. 
The reaction was initiated after incubation for 
t hr. at 37° by addition of 20 pl R-5-F to all cuvettes. 
An additional cuvette was set up using the standard 
water. The reaction was monitored at 340 nm at 37° using 
a li1SE Vitatron. 
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(vi) Variation in phosphate-conc~ntration 
This experiment .was designed to vary the phosphate 
concentration but maintaining the buffer capacity of the 
reaction. This was achieved by preparing stock Tris/HCl 
a.Iid phosphate buffers at90 mM, pH 7"4 
Tri:=. buffer 
Stock solution 
'liorking buffer 
43. 61:g Tris made up to 1 litre with 
water (360 mM) 
50 ml stock Tris buffer and 144 ml 
0·1 M HCl diluted to 200 :nl with 
water (90 mM, pH 7•4) 
Phosphate buffer prepared as for the assay of total 
enzymic activity. The reagents were prepared in both 
Tris/HCl (solution X) and phosphate buffer (solution Y), 
the pH of both solutions were adjusted to 7•4. Four 
working solutions of the reagents containing varying 
amounts of phosphate, were prepared from appropriate 
mixtures of solutions X and Y as shown in the following 
Table 9 • 
Table. 9 Phosphate content of reaction mixture. 
Phosphate content colution x(ml) Solution Y (ml) 
None 30 0 
1 m!' I[ 29•5 0·5 
20mM 2 01 9·9 
60tru'll 0 30 
Haemolysates were prepared in water from freshly collected 
heparinised blood samples. 
Conditione and procedure of assay for enzymic activity 
were identical with those used for total FRFP synthetase 
activity, 
68 
( vii) lnhi.bition stud'ies 
The working reagent solution is. prepared at 4/3 times 
the concentration for all reagents cited for the assay of 
PRPP synthetase. The following procedure i·s used for all 
inhibition studies, only the nature and concentration of 
the inhibitor are varied. 
200 J-ll of haemolyeate is added to 2 test and 1 blank 
cuvettes containing 1 • 5 ml o-f working ·reagent. 500 J-11 of 
inhibitor is added to one of the cuvettes and 500 p.l of 
water i·s a.dded to the o.ther two cuvettes. The solutions 
·0 
are incubated at 37 , 20 pl R-5-P is added to the 2 test 
.cuvettes and 20 p.l water is added to the blank cuvette. 
The progress of the 2 reactions, one inhibited and the 
other uninhibited· is moni.tored for 30 minutes at 340 nm 
at 37° against the blank reaction. 
Calculation 
% Inhibition - A A x 100 
-( uninhibited- inhibited) 
Auninhibited 
Where A 'nh'b't d is absorbance of uninhibited reaction 
.un~ ~ ~ e 
after blank correction A.nh'b't· d is absorbance of inhibited 
- ~ ~ ~ e ' 
reaction after blank correction during a fixed time interval 
(say 20 minutes) provided that all reactions are linear. 
The inhibitors studied and the range of concentration 
investigated are given in Table 10 • or using fixed 
concentration Table 11 
b) Glutathione Reductase .• 
In the presence of NADH or NADPH, the flavin en~yme 
glutathione reductase catalyses the reduction of oxidised 
glutathione (GSSG) to reduced glutathione (GSH) 
G;;:SG + NADH + H+ Glutathione reductase 2GSH + NAD+ 
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( c) 
Buffer ctock solution A) o·· 2M Na2HP04 2H20 35 • 61 g/1 
B) 0'• 2M Na H2P04 2H20 31 • 21 g/1 
·:iorking buffer solution 
C) 32 ml A, 68 ml B and 2•92 mg EDTA. 
Reagent: To 40 ml buffer C) add 6•6 mg NADH 
2tock G2SG 139•7 mg GSSG in 2 ml water (114 mmol/1) 
i<lethod: 200 pl haemolysate or plasma is added to 
each of two cuvettes containing 1·8 ml working reagent 
and incubated for lO minutes at 37? 20 pl subs.trate 
(stock GESG) is added to one cuvette and 20 pl water 
added to bxank. The change in absorbance of the 
substrate against the blank is monitored at 340 nm for 
10 minutes at 2 minute intervals using an MEE Vitatron. 
Reaction strength of reagents G~SH = 1•13 mmol/1 
NADH = 0•23 mmol/1 
Calculations for Glutathione reductase. 
Molar extinction coefficient for NADH = 6220 
~nzymic activity as f .mol/mg/ml protein/hr 
=AA x 2 · 02 x 1 o6 
0•2 X 6220 
= 1 623 '8 .t:l A 
whereAA =change in absorbance/hr 
For Plasma 
Enzymic activity= AA x 1623'8 p mol/ml/hr 
Adenosine Deaminase 
i::erum adenoeine deamina~:;e is assayed by using an 
indophenol reaction to monitor the ammonia liberated. 
(Martinek 1963). 
ADA Adenoeine ----+Inosine + Ammonia 
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Buffered substrata: 
are dissolved in. 50 ml preboiled distilled water. 18 mg 
adenosine are then added and the volume made up to 100 ml 
using the same water. The pH, 7•05, is checked. Reagent 
is s.table for 3 months at 4°. 
Phenol colour ree.gent: 5•4 ml liquified phenol and 25 mg 
sodium nitroferricyanide were dissolved in 500 ml distilled 
wat.er. This solution is stable for 3 months at 4°. 
·Alkaline hypochlorite reagent: 62"5 ml M NaOH and 4•2 ml 
sodium hypochlorite (5%) were made up to 500 ml with 
distilled water. . ·o Reagent stable for 1 year at 4 • 
Nitrogen standard 
Stock solu.tion: 353 • 9 mg anhydrous ammonium sulphate 
made up to 250 ml in distilled water. 1 ml of this 
solution contains 0•3 mg of nitrogen. 
~orking solution: The stock solution was diluted 1 in 5 
so that 1 ml of this solution contains 60 pg nitrogen. 
Method. 
A blank and test cuvette containing 0•5 ml buffered 
substrata are incubated at 37° for 5 minutes prior to 
the addition of 50 rlof unhaemolysed serum or plasma 
to the test cuvette. The cuve.ttes are stoppered and 
mixed prior to incubation at 37° for 1 hour. 2•5 ml 
phenol colour reagent is added to both cuvettes. This 
reagent stops the reaction. 50 ?1 of the serum is 
added to the blank cuvette and 2•5 ml of the al~aline 
hypochlorite reagent added to both tubes. Each cuvette 
is mixed and incubated for 15 minutes at 37° for colour 
development. The colour is stable for 20 minutes. 
The absorbance of the test is read at 640 nm on a Gilford 
~tasar III spectrophotometer ag·ainst the reagent blank 
adjueted to 1CO% transmittance. 
7 I 
d) 
A calibration curve ic prepared by substituting 50 pl 
of standard solutions o-f differing· ni troge·n content for 
50 pl serum in the usual assay procedure. A graph, 
which is checked at regular intervals, relates the 
units of ADA ac,tivi,ty to absorbance. One unit of ADA 
activity is the amount that wili liberate 1 pg of 
ammonium nitrogen per ml of serum or plasma per hour ai; 
nypoxanthine-guanine phosphoribosyl transferase. 
This analysis measures GTP production and is 
essentially the continuous spectr-ophotometric assay 
reported by Giacomello and Salerno (1977) which uses 
the follo~ing linked reactions 
Guanine + PRPP 
GMP + ATP 
ADP + GDP +2PEP 
2 .pyruvate + 2NADH + 2H+ 
HGI'RT Gfi!F + FFi 
_ _:G;.;;K;;._~ ADP + G DP 
FK ATP + GTP + 2 pyruvate 
Mg++,K+ 
LDH + 2 lactate + 2NAD 
:auffer Tris/HCl, 0•05 M, pH 7•5 consisting of 25 ml 
0•2 M Tris and 40 ml 0•1 M HCl made up to 100 ml with 
water. 
Stock reagent. 
ATP (disodium salt) 36•3 mg, FEF (monocyclohexyl-
ammonium salt) 46'5 mg, Hg804 '7H20 985•9 mg and KCl 
969'2 mg made up to 1CO ml with Tris HCl buffer. 
~tock guanine solution. 
17•8 mg guanine made up to 50 ml with distilled 
water containing 1 ml 0·1 H NaOH. 
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and Gel Bond electrophoresis film from Marine Colloids Ltd. 
Other reagents and enzymes obtained from BDH Ltd or 
Boehringer Corporation Ltd. 
~handon Vokam power pack. 
Hoeoecht electrophoresis tank with cooling plates. 
Stock bridge and gel buffer. 
Eodium barbitone 20·6g, barbitone 3•7g, Calcium lactate 
0'5g made up to 1 litre with water. 
Working bridge and gel buffer. 
The £tock buffer is diluted 1 in 2. This gives a working 
buffer of ionic strength 0·05, pH 8•6 
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Preparation of gel. 
l~~ (w/v) ~garo&e was prepared in the buffer. The .solution 
was magne,tically stirred· and' heated .to the boil to 
clarify it. 30 ml aliquots can be stored a:t 4° for 
4 days. 
The gel was cast by placing a sheet of Gel Bond 
film (114x225 mm) with the hydrophilic side uppermost 
onto a wet.ted g·lass plate of the same dimension. Excess 
water was squeezed from under the film and a gel casting 
frame placed ov:er the film and clamped into position 
with spring cli~s. 
The film and casting frame were placed on a levelling 
table and prewarm~d with a hair dryer before the agarose 
was poured. \vhen the gel had set a scafpel was run 
around the edge of the casting frame prior to its removal. 
The agarose plates were then kept at 4° for 1 hour 
before use. 
Sample application. 
5 pl 6f sample was applied to precut wells. 
Ru.nning conditions, 
All gels were run at constant current of 80 mA 
for 1i hours and cooled to 10°, 
(II) Agarose lsoelectrofocusing. 
Agarose IEF and ampholines obtained from Fharmacia 
Fine Chemicals. 
Other reagents from BDH. 
LAB 21·03 High voltage power supply. 
LKB 2117 iiiultiphor electrophoresis tank. 
Gel composition. 
Agarose (IEF) 0•3g; ~orbital 3.•6g, distilled water 
21·0 ml. and ampholine (range 3·5-9·5) 1·9 ml. 
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Gel preparation. 
The agarose arid .sorbitol were d·issolved in water, 
heate~ wiih magnetic stirring until a c.lear solution 
was obtained. The solution was cooled' to 600, the 
ampholine added. and, after mixing, the sclution was 
poured onto a Gel Bond film .Prewarmed and prer.ared as 
outlined for ~garose electrophoresis. 
El~ctrode solutions. 
Cathode Il\1 NaOH 
Anode 
Sample application, 
Samples were obtained from -che deep frozen stock 
of haemolysates. After thawing, 2 mercar-toethanol was 
added. to give a final concentration of 20 mmol/1. 
20 pl samples applied to gels on filter paper applicators 
which are removed after 45 minutes. 
Running conditions. 
The constant power s~pply ~as set to deliver a 
maximum of 1 5"rl at 1 500 V. The gels were run for 1t hours. 
( .. ·.)Staining methods. ~~~ 
a) FRPF synthetase isoeri~ymes. 
This method is .based on the Switzer (1968) assay 
for enzymic activity. It is essentially the reverse 
of the reaction used for assay in the current study. 
Switzer's method has been modified to include an ATF 
regenerating stage in an attempt to intensify the 
staining reaction. (Lebo and ~artin 1977). 
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FRPP X AMP 
R- 5-1- ATP 
Glucose 
kinase 
FEF -
ADP Gl!f-7~-~DPYDiaphorasyNBT 
6-p~osphoglucona~NADFH ~Diaphorase~ 
' Formazan 
Stain preparation. 
~orensen's phosphate buffer pH 7•4, 60 mM containing 
2 mmol/l magnesium chloride and 2 mmol/l EDTA. 
D glucose 1 ·8 mg, disodium PRPP 4•7 mg. AMP 7·0 mg, 
NADP+ 3•3 mg, G-6-PD/HK in glycerol100pl (180 u/ml/100 u/ml) 
PK 10 p.l, diaphorase 20 p.l (1050 u/ml), NET 3 mg 
made up to 10 _ml with buffer. 
Stain application. 
10 ml stain reagent was added to 10 ml of 2% Oxoid 
ion agar in water at 60°. The agar was, poured quickly 
and evenly as an overlay to the film following electro-
phoresis. The film was incubated for 2 hours in the 
0 dark at 37 for the colour reaction development. 
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b) Glutathione reducta~e isoenzymes. 
A modified method of Long's· (1'967) two stage method 
employing a reverse form agar staining technique has 
been developed. 
GSSG + NADH + H+ + NBT + Methylene blue 
(Blue formazan complex) 
2 GSH + NADP+ (oxidized formazan complex) 
Stain buffer 
Phosphate 100 mM pH 7·4 
Stock buffer solutions 200 mM 
Na2HF042H20 35•61g/l 
NaH2F042H20 31 •21g/l 
Working buffer solution 
Stock Na2HP042H20 
Stock NaH2P042H20 
EDTA 
KCl 
81·0 ml 
1 9 • 0 ml. 
175 mg 
11 mg 
made up to 200 ml with distilled water. 
Staining solution. 
NADPH 6mg, GSSG 15mg, NBT 9mg, 0·5% methylene blue 
200 pl made up to 10 ml with stain buffer. 
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Stain application 
The stain was applied ae an overlay to the electro~ 
phoresed film after mixing iO ml of 2% Oxoid ion agar 
in water at 60° wi1;h tO m1. staining solution. The over-
1 "d l f"l · b t d · the d·ark at 37° for a~ ge ~ m was ~ncu a e ~n 
reaction deve~opment. 
No mercaptoethanol was. added to the haemolysates .• 
No plasma was investigated. 
c.) Adenosine deanlinase isoenzymes 
The staining technique was a modification of that 
used by ~pencer et al (1968). Diaphorase was used as 
hydrogen carrier instead of phenazine methasulphate. 
Adenosine 
ADA. 
Inosine 
+ phosrhate 
NP or arsenate 
Hy:r;;oxan.thine 
XOD 
N!.T 
Diar:horaEe 
Formazan 
Xa:nt!tine 
Standard haemolysate preparations were used with the 
addition of 2-mercaptoethanol at a final concentrabion 
of 20 rnmol/1. 
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Stain buffe-r 
::C:tock solution toluti·on A 0'2M, Na2HP042H20, 35. 6,1,g/l 
Soluti'on B 0•2M, NaH2P04 2H20, 31 •21!g/1 
Working solution 84 ml solution A and 16 ml solution B 
made up to 400 ml with distilled water_ (50 mM phosphate 
Reaction stain 
Adeno_sine 8 mg, NET 2 mg, Xanthine oxidase 10 ).11 (4u/m1) 
nucleoside phosph.orylase 20 pl (20 u/ml), diaphorase 
20 pl (1050 u/ml) made up to 10 ml with phosphate buffer 
50 mM, pH 7'5· 
~tain application 
By the overlay technique using a mixture of 10 ml 
stain solution and 10 ml 2% ion agar in water at 60°. 
The overlaid gel was incubated at 37° in the dark for 
the colour reaction to develope. 
(d) HGFRT isoenzymes 
The staining method dev&loped was based on the 
assay used by Giacomello and Sal&rno (1977) using a 
reversed formazan staining technique as follows:-
Buffer 
Stock solutions Solution A, 0•2M Tris, 24'23 g/1 
Solution B, 0 •1 M HCl 
Working solution 25 ml solution A and 40 ml of 
solution B made up to 100 ml with 
H20, 0•05 M Tris/HCl, pH 7•5 
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Reagents. 
Stock guanine ,r7 •iS mg guanine were dissolved in 
50 ml water containing l ml of 10M NaOH, 
St.ock stain reagent. Disodi~ ATP 38• 3 mg, PEF 
-(DionocyclohexY;l ammonium salt) 46•5 mg, MgS04 985•9 mg·, 
KCl 969'• 2mg. made up to 1 00 ml with buffer. 
\~orking etcdn reagent. Monosodium PRPF 6 · 7 mg, 
NADH l• ~14 mg, st.ock guanine 850 ,uJ.., PK 1• 6pJ..,, LDH 8 pl, 
0. 5% methylene blue 200 p+' diaphorase 20 pl ( 1:050 u/ ml) 
made up to· 10 ml with stock reagent arid prepared 
immediately before use. 
Stain application. 
ro uil working stain mixed Id th 10 ml of 2% Oxoid 
ion agar in water at 60° and poured as an overlay onto 
the gel following electrophoresi~. The overlaid strip 
was incubated at 37° in the dark for two hours for 
colour development. 
9) Column Chromatography. 
Khym (1974) has achieved group separation of 
ribonucleotides, ribonucleosides, puriries and pyrimidine 
bases on Bio-Gel F~2 ~esh 200-400, using borate buffer 
pH 8• ? as eluant.. In the .current study, this eluant 
did nOt give consistant elution profiles and physiological 
saline gave better resolution of the absorbance peaks 
monitored at 290 nm. 
Bio Gel F-2, mesh 200-400 (Bio Rad Laboratories Ltd) 
was washed with 0•9% saline and applied as a slurry to a 
column ( 30 cm x 1 cm diameter). The .packed gel was 
washed with 0•9% saline until zero absorbance was record-
ed on a LKB Uvicord at 290 nm. 
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Serum and urine samples were filtered through 
Amicon Centriflo cones at 2000 r p m for fifteen minutes. 
0•5 mJ. of the filtered serum or urine was applied to 
the column and eluted with 0•9% saline at a flow rate 
of 0·6 ml/min d'elivered from ·a Technicon proportioning 
pump. The eluant was monitored continuously on a LKB 
Uvicord at 290 nm. The column was washed with 0•9% 
saline after each application to zero absorbance at 290 nm. 
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REBULTS 
Urate binding to plasma proteins, 
1) Occlusion .at diastolic pressure. 
The analyses of the blood samples obtained from 
these experiments .are summarised in Table'] 2. The 
percentage changes in several serum components 
together with those of Christianseri et al 1 975, are.· 
given in Table 13 .• 
2) Ultrafiltration 
3) 
The uric acid content of serum and the filtrate 
following filtration with Centriflo membrane cones 
are presented in Table 14 ; 
Electrophoresis 
One blue staining band was observed in all sera 
and this band had the same mobility as the laboratory 
standard containing uric acid. Sounterstaining 
of the cellulose acetate strips with ?oncegu S 
for the location of serum protein bands indicated 
that the uric acid. migrated towards the anode 
faster than the pre-albumin bands. 
4) Gel Filtration 
The elution profile for protein content, ~s monitor-
ed at 280 run and uric acid con'tent of each· fraction 
collected after gel filtration with 3ephadex G 200 
is shown in Figure 6 
Hyperlipidaemia 
Figure 7 ohows the diE.tribution curves for plasma 
uric acid values in a population of healthy individ-
uals c.nci in individuals found to have Type IV hyper-
lipidaemia. 
Figure 8 shows the distribution curves for plasma 
uric acid content in the same healthy controls and in 
82 
individuals found to have Ty-pe IIb hyperlipidaemia. 
The mean plasma uric acid content of the healthy group 
is 31 7 }J. moles/1 whilst that for the Fredrickson type IV 
group is 433 }J. moles/l and 400 p. moles/l for the Type 
IIb group. 
Distribution of urates. 
1) Erythrocytes 
No absorbance peak at 293 nm was observed following 
the elution of the h~emolysate from the Dowex 
ion exchange resin. Similar treatment of a serum 
resulted in an· absorbance peak at 293 nm. The 
addition of uricase to the fractions showing 
absorbance at 293 nm caused a marked decrease in 
absorbance at this wavelength. 
2) Leuc·ocytes 
No colour development is seen in the test or 
blank tubes whereas a red colour dev:elopes in the 
standard tube after 2 hours at room temperature. 
Re-examination of the tubes after 24 hours shows 
that a red colour has developed in the reaction 
tube whereas only a faint colour is apparent in 
the blank tube. The intensity of colour increases 
appreciably in the tube after 48 hours at room 
temperature but no apparent increase occurs in the 
blank reaction. 
The exclusion of air from the surface of each 
tube by a covering of liquid paraffin produces 
identical observations to those recorded above. 
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Serum uric acid content 
The serum uric acid content (mean and_ SD) for 
141 individuals divided into their three clinical 
groups is given in Tab!Le 15 • The data has been fur-
ther analysed by segregation into male and female 
populati~ns and the corresponding results are included 
in the same Table. 
Enzymology 
PRPF synthetase in erythrocytes 
)1 Enzymi6 activity 
Histograms and .confidence intervals of enzymic 
e.ctivi ties for normal., .gou:ty and hyperuricaemic 
individuals are shown in Fig. 9 The enzymic· 
activities (mean and SD) for 141 individuals divided 
irito the three clinical groups-studied is giveri in 
Table 1 6 The data has been further analy.sed 
by segregation into ma~e and female and the mean 
enzymic activity and SD for the various groups is 
also included in Table 16 
2) Kinetics 
a) Effect of varying concentration of R-5~P 
R-5-P profiles were obtained for erythrocyte PRPF 
synthetase in six individuals (2 controls, 3 go~t 
patients and 1 patient with hyperuricaemia). All 
curves were very similar and Fig. 10 shows the 
profiles obtained for i) a control subject and 
ii) a patient with tophaceous gout. Lineweaver 
Burke plots for the same two individuals is shown 
in Fig. 1 1 All the data was examined statistically 
and regression equations were derived from the 
Lineweaver Burke plots for each individual. Thi~ 
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=-- ··:· data is given in Table 1 7 • Michaelis constants 
and maximum velocities have been calculated from 
all such plots and this data is shown in Table 18 
b) Effect of varying the concentration of .magnesiu~ 
c) 
Fig. 12 a shows the effect on the enzymic activity 
of varying magnesium ion concentration, at a fixed 
concentration of ATP (1•33mmol/l). The Lineweaver 
Burke plot for these investigations is given in 
Fig • 1 2 b. This data indicates a Michaelis constant 
of 7• Ox1 o-:-4 with a maximum velocity of ~<092 umol/ ml-/hr 
(Table 18). 
Effect of varying the concentration of ATP 
The effeGt of variation of ATP concentration on the 
enzymic activity, at a fixed concentration of 
magnesium, is shown in Fig. 1 3 for the haemolysates 
of four individuals investigated. The corresponding 
Michaelis constants and maximum velocity's, calculated 
from Lineweaver Burke plots are given in Table 18 
d) Effect of vary-ing the concentration of Fhosphate 
The change in enzymic activity with change in 
phosphate concentration for three haemo'lysates 
is shown in Table 1 9 
e) Effect of pH 
The effect of varying the pH of the medium cin 
erythrocyte PRPF synthetase activity is shown in 
Fig. 14 
3) Inhibitors 
a) Alcohols 
i) Ethyl alcohol 
The mean percentage inhibition of PRFF synthetase 
using varying Concentrations of ethyl alcohol in 
25 individuals with their distribution amongst 
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the three clinical. groups is shown in Tab!1e 2:0, •. 
The average inhfbition profile of the enzyme with 
ethyl alcohol: is given in Fig. 15 Two types· 
of profile were .observed' amongst the 25 individuals 
and these differing curves are shown in Fig. 16 a 
and b. The population of 25 were divided 
according to their ethyl alcohol profiles and the 
mean inhibition· of the enzyme for each alcohol 
concentration is shown in Table 21 
ii) Methyl a~cohol 
The inhibition prof-ile for varying concentration 
of methyl alcohol is presented in Fig. 17 
No variation in profi!1e ·was .obtained from individuals 
from the three clinical groups. 
iii) Propanol 
The range of propanol used for inhibition 
studies was restricted by the fact that the blank 
reaction was more sensitive to increasing concentrations 
of this alcohol than PRPP synthetase. At a 
concentration of 4·5% propanol only 6% inhibition 
was observed~ Some activation occured at lower 
concentrations of alcohol but these were of in-
sufficient magnitude to establish the confidence 
to extend the studies beyond an exploratory 2 or 3 
samples from haemolysates of each of the three 
clinica~ groups. 
iv) Butanol 
The mean percentage inhibition of FRFF 
synthetase from 3 normal, 2 gouty and 1 hyper-
uricaemia haemolysates is shown in Table 2 2 . 
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b) 2.3 Diphosphog~ycerate 
The inhibition profiles of a) a control and 
b) a tophaceous gout haemolysate for FRPP synthetase 
using varying concentrations of DPG are shown in 
Fig, I 8 The .percentage inhibition of the 
enzyme by 5•4 mmol/l DFG in the haemolysates from 
11 individuals is given in Table 23 
c) Nicotinamide 
The inhibition profile of the mean percentage 
inhibition obtained for PRPP synthetase in the 
haemolysates from 1,4 individuals ( 5 controls; 
7 gouts and 2 hyperuricaemics) using a range of 
concentration of nicotinamide is Rhown in Fig. 19 and Tri.ble.24 
d) Nicotinic Acid 
Similar shaped inhibition profiles were ob-
tained for nicotinic acid ·and nicotinamide .• 
e) 2-Mercaptoethanol 
At a fixed concentration of 25 mmol/l this 
inhibitor produced a large range of effect from 
58~h activation to 29~ inhibition for PRPF synthetase 
in 30 different haemolysates. This distribution 
of activation or inhibition is chown in Fig, 2 0 a 
If the data is divided into three subgroups so that 
the first group is characterised by an inhibition 
) 10, the third group is characterised by an 
activation > 10 then the second group will 
consist of individuals showing an activation < 
or an inhibition ( 10, The distribution of 
the three clinical classes amongst these subgroups 
is shown in Fig, 2 0 b Averaging tne figures 
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algebraically gi:ires an overall activ:ation for 
normals = 4"7., for gouty patients , 2•8 and' for 
hyperuricaemia individuals 5•1 but the differences 
are not significant. 
f) Dithiothreitol 
A similar effect to 2-mercaptoethanol was obtained 
but fewer individuals were investigated. Again a 
large spectrum of resul.ts were observed with values 
from 37% inhibition of l'RPF synthetase to 52% 
activation. 
g) Histidine 
The inhibition profile for PRFP synthetase usin·g a 
range of concentrations of'histidine is Ehown in 
Fig. 2 1 The effect of using a fixed concentration 
of 22•5 mmol/1 histidine in many samples showed only 
experimental variation in percentage inhibition 
obtained. No difference was observed between the 
inhibitive characteristics of the enzyme from 
gouty and normal individuals. 
h.) Uric acid 
No inhibition of PRPF synthetase was observed in 
many haemolysates using 1•1dl mmol/1 uric acid. 
This concentratioh was the limit of solubility 
of uric. acid It is possible to prepare metastable 
solutions of higher uric acid content but these 
were unsuitable for our use. 
j) Formaldehyde 
Inhibition profiles for FRPr synthetase from a 
control individual and a patient with tophaceous 
gout with a range of concentretions of formaldehyde 
are ehown in Fig. 2 2 The percentage inhibitions 
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using two fixed concentrations of formaldehyde 
for a number of individuals are sh~n in Table 2 5 
k) Other inhibitors 
No inhibition of l'RPP synthetase was observed. 
using .1.•8 ·mmol/l lithium carbonate. Neither 
tryptophan nor caffeine wer.e found to inhibit 
the enzyme at the concentrations used. So~ubility 
was the determinant. 
4) Electrophoretic studies 
A photograph of a typical agarose gel stained for 
PRPP synthetase following electrophoresis is shown 
in Fig. 2 3 A single band which migrates toward 
the anode, 'slower than haemoglobin, has been observed 
for all samples. 
Glutathione reductase in erythrocytes 
1) Enzymic activity 
The enzi~ic actiyities (mean and SD) for 141 individ-
uals divided into the three clinical groups is shown in 
Table 2 6 The distribution of the activities and 
confidence intervals in the three groups is shown in Fig. 14 
The data has been further analysed by segregation into 
male and female and the mean enzymic act±vity and SD 
for the various groups is also included in Table 26 
2) Electrophor~tic studies 
Fig. 2 5 shows a typical electrophoresis after 
staining for glutathione reductase in several different 
haemolysates. Residial staining was observed on the 
origin. All samples had one band which migrated towards 
the anode just faster than haemoglobin. A few samples 
had an additional slower band which wae located between the 
origin and haemoglobin. This variant did not segregat~ · 
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into a clinical type.· 
Glutathione reductase in plasma 
1) Enzy~ic activity 
The d'istribution of enzymic activities and con-
fidence int.erval of sampl:e13· in each of the clinical 
groups studi-ed· iE. shown in Fig. 2 6 The mean activity 
and SD for 141 individuals, divided into 3 clinical 
groups and subd;i vided according to sex, is given in 
Table 2 '7 
Adenosine deaminase in erythrocytes 
1) E~ec~rophoretic studies 
In the absence of mercaptoethanol a single isoenzyme 
was found running a.xiodic'ally to haemoglobin. Mu~tiple 
staining bands were obtained after the addition· of 
mercaptoethanol (20 mmol/1) and these are shown in Fig. 27 
In some of the samples, 3 ano.dic bands migrating faster 
than haemoglobin were visualised in addition to the 
comparativily slow anodi:c band migrating behind the 
haemoglobin. Several possible polymorphic variants may 
be present but none of the variants were confined to 
one clinical group. 
Adenosine deaminase in serum 
1) Enzymic activity 
Random samples of sera received by the routine 
laboratory were divided into the three clinical groups 
defined in the current study. The uric acid content 
of all Epecimens were checked and the mean serum ADA 
activities found in each group are presented in Table 2 8 
9.0 
Hypoxanthine -guanine phosphori·boeyl transferase in erythrocytes 
1) Enzymic activity 
The haemol:ysates from most cif the gout samples 
and several control samples were assayed for enzymic 
activity. The results obtained are presented in Table 29 
2) E~ectrophoresis 
One or two isoenzymes were visualized in thesamples 
after staining following electrophoresis (Fig 2.8 ) • 
Both bands migrated anodically but at a ·slower rate than 
haemoglobin, The two band pat.tern., although less frequently 
observed than the single band, was not confined to one 
clinical group, 
Column Chromatography 
The elution pattern of serum obtained after elution 
with 0 • 9% saline and moni tared at 290nm is shown in Fig. 2 9. 
The composite results obtained after the elution of 
markers added singly to a sample of pooled sera are 
presented in Fig. 10 Typical elution patterns for 
a hyperuricaemic serum and two sera from an individual 
with gout and another with familial primary gout are 
given in Fig. 3 1 
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Discussion 
The bind·ing of urate to plasma proteins remains 
a provocative topic: and we have invectigated this not 
only by mod•ifications of recognised procedures but also 
by an oc~lusion study, which is a first attempt under 
physiological condi:tions. l!t is known that venous 
stasis induces a dissociation of the protein-bound 
constituents in blood (Dent 1962;. Berry et al 1973., 
Husdan et al 1974). The phenomenon has been attributed to 
a change ih the protein-bound fractions, parallel to 
the change in serum proteins while the free frac·tions are 
assumed to be constant (Berry et al 1973). It can be seen 
from our results in Table IQ that we have no ~vidence from 
our occlusion experiments that uric acid bindin~ is present 
at the time of doing our investigations. Horeover this 
observation is inde~endent of temperature since experiments 
3 and 4 are effectivily the same. Each blood sample was 
0 0 divided - one half was processed at 4 and the other at 37 . 
One must query whether t:.e method of analysis would different-
iate between free and protein-bound uric acid. .h.n enzymic 
calorimetric assay has been used with uricase, catalase 
and 2.cetylacetone. It would have been desirable to 
supplement the analysis with a purely chemical illethod 
fo~ the assay of uric acid. Freliminary ex~eriments 
ue,ing both chemical and enzymic methods of assay had 
indicated no statistical differences but overall the 
enzymic method ga*e consist~ntly more reliable results 
with smaller sample aliquo.ts and was selected as our 
standard assay. The results in Tablel~ do however ~ive 
some indication that the ten minute occlusion has re-
sulted in the release of bound calcium into the serum 
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in all cases and in amounts comparable to those reported 
by Chris~iansen et al (1975). There is an increase in 
¥-globulin which is probably too small to account 
for the increase in plasma protein following occlusion.-
Christiansen et al (1975) report a mean increase in 
globulin of 7%after venous stasis in nine~een epileptic 
patients. They also report increae,es in c:i(. 1 , o<. 2 and 't' 
-globulins which we have not investigated. It may 
be that the apparent increase in all plasma protein 
fractions may be due to the large oligome~ic molecules 
dissociating into smaller units which would indicate 
a higher protein content using the modified Biuret 
analytical procedure outlined in Appendix 1 . 
We can see from Table 1~: that ultrafiltraticn 
using Amicon cones gives less cl~ar cut results ~nd 
in one case there appears to be evidence for appreci~ble 
binding (""'14%). This apparent urate binding wc.s found 
in the serum from a patient wi_th gout and other invest-
igations (e.5. Klinenberg and KipJ:en, 1970 and Alvs·aker 
1968)report that urate binding is less in hyperuricaemia 
individuals than in normal controls. Such a report 
should not. be regarded as definitive since an inspection 
of their resu.lts shows that few individuals have been 
investigated and r:10reover a wide range of values are 
found in controls and the hyperuricaemia group. It 
is felt that the experimental error in our ultrafilt-
rations is considerable in so far as the retained high 
molecular weight complexes are very gelatinous and ic 
is impossible to spin down to a dry mass. Furthermore 
the J:hysical appearance of ~he deposit clearly varies 
from one sample to anotner. Frier to uric acid assay 
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the volume of the filtrate was adjusted' by ad'di tion of 
water, which varied from sample to sample, to 5ml. 
In view of the limitations of the method it was felt 
to be unprofitable to examine more samples. It is 
noteworthy that Farrell et al (1975) found a range of 
0-3% urate binding in heparinised plasma ·from seven 
uraemic patients compared with 7% binding in heparinised 
plasma from one healthy control and 6% binding in citrated 
normal plasma. Further investigations sho~ compare 
the effect of anticoagulants on binding. 
in the current study. 
Sera was used 
Electrophoretic studies have failed to reveal any 
binding to protein although a fast moving uric acid 
fraction was observed. The mobility was greater than 
any of the plasma proteins. The staining technique 
involved uricase, peroxidase and 4-aminophenazone. 
Our results can be interpreted in two ways: either 
the staining techniqu• is specific for onli free uric 
acid or we have no experimental evidence ofo urate bound 
to plasma protein. 
None of our experiments to study urate binding 
to plasma protein are devoid of criticism but the 
integrated picture is indicative of the absence of 
appreciable binding of urate to plasma protein. 
Supportive evidence for this conclusion arises 
from Figure 6 which depicts the results of molecular 
sieving of serum through Sephadex G 200. Fractions 
containing uric acid were located, together with low 
molecular. weight components of serum after the albumin 
and pre-albumin fractions of the eluant, 
The results given in Table 30 give the uric acid 
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conten-;; of sera from fasting individuals segregated 
into groups fo~~owing lipid analysi~ and classification 
according to Fredrickson. It is apparent that the mean 
uric acid level of each group of hyperlipidaemics is 
in the order Type 1 V ) Type 11 b ) Type 11 a ) nor:nal 
control. In other words it is probable that individuals 
with hyperuricaemia will be classified as Fredrickson 
Type 1V hyperlipidaemia. itle can:. see from Appendix I that 
the serum cholesterol level of this· Type 1 V group is 
either normal or slightly increased whereas the tri-
glycerides are modera~ely increased. Type 11b is cla.Es-
ified by greatly increased serum cholesterol and tri-
glycerides. These results suggest that en increased 
serum triglyceride level may be an ancilla~y ~arameter 
in hyperuricaemia whereas the serum cholesterol level 
ito not. CUCh an hypothesis iE> in &C.COrd Id th the WOrk 
of Nishida et al (1975) who reported elevated plasma 
triglycerides and free fatt~ acid levels in 107 gouty 
patients but no significant differences in plasma 
cholesterol end phospholipid levels as compared with 
control subjects. 
It was suggested by Gibson and Grahame (1974) 'llith 
supper~ from Nh:hida et al ( 1975) that an excessive 
intake of alcohol may play an impo~tant role in inducing 
hyperlipidaemia in gout. However Naito and Mackenzie 
(1980) found that neither alcohol intake nor hyperuricaemia 
per se appeared to be the cause of the lipid and lipoprotein 
disorder. These workers selected 30 patients with primary 
gout, rendered asymptomatic by therapy, to examine the 
frequency and type of hyperlipidaemia and compare the 
findings with an age group of controls. It was found 
t}lat ~ype IV and IIb lipoprotein electrophoretic patterns 
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were most prevalent in the gout group and the study 
suggested that there was no evidence of liver or kidney 
dysfunction but diet and possibly d'efective clearance 
of triglycerides may be etiplogical factors associated 
with hyper~ipidaemia in gout. Obesity did appear to be 
a major underlying factor associated with the lipidaemia. 
Blood samples collected from the three groups of 
individuaJ:s investigated in the .present study ·did not 
fulfil the requirements of a 10 hour fasting period 
so that lipoprotein electrophoresis was not practical 
in these samples. However it is apparent from our 
hyperlipidaemia typing together with the observations 
of Naito and Mackenzie (1980) that future work should 
embrace not only patients with uncontrolled gout bu:t 
others having hyperuricaemia without gout. 
There is at present no evidence for the occurence 
of uric acid in red blood cells, but the current study 
has indicated the presence of uric ·acid or its pre-
cursors in leucocytes. It seems improbable that free 
uric acid occurs in the cytoplasm of the leucocyte 
since a colour reaction was not vi~ible immediately 
after additiort of the chromogenic reagents. Twenty-
four hours were required for the colour to be observed 
and one must query whether the colour production could 
be attributed to atmospheric oxygen. Such an hypothesis 
seemed unlikely since the 'blank' reaction showed 
only a faint coloration which, in contrast to the 
leucocyte and standard uric acid tubes, did not intensify 
appreciably after forty eight hours. The possibility 
of atmospheric oxidation was eliminated when identical 
observations were obtained if the surfaces of the 
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solutions in ea·ch tube were covered with a layer ·Of 
liquid paraffin. The colour obeerved may be formed 
by a. reagent other than uric acid but such a concept 
is very improbable since one of the reactions preceding 
the formation of the colour complex is dependent on 
uricase which is specific for uric acid and moreover 
the same type of colour developed, albeit more quickly, 
in the tube containing only uric acid following the 
addition of the chromogen reagents.· Our observations 
do, however, indicate that uric acid is either bound 
in a sack like structure ·such as a lysoeome or is adsorped 
to the cell wall or to proteinous components of the 
leucocytes. If this were true then uric acid could be 
released slowly by degeneration of the cell wali or 
by desorption. It would appear worthwhile to extend 
these investigations by pre,treating the leucocytes with 
lysozyme or a protease to find out whether a colour 
reaction developes quickly after the addition of the 
chromogenic reagents. If, after such treatment, the 
slow colour development persists it would seem likely 
that the precursors to uric acid production ar~ present 
in the leucocyte suspension and are still functioning. 
The selection of the individuals in our gout controls 
was made from the diagnosis of a G.F. or consultant 
who were requeeted to send heparinised blood samples 
from such patients. It is significant that 47/54 patients 
were male. This uneven distribution of the sexes in 
our sample is indicative that more males than females 
are diagnosed clinically as gout in the Torbay area. 
The selection of the control group and hyperuricaemic 
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ibdividuals was essentially identical and therefore the 
distribu-tion of ,;he sexee chould be the same in theee 
two groups. \~ e see frolll. Table 1 5 however that there is 
a higher incidence of hyperuricaemia in males than in 
females. Appendix II represents a crude analysis of 
the serum uric acid levels reported by a routine 
clinical laboratory of all samples assayed during 
the period 1970-1979. Any sample with a uric acid content 
greater than 420)'1 mol/1 is classified as abnormal or 
hyperuricaemic. The results show no significant variation 
in the proportion of hyperuricaemic sample from month 
to month over a six year period. (Fig. 3'2 ) but during 
this period there has been an apparent 10% increase in 
the percentage of hyperuricaemics reported (Table 31 ). 
I'his may be due to our survey containing repeat samples 
from the same individual during the period that the 
hyperuricaemia was being controlled. It would appear 
rather more significant that from 1975 onwards the 
percentage of abbormal or h;y:;::eruricae:nic blood camples 
remains remarkably constant (Table 32 in spite of 
the ever increasing requ.estE for serum uric acid assays 
each year (Fig. 3 3 ) . The samples from January ~976-
April 1978 iriclu~ive have been separated by sex and the 
percentage with hyperuricaemia determined. These results 
are presented in Table 33 and show that the incidence 
of hyperuricaemia in males is almost twice that found 
in females. ~he selection of samples sent to the clinical 
laboratory for s.erum uric acid asoay is certainly not 
sex biased, but these results do provide convincing 
ancillary evidence to the deduction from our current 
study that hyperuricaemia has a higher frequency in males 
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than females. 
It was necessary to select an-assay for FRPP syn~hetase 
which was not only accurate and re.produc:i.ble but adaptible· 
to semi-au,tomation. This was desirable because it was 
planned to screen a statistically valid number of 
samples of our three groups of individuals for PRPP 
synthetase activity and ultimately extend the work 
to the use of enzyme inhibitors with a view to exam-
ining their usefulness as diagnostic aids for the 
condition of clinical gout, Euch a to.ol wo.uld be 
invalua·ble for determining any genetic factor that 
might be .present in our sample of gout patients. 
Many of the currently used assays for PRPF synthetase 
involve a procedure in which the FRFP formed by the 
enzyme is reacted with a radioactively labelled base 
( 14 . ( 14 ) such as 8 C) aden~ne (Beaker et al 1973) or 8 C 
hypoxanthine (Hershko et al 1969) in the presence of 
the appropriate partially purified purine phosphoribosyl 
transferase. The corresponding isotopically labelled 
nucleotide produced is separated by high voltage 
electrophoresis (Fox and KelleY 1971) or paper or thin 
layer chromatography (He:Z.shko et al 1969, Beaker et 
al 1973). These methods are expensive and time consuming. 
( 14 ) . The same objection can be raised when C ATF is used 
as substrate (Fox and Kelley 1971) or ATP-~-32F is used 
for the assay of PRFF synthetase based on enzymic transfer 
of radioactivity from ATF-r-32F to FRPP (Johnson e.t al 
1974). There was no p counter available in the department. 
The assay of AMP production described by Valentine and 
Kurschner (1972) appeared to be most suitable for our 
requirements. Using apparently identical conditions 
to those described by these authors many difficulties 
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were encountered *nd ~eproducibility was abysmal. It 
was subsequently shown that whereas the assay was re-
ported to be performed at pH 8, the buffer capacity 
was quite inadequate to accomodate the reagents. (pH 
lowered from 8 to 6•8). Moreover varying amounts of 
NaOH were required to restore the pH of the ·medium to 8 
depending on which aspect of kinetics·was being invest-
igated. Increacing the buffer strength from 20 ~~ to 
40 mN .still did not maintain the pH at 8 on addition 
of the reagents .(pH lowered to 7•4). It was ultimately 
decided to use a phosphate buffer of 60 mM and to 
maintain the pH of the assay at 7·4 in spite of the 
sub-optimal pH of the reaction (Fig. 14 ), 
There was a reasonable doubt about the validity 
of the method since the linked enzyme system could be 
measuring the endogenous AHF present in the haemolysate 
and not the product of the PRPP synthetase. This 
objection was surmounted by estimating blanks. con-
taining no R-5-P for each haemolysate studied. 
Other methods were tried for the assay of FRPP 
synthetase to check and substantiate our confidence 
in our modified "Valentine" procedure. The same 
linked system of assay had been used by }'errari et al 
(1978) who dialysed all erythrocytes against 8 mM sodium 
phosphate buffer pH 7•4 containing 1 ~1 EDTA and 2mM 
mercaptoethanol for two hours prior to lysis. PRPP 
synthetase was assayed by a two step procedure. First 
the enzymic reaction was terminated by addition of 
perchloric acid, second the reaction producing AI-!P was 
monitored at 340 run by using the following NADH linked 
method. 
1'01 
AMP + ATP __ AK_· -~ 2 ADP 
PK 2 ADP + 2FEP r-tif*K ,. 2 ATF + 2 pyruvate 
± LDH + 2 pyruvate + 2NADH + 2H -----9' 2 lactate + 2 NAD 
Dialysis of the haemol.ysate was not found to be necessary 
but the method.was not suitable for routine assay of a 
large number of samples. ~imil.ar enzylliic activities 
were found in samples assayed by Ferrari and by our 
modified "Valentine" procedures. 
The enzyme was al.so assayed by the reverse reaction 
according to Switze~ (1969) by coupling the action of 
hexokinase and gl.ucose-6-phosphate dehydrogenase. 
PRPP + AMP ;.- R-5-P + ATP 
Glucose + ATP HK~ G-6-P + ADP 
G-6-FD 
G-6-P + NADP+---!:11"~ 6-phosphogl.uconate + NADPH + H+ 
This method was rejected since in al.l. cases l.ess activity 
was observed (,.._50%) of that found using our "Valentine" 
modification. There was additionally a problem of 
reagent precipitation due to the fortifying enzymes 
being present in saturated ammonium sulphate. Precipit-
at ion of magneeoium ammonium phosphate was avoided either 
by dialysing the fortifying enzymes or by using these 
enzymes contained in glycerol. . Our kinetic studies 
using this assay were not onl.y non linear but a wide 
variance of duplicates was observed. The commercial. 
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substrata PRP:P, although expensive and difficult to 
~btain, was often contaminated with inorganic phosphate, 
R-5-P and pyrophosphate .and such impurities would explain 
our unsatisfactory results using this assay. 
Valentine and Kurschner (1972) also assayed PRPP 
synthetase by measurement of FRPP using the following 
linked reactions:-
orotidylic 
5-fluoro orotic acid + PRPP 5-fluoro orotidine-
pyrophosphorylase 5-phosphate 
5 fluoro UMP + co2 
orotidylic 
decarboxylase 
The reaction is followed spectrophotometrically at 295nm 
during the conversion of fluoro orotat~ to fluoro~UMP. 
This is a sensitive assay but the cost and slow deliyery 
of the reagents for the coupled reactions ~liminated 
its usefulness for our purposes. It was moreover an 
unsuitable· method for even semi-automation. All PRPF 
synthetase studies in the current work used our modified 
"Valentine" procedure. Good reproduction was obtained 
using this assay and for nine repeats of the same haemolysate 
the average activity was 45•08 p mols/mg protein/ml (SD=1 ·19). 
The apparent instability of FRFP synthetase has 
been the cause of many established workers in the field 
of purine metabolism neglecting to study possible changes 
in properties in the enzyme caused by pathological 
conditions (Simmonds, private communication). Fox 
and Kelley (1971) report that the human erythrocyte enzyme 
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can be protected at -70 by 1 mM dithiothreitol but the 
enzyme is inactivated by 1 mM mercaptoethanol whilst 
any purification of the enzyme is apparently accompanied 
by inactivation with ~ithiothreitol. Reports by Kornberg 
et al (1955) and Flake (1963) that pigeon liver PRPP 
synthetase requires high levels of reduced .glutathione 
for max:i:mal activity prompted the examination of a number 
of thioils for. their effect on the· erythrocyte enzyme. 
Reduced glutathione and 2 mercaptoethanol at 1 mmol/1 
concentration resulted in marked· denaturation of our 
0 
enzyme preparations during storage ·at -20 • Fox and 
Kelley (1971) al!so report an a;bsolute requirement for 
phosphate which they demonstrated by desalting the 
enzyme with a Sephadex G 100 column equilibrated with 
50 mM Tris chloride pH 7•4. No assayable activity was 
observed under such conditions but it is possible that 
the enzyme is inhibited by 50 mM Tris chloride at pH 7•4. 
Our observations in the current study ehow that the enzyme 
is inactive in Tris buffer in the absence of phosphate 
but the effect of decreasing the amount of Tris and 
increasing the amount of phosphate on the enzymic 
activity is sigmoidal (Fig. 34 ). The presence of 
inorganic phosphate is now accepted as an essential 
requirement for the expression of PRFP Eynthetase activity 
since replacement of inorganic phosphate by dialysis 
of the enzyme against buffers containing either Tris-
HCl or HEPES resulte: in no major loss of enzymic activity 
provided that enzyme assay occurs in the presence of 
inorganic phosphate (Roth et al 1974). Washed, packed 
0 
erythrocytes stored at -20 without addition of protective 
agents retain their enzymic activity for about two weeks 
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whilst crude haemolysates (1:3 haemolysis) have been 
found to have lost half their enzymic activity in 48 hrs. 
at 4°(Yip et al 1978.). No loss of FRPP synthetase 
activity has been· found in the crude haemolysates stored 
with 0·3 mM ATP after 48 hours at 4° (Yip et al 1978), 
No data from these· authors is available for longer 
storage of haemolysates. But the changes in PRPP 
synthetase from normal human erythrocytes upon storage 
have· been investigated by gel filtration on Sephadex 
G 200 (Yip et al 1978), PRPP synthetase from fre~h hormal 
erythrocytes had the majority of its enzymic activity 
eluted in the void volume. Storage for 17 days at -70°, 
although producing only a slight decrease in enzymic 
activity, showed a drastic shift of the PRPP synthetase 
molecular size with the elution of two active components 
(one high and one low molecular weight). After three 
0 
months storage at -70 only trace amounts of the large 
molecule remained· and 40% of the activity ·was lost. 
'flhen haem'olysa tes were stored at 4 °. a rapid decrease 
in the PRPP synthetase activity and molecular size occured. 
The addition of 0•3 mM ATP to the haemolysate during 
storage preserved the ehzymic activity for 48 hours at 
4° but did not prevent the dissociation of the enzyme 
molecule into subunit fractions. In all instances the 
decrease of the larger molecule results in a concomittant 
appearance of the smaller enzyme molecule with decrease in activity 
An overview of the reported storage experiments 
does suggest that the same preparation has been used 
for the assay of enzymic a:ctivi ty of l'RFF E,Ynthetase 
by m~ny workers. If this is true then it is not sur-
prising th&t a decrease in both enzymic activity and 
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moil:ecular weight is observed on storage. Repeated 
freezing and thawing of the same sample produces de-
naturation associated with loss. in acti:vi ty and hybrid-
'" ,. 
ization of enzyme molecules, such as lactMe dehydrogenase, '~<-
presumably by initial dissociation into sub-unite of the 
large enzyme molecule. In this study it was decided to 
store haemolysates of all blood samples in small aliquots, 
any one of which could be used for the day's investigation. 
All haemolysates contained 45mM phosphate and 2 mmol/1 
EDTA. Under these conditions the PRPF synthetase was 
maintained following storage at -20° for six months. 
We did not inv~stigate any changes in molecular character 
as determined by gel filtration. Electrophoretic 
investigations were performed after the addition to 
haemolysates of 2 mercaptoethanol (20 mmol/1) which is 
known to eliminate the storage bands which sometimes 
appear on staining following electrophoresis of old 
samples. No mercaptoethanol was used for the glutathione 
reductase electrophoresis. 
Van Maris et al ( 1 980) have r01easured FRPF and some 
enzymes of purine metabolism in erythrocytes from 43 
young hyperuricaemic males. They report that the mean 
erythrocyte PRPF synthetase activity in their hyper-
uricaemic individuals was slightly but significantly 
(P < 0·01) higher than the means of their control group. 
The latter consisted of only 10 males which is insufficient. 
Meyskens and ~illiams (1971) have assayed the concentration 
and synthesis of PRFP in erythrocytes from normal, 
hyperuricaemic and gouty subjects and found no difference 
in FRPF synthetase activity amongst the 3 groups of 
individuals. Table ·-1 6 summarises the PRPP syn-thetase 
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activities folind in our three groups of individuals. 
]n the case of the gout patients, the increase in SD 
found overall i:eo mainly due to the SD found in female 
patients. In the small number of female gouts investigated, 
the figures are biased by this one individual and if we 
eliminate her from the sample the mean PRFP synthetase 
activity found in gout ~ompared to normals· increases 
by the s~e amount for males or females. Thus it is 
possible to ignore the sex and look at the combined 
figures. These show a significant increase in enzymic 
activity for the gout and hyperuricaemic groups compared 
with the healthy controls.(O.Q01< P< 0·01), Table 16. 
Such an increase i:e :inadequate for the use of PRPP 
synthetase activity in the diagnosis of gout. The 
histograms and confidence limits, Fig. 9, clearly ill-
ustrates these differences in the mean PRPP s;ynthetase 
activities of the three groups We have as yet no 
evidence for a genetic variant of FRFP synthetase 
characterized by high enzymic activity as reported by 
Becker et al (1973). It is however proposed to investigate 
in depth repeat samples from tne female gout patient 
already mentioned and investigate her family if any 
unusual properties of the enzyme emerge. 
Very similar substrate profiles were obtained 
for FRPF synthetase activity when the concentration of 
R-5-F was varied. In all, six profiles were obtained 
and the data used to calculate regression equations from 
the double reciprocal plot of initial velocity against 
variable concentration of R-5-P and fixed A~F (Table 17 ). 
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All substrata profiles appeared· to be hyperbolic and 
this was substantiated by the linear Lineweaver Burke 
plots·, Michaelis constants were calculated and compared 
with values outaihed by other workers using PRPP synthetase 
obtained from different sources{Table 34 ). Our mean 
value for ~-5-P is very similar to the one reported 
by ~ox and Kelley ( 1 972) and. Sperling et al ( 1 973) for 
the erythrocyte enzyme, There is no apparent difference 
in R-5-P profile between individuals classified as normal, 
gouty or hyperuricaemic.. The mutant PRPP synthetase 
found in the erythrocytes of a gouty patient with excessive 
purine production and the normal enzyme did not differ 
in respect to their K~s reported for ribose-5-phosphate 
( Sperling 1 973 and Table 3 4 ) • 
The ATP profile shown in Fig, 13 appears to follow 
a hyperbolic curve with increasing amounts of ATP. But 
at high ATP concentration the curve ceases to be asymp-
totic and starts to dip (Fig. 13 ). It was initially 
believed that this "dip" may be due to the fall in pH 
(7·4-7·2) which occurs ~hen high ATP concentrations 
are used; in other words the buffer capacity of medium 
is insufficient to maintain the pH under these conditions. 
Another explanation would appear to be more apt since 
the fall i·n pH mentioned above is"'- 0·2. An inspection 
of Fig. 14 shows that a drop in pH of this magnitude 
does have an appreciable effect on FRPP synthetase 
activity at pH 7•4• But the true substrata for the 
2-
enzyme in addition to R-5-P is ATP r'lg not ATP and 
at the high values of ATP used, we have insufficient 
Mg2+ present in the medium to form the complex salt. 
It is therefore essential that the design of future 
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experiments must hav:e due regard' to the amountof Mg2+ 
required to convert ATP into the complex ATP Hg2'-
Additionally ATP induces aggregation of the small 
molecular weight erythrocyte PRPP synthetase. Therefore 
the possibility that the dissociation produces an in-
active enzyme molceculle, which appears to be active 
due to the presence of ATF in the assay mixture, cannot 
be compleiely rulced out (Yip et al 1978). 
The activation profile shown in Fig. 12 shows a 
hyperbolic increase in enzymic activity of PRFP synthetase 
with increasing concentrations of magnesium ions. It 
can be calculated that at least 99•8% of the ATP added 
present in the current assay conditions as Mg-ATP2 -was 
(Martell et al 1964, Keech and Barritt 1967). Our data 
shown in Fig. 1 2 clearly indicates that free Hg2+ 
stimulates PRPP synthetase. Such an effect has been 
reported by Murray and lt/ong ( 1 967) in their studies 
of the enzyme isolated from Ehrlich ascites tumour cells. 
In the presence of an excess of Mg 2+ the. initial velocity 
of PRFP synthetase shows hyperbolic responses to increasing 
2-concentrations of both MgATP and R-5-P from sources 
of enzyme as diverse as Ehrlich ascites tumour cells 
(Wong and Murray 1969), human erythrocytes (Fox and 
Kelley 1972, Becker et al 1973) rat liver (Roth et al 1974) 
and Samonella typhimurium (Switzer 1971 ). Although 
the role of magnesium in our investigations can be 
classified as "bound" or "ionic" it is highly probable 
2-that MgATF cannot account for all the bound magnesium. 
In fact the fortifying enzymes are usually supplied in 
saturated solutions of ammonium sulphate and unless the 
ammonium salt is removed by dialysis against a suitable 
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buffer, precipitation .of magnesium ammonium phosphate 
occurs during the assay. Additionally magnesium phosphs.te 
may be precipitated at high phosphate or high magnesium 
concentrations. JV[agnesil.im aiso has ail affinity for 
R-5-P and some workers query whether the magnesium 
R-5-P complex is one of the true substrat.es for FRPP 
synthetase. (Switzer 1·971 c). There is however no 
doubt th·at Mg2 + · t · t f th d · t J.s an ac J.va. or or e enzyme an l. 
ie believed to function by direct ~ction on the enzyme 
by bind'ing at an active site remote from the R-5-P 
active site. The dependence of initial veloaity on 
111gCl2 and ATF concentration may be analysed by comparison 
to various steady state kinetic models for metal ion 
activation (Dixon an~ Webb 1'964). The treatment of such 
data is very complex when the total concentrations of 
substrata and activators are used but also the concentration 
of substrata MgATF2 - and activator cannot be varied 
independently, lt is therefore desirable to perform 
two sets of experiments, one in which the total MgCl2 
is held constant and the total ATP concentration ~aried 
and the other in which the roles are reversed. A set 
of conditions can then be found in whiGh one reactant 
is essentially constant and a profile can be deduced 
for a range of concentrations of the eecond reactant. 
This has not been done in the present study. Due regard 
should be paid to the pH of the react:i:on. It seems 
probable that the complex kinetics encountered in the 
present study could be attributed to the distribution 
of the A'rP among two or more ionic forms (e.g. HgHATF-
and MgATF 2-) at pH 7•4 whereas at pH=8 nearly all the 
ATP is present as MgATF 2 - (O'Sullivan and Ferrin 1964). 
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At the time the current study was started, most 
workers were using buffers at 7•4 and this determimed 
our working conditions. 
Gibson and Switzer (1980) have investigated the 
stereochemistry of the complex r1g ATP2 - substrata 
for PRFP synthetase from S.typhimurium. They report 
that the enzyme sho~s absolute specificity for the 
A( S) enantiomer of adenosine 5-0- (1,-thiot riphosphate). 
The enzyme has similar affinity for ATP and the thio 
derivative which enabled Gibson and ~witzer to propose 
the structure and stereochemical configuration for 
2-the Mg-ATP complex at the active site of PRPP 
synthetase (Fig. 3 5 ) . 
Inorganic phosphate is neither a substrata nor 
a product of FRFP synthetase but Switzer (1969) reports 
that although PRFP synthetase from S. typhimurium has 
an absolute and specific requirement for inorganic 
phosphate the effects of phosphate are complex and 
appear to involve two modes of action : activation 
and inhibition. His kinetic data indicates activation 
of lJRPP synthetase at high phosphate concentration 
but inhibition of the enzyme at low phosphate concentration 
Hershko et al (1 969) have found that the· formation of 
PRPP in human red cells.is characterized by a sigmoid 
inorganic phosphate curve whereas in haemolysates the 
curve becomes hyperbolic. The hyperbolic inorganic 
profile of FRFF synthetase becomes increasingly 
sigmoidal when increasing amounts of ADP are added to 
the reaction (Hershko et al 1968). Atkinson and Fall 
(1967) suggested that the inhibition of the enz;yme by 
ADP acts as a regulatory device of the erythrocyte to 
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obviate excessive expenditure of energy i'nvolved in 
the formation of PRPP and its subsequent utilisation 
in the biosynthesis of nucleotides.. Flake ( l963) 
has suggested that the essential requirement of FRPP 
synthetase fo~ indrganic phosphate may be ascribed to 
its stabilising effect on :FRPI- by prevention of the 
metal catalysed decomposition of IRPP by sequestration 
of the divalent cations in the reaction medium. But 
although'EDTA, a po~ent metal chelator, is more 
efficient than inorganic phosphate in preventing the 
decomposition of PRPP during the course of inctibation, 
it neither activates FRPP synthetase nor overcomes 
inhibition of the enzyme by ADP. Our apparent sigmoidal 
dose-response curve with inorganic phosphate, which is 
very different to that described by Fox and Kelley ( 11972), 
indicates that the role of this metabalite is likely 
to be described in terms of an allosteric mechanism·, 
although the action of inorganic phosphate is .unlikely 
to potentiate subunit aggregation of the molecule. ~e 
have found that the stimulation of the ·enzyme in human 
erythrocyte with increasing phosphate concentration 
continues to at least 60 mM, which is well above the 
accepted physiological level in erythrocytes (0·5-
1 ·5 mM). The phosphate profile (Fig. ·34 ) lacks pre-
cise definition and further studies at other phosphate 
concentrations are clearly desirable. ~perling et al 
have reported a hyperbolic reEponse of a mutant FRPF 
synthetase to increasing inorganic phosphate concentration 
in a gout patient's haemolysate but our limited invest-
igations have not shown such a response 
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The pH profile shown in Fig. 1 4 is very similar 
in shape to the data produced by S.witzer ( 1'969) for 
PRFP synthetase from S. typhimurium and by Fox and Kelley 
(1972) for the human erythrocyte enzyme following gel 
filtration on Sepharose 4B. In all cases there is a 
pronounced shoulder from pH 7 to 8 and the activity 
is low below 6. 
After indulgence of alcoholic beverages there is 
an increase in serum uric acid with an increase~-in 
gouty attacks in some susceptible individuals. This 
was believed to be caused by deposition of urates in 
consequence of a diminished renal uric acid excretion 
induced by alcohol hyperlactaemi~Lieber et al 1962). 
Such an explanation is not really plausible because 
the increased serum lactate observed after alcohol 
indulgence is much lower than that required for 
decreased uric acid output (Grunst et al 1977). The 
relationship between ethanol metabolism and increased 
hepatic uric acid production is not clear. It could 
be that ethanol may induce the de novo synthesis of 
purines or enhance nucleotide catabolism in the liver. 
Oxidation of the alcohol would cause a shift of the 
redox system to a more reduced state with a consequential 
decrease in ATP content in the liver. The changes in 
cellular ATP, which are known to regulate many enzymes 
of purine metabolism could account for the increased 
serum uric acid after alcohol. In the current work 
the effect of ethyl alcohol on FRFP synthetase shows 
that an in vitro inhibition of the enzyme occurs 
(Fig. 16 ). However the concentrations of ethyl 
ll3 
a1coho1 used in t:~ese experiments ·Was very much in excess· 
of those found in vivo after a heavy drinking session. 
At low concentration of alcohol some activation of the 
enzyme is found. These effects of activation of an 
enzyme at low concentration ofalcohol and inhibition 
at high concentration is not unusual (e.g.plasma 
-
cholinesterase \'/hi ttaker 1968). The inhibition effect 
is probably caused by denaturation of the protein. Bu11 
and Breese (1978) have shown that the denaturation of 
protein by alcohol is first order with respect to the 
protein but between e1eventh and eighteentn order with 
respect to alcohol;. They report neither dependence on 
pH nor difference in susceptibility to alcohol denatur-
ation between the various proteins. 
The two types of inhibition curve found for ethyl 
alcohol (Fig. 16) is however more difficu1t to explain. 
Neither curve is a characteristic of any one of our 
c1inica1 groups. One can however speculate that some 
people, notably the Japanese are very susceptible to 
a1coho1 whilst others are ab1e to imbibe freely, The 
two groups have been characterised by differences in 
their liver alcohol dehydrogenase. Are we now meet-
ing such a po1ymorphism? This hypothesis seems improbable 
but it is worthy of some speculation. 
The effect on FRFP synthetase activity of altering 
··the chain length of the alkyl radical; has been studied 
using methyl, ethyl, propyl and n-butyl alcohols. No 
difference in concentration profile for a single alkyl 
alcohol has been observed in any of the three clinical 
groups. The concentration of alcohol for maximum enzymic 
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activity of FRiFP synthetase was observed· to de.crea.se with 
increasing chain leng:th of the a.1kyl radical. High 
concentrations 'of the higher edcohols were not feasible 
owing to lo.w miscib:i:li'ty with the aqueous medium. A 
technical difficulty was the ready appearance of a.ir 
bubbles after the addition of n-butanol to the enzyme 
assay system. This was overcome by preincubation of 
butanol for a fixed period prior to initiation of reaction 
·by the addition of R-5-P. Unlike ethyl alcohol, the 
other a.lcohols did not yield two typef! of inhibition 
profile for PRPP synthetase • Hershko et a.l (1969) 
report~d that 2,3-DPG, at concentrations within the 
range of the high physiological amounts found in human 
erythrocytes(: Ba.rlett 1959), produced a marked inhibition 
of FRPP synthetase in human erythrocytes. This observ-
ation was not onl:y confirmed by Fox and Kelley ( 1·972) 
but the inhibition was shown to be competitive with 
R-5-P and PRPF. These workers also proposed, by analogy 
to the control of the state of haemoglobin oxygenation 
by 2,3-DPG, Mg2+ and MgATP (Bunn et al 1·971), that 
the rate of erythrocyte PRPF synthesis may be indirectly 
affected by haemoglobin oxygenation. This aspect of 
2,3-DPG has not been investig~ted in the current study 
but identica.::L inhibition profiles have been found for 
a normal control and a. patient with tophaceous gout 
(Fig. 18 ). No statistical difference in the percentage 
inhibition of PRPF synthetase using a. fixed concentration 
of 2,3-DPG (5•4 mmol/1) has been found in our three 
clinical groups. Such an observation is in agreement 
with the findings of Meyskens and Williams (1971) who 
showed that the inhibition of FRFF synthetase by 2,3-DPG 
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was similar in erythrocyte lysates from normal, hyper-
uricaemic and gouty patients. It has been reported 
that purified rat liver PRPP synthetase responds to 
a comparati:vily wide· range of inhibitory compounds in 
. . 
the absence of albumin, .EDTA or dithiothrei tol but 
"stabilisation" of the enzyme by addition of these 
compounds results in a markedly restricted range of 
inhibitors (Roth and Deuel 1974). The "stabilised" 
enzyme was found to be unaffected by 2,3-DPG. In 
spite of the presence of EDTA in ~11 haemolysates, 
appreciable inhibition of PR:PP synthetace has been 
found with 2,3-DPG during the current work (Fig.18 ). 
Pr.ev.ious work on the inhibition of PRPP synthetase 
from sources as diverse as human erythrocytes (Hershko 
et al 1969, Fox and Kelley 1972) Ehrlich ascites tumour 
cells (~long and Murray 1 969) rat liver (Roth and Deuel 
1 974) and s. typhimurium (~witzer 1 971 ) has been confined 
to two main classes of inhibitor: purine and .pyrimidine 
derivatives such as nucleosides, nucleotide and phospho~ 
nucleotides and carbohydrate derivatives such as phos-
phomonosaccharides and glycolytic .substrates. 
The charicature of an old man with gout sitting 
in an armchair, heavily bandaged foot on a stool, a 
bottle of port at his side and smoking a pipe provided 
the stimulus to study nicotine as a potential inhibitor 
of FRPP synthetase. It. was impossible to maintain the 
pH of the reaction medium using the standard buffer 
capacity in the presence of nicotine and it seemed 
probable that the observed ac.tivation of IRPP synthetase 
activity could be attributed to a pH effect. Nicotinamide 
and nicotinic acid were investigated for their inhibitory 
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effect on the enzyme. S:imi~ar inhibition profi~es 
were obtained for the two inhibitors and: no difference 
was apparent in severa~ samples taken from the three 
c~inica~ groups. 
The effect of uric acid on the activity of FRFF 
synthetase wa.s st.udied a.nd for the purpose of a. pre-
~imi:na.ry screening, the ~a.bora.tory standard uric acid wa.s 
used. Apprecia.b~e inhibition of the enzyme was observed 
which could not be reconci~ed with the ~a.ck of inhibition 
observed with s~ight~y ~ewer concentrations of uric 
acid made up either in phosphate buffer or water. The 
~a.bora.tory standard was made up in ~ithium carbonate, 
forma~dehyde a.nd su~phuric acid. Any component in 
this· mixture cou~d be expected to affect the enzymic 
activ~ty but no inhibition was found with ~ithium car-
bonate. A~though the inhibition profi~es of FRFF 
synthetase,, using varying amounts of forma~dehyde for 
a. contro~ individua~ and a. patient with tophaceous gout, 
appear to diverge at O•OB% forma.~dehyde, no difference 
in percentage inhibi:tion of the enzymic activi.ty was 
observed with several haemolysates using 0·08% form-
a.~dehyde. Some differences were found with 0•02% form-
a.~dehyde but more screening at this concentration is 
. required to substantiate our pre~iminary resu~ts. 
Inhibition studies of FRJ·p synthetase with a fixed 
concentration of 2 merca.ptoethano~ produced a wide range 
of results (Fig. 20 ) . In spite of this vast spectrum, 
some remarkab~e results were obtained- a.~beit not confined 
to one particular c~inica~ group. One gout patient had 
been bled twice; the samples differed in age by three 
months and yet haemo~ysates gave activation with 
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mercaptoethanol and showed good agreement (26·5% and 
32% respective1y). A ~econd gbut pat~ent had two samples 
taken at an interval of one week. Both haemolysates 
showed inhibition of 4% and 7•5% respectively. Although 
it is. not possible to predict the characterifitic i:nhibi tion 
pattern of PRPP synthetase of any of the three clinical 
groups using 2-mercaptoethanol, repeat sampl:es from 
the same individual do show the same inhibition character-
istics. Similar effects were found using dithiothreitol 
as differential inhibitor. The .two inhibitors, used 
singl!y, did not give the same inhibition for PRPP syn-
thetase and some haemolysates gave enzymic activation 
with one thiol derivative and inhibition with the other. 
Neither negative nor positive correlation was o.btained. 
There would appear to be a total po:t:.ulation polymorphism 
which is worthy of further investigation and family 
studies. 
Histidine is a metabolite of an alternative metabolic 
pathway ·to de novo purine biosynthesis for PRP·P; The 
use of this compound as inhibitor did not differentiate 
the samples into their three clinical groups. An 
atypical inhibition profile for histidine, compared with 
other inhibitors was obtained for PRPP s~•nthetase . It 
is however very similar in shape to the inhibition profile 
of FRFF synthetase for ADP reported by Sperling et al (1978). 
Further studies are clearly necessary. The effects of 
other pharmacologic and chemical agents, such as trypto-
phan, caffeine and allopurinol, on the activity of FRFF 
synthetase were investigated. These exJ:eriments were 
limited either by the low solubility of the chemical 
or by the lack of ready access to the pure chemical 
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present in commercial samples of the drug. No useful 
data was produced from these studies which need dra·stic 
revision prior to future experimentation. None of the 
inhibitors used in the current work were able to differ-
entiate between the three clinical groups investigated 
but some extension of these studies may reveal a population 
polymorphism. 
Erythrocyte glutathione reductase acti~ity is in-
creased in patients with neoplastic disease (Kerpola 
et al 1959) hepatitis and obstructive jaundice (loc. cit) 
and in most patients with anaemia (Ramachandran and Iyer, 
1974). The enzymic activity is reported to be redu6ed 
during protein-calorie malnutrition (Verjee and Behal 1976).· 
A decrease in erythrocyte glutathione reductase, compared 
to normals and hyperuricaemics, was found in gouty 
patients (Table 26 ). Overall this decrease in enzymic 
activity is significant (just less than l in 100 ) 
compared with controls but 1 in 1000 compared with 
hyperuricaemics. There is no significance between the 
glutathione reductase activities of the normal and 
hyperuricaemi:c groups, (Table .3 8 ) • But the difference 
between the control group and the gouty patients may be 
masked by an age. effect. Long ( 1 962) has reported an 
elevated activity of red cell glutathione reductase in a 
group of Caucasians with untreated primary gout, and in 23/28 
American negroes with gout (Long 1967). Although Long (1967) 
has found a correlation between the increased glutathione 
reductase activity and a fafot moving electrophoretic variant 
of the E>ame enzyme, Eiome caution is counselled in the 
interpretation of his results. The blood samples used 
in his study were collected for the investigation:of 
119 
G-6-FD variants occuring with sickle cell anaemia. It 
is true that many of this negroid group did have gout 
but West et al. (1~61) has found increased values of 
glutathione reductase activity in most patients with 
sickle cell. anaemia. Euch findings have prompted Beutier 
(1~69) to question the reliability of previous measu~ements 
of glutathione reductase activity which is dependent 
not only on certain disease states but on vitamin comp-
ounds such as riboflavin and nicotinamide. 
Plasma glutathione reductase levels (Table 38 ) 
show no differenc·e bet.ween normal.s and hyperuricaemias 
but significant difference between gouts and normal.s 
(. p ( 0•01) and between gouts and hyperuricaemics (.p ( 0•001). 
There is remarkable constancy in SD calculated from 
group to group. 
Nishizawa et al. (1975) found a significant increase 
of ADA activities in erythrocytes of gouty patients 
whereas Van l'laris et al. (1980) has found no elevation of 
ADA activity in erythrocytes from the same number of 
hyperuricaemic males. ADA activities in the haemol.ysates 
collected ih the currerit study have not been measured, 
but a random of sera have been segregated accord-
ing to their uric acid content and the serum ADA activities 
measured in normals and hyperuricaemic individu~.ls 
(including gout). The results presented in Table 28 
show a significant increase in serum ADA activity of 
hyperuricaemics compared with normal. controls. 
The contribution of reduced purihe sal.va~e to the 
hyperuricaemia associated with HGPRT deficiency has 
been studied by measurement of enzymic activities in 
the haemol.ysates from our clinical. groups. The results 
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shown in Table 2·9 :i:ndicate. no significant difference 
b•tween the enzymics activities of the ha•molysates 
from the gout patientf? compared with normal controls. 
This is in accord with the findings of Van Maris et al 
( 1 980). No HGPRT deficiency was det.ected in the current 
work. 
It seemed worth whiJ.:e to find out whether any 
correlations existed amongst the parameters that had 
accumUlated during the current study. Age was the first 
consideration. The two pathological groups were older 
tnan the control group and so any changes found in gouty 
patients or hyperuricaemic individuals could be an age 
effect and not the resuJ.:t of the malady. A positive 
correlation (0•5) with age has been found for both eryth-
rocyte and plasma glutathione reductase (Table 36 ) • Both 
enzymic activities increase with age in normals but there is 
only slight evidence for this correlation with plasma gluta-
thione reductase in the hyperuricaemic group (0·27) and none 
for the gouty group. It can be assumed .that there is some-
thing swamping the age correlation in gout but. it is pointless 
to eliminate the age factor in this group because the effect 
is real and would be magnified by taking age into account. 
There is no correlation of PRFP ~ynthetase activity with age 
in any of the three clinical groups (Table 3 6 ) • It can there-
fore be concluded that there is no need to consider 
age any further. There is a positive correlation between 
erythrocyte glutathione reductase and plasma glutat~ione 
reductase P·51) but only low correlation for the two 
enzymes in the hyperuricaemic group P·25) and none in 
the gout group (o. 2) . On the other hand we find good 
correlation between erythrocyte PRPF synth•tase activity 
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and erythrocyte glutathione reductase in both the hyper-
uricaemic and gout group 0•45 and 0•43 but low correlatipn of 
these two enzymes in the control group (0•25)(Table 37 ). The 
mechanism caucing the reduction of erythrocyte gluta-
thione reductase activity is not responsible for the increase 
in PRPP synthetase activity in the gout or hyperuricaemic 
patients since a negative correlation between the two is 
observed, whereas in the normal controls the two enzymes 
are linked with a positive correlation. Plasma uric acid 
showed negligible correlation wit~ the enzymes studied in the 
current work in any of the clinical groups apart from a 
positive correlation (0. 32) with plasma glutathione reductase 
in the hyperuricaemic group. 
None of the electrophoretic studies produced any variants 
which could be confined to one of our clinical groups. In all 
systems there was some indication of probable polymorphisms 
which were undoubtedly a population effect. Repeat samples 
and family follow up studies will be necessary to confirm the 
polymorphism and at this stage it is impossible to decide 
whether there may be an uneven d·istribution of variants 
amongst the three clinical groups. 
The electrophoretic characterization of human erythro-
cyte FRFF synthe~ase was first described by Beer et al (1974) 
using a radiochemical assay following electrophoresis on 
cellulose acetate; An anodic single band was observed which 
migrated faster than haemoglobin at pH 8•5. A slower Eecond 
band was observed in stored haemolyeate Johnson et al (1974) 
also used cellulose acetate strips for electrophoresis but 
used the reverse reaction of FRFP synthetase coupled to the 
hexokinase, G6PD and NADP+ reactions according to Switzer (1968). 
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They also included creatine phosphate and creatine phos-
phokinase in their staining fluid as an ATP generating 
system. A single anodic band, migrating at a slower 
rate than the "nothing de'hydrogeinase" was found in all 
samples except for their mutant enzyme (Becker et al 
1973) which also was a single band coincident with the 
"nothing dehydrogenase". Current investigations have 
been done on agarose and in agreement with these workers 
a single band has been observed in all cases but it 
migrated at a slower rate. than haemoglobin. The 
change in supporting medium could account for the 
differing relative migrations between. the current and 
previous work. A large variation in intensity of stain 
has been observed in the current work and this variation 
oannot be attributed to the relative size of the applied 
sample since the intensity of the haemoglobin fraction 
is not proportional to PRPP synthetase intensity. All 
investigations have heen done at pH 8•6 and it seems 
desirable not only to change the pH using the. present 
supporting medium but to use acrylamide or starch gel 
for betcer resolution. Isoelectrio focusing on ultra 
thin acrylamide gels or two dimensional electrophoresis 
sho.uld resolve any multiple bands that are not unmasked 
by the present technique. 
Long (1967) has reported that glutathione reductase 
migrates as a single band in starch gels at a rate 
slower than haemoglobin. He also found a variant 
electrophoretic band which is associated with gout in 
negroes. Thib variant has a greater mobility than the 
usual band and family studies indicate that it has a 
recessive inheritance with a broad band indicative of 
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the hete:rozygous individuals.. Anselsle:t.ter and \'/eidemann 
(1979) hav:e separated glutathione reductase in human 
serum by gradient polyacrylamid'e gel electrophoresis 
at pH 8•2. Two glutathione reductase bands were seen. The 
faster one could be resolved into a triplet by addition 
of 2-mercaptoethanol at a final concent~ation of 12·8 mmol/l. 
These authors had earlier used agarose electrophoresis 
and homogenous polyacrylamide gel and found only one slowly 
moving glutathione reductase band which remained after 
incubation of all .sera with 2-mercaptoethanol (Weidemann 
and Ans.elsletter 1977). The present observations are 
in agreement with the polymorphism described by Long 
(1967). Some haemolysates have one band just anodically 
faster than haemoglobin whilst others have an additional 
band behind haemoglobin. The samples with two bands 
are presumably the heterozygotes described by Long (1967). 
No single slow band has yet been observed but one must 
remember that Long's patients and healthy controls were 
negroid and it is not unusual for the gene frequencies 
of enzyme polymorphisms to be altered by ethnic factors 
(Harris 19'75). Isoelectric focusing of erythrocyte 
glutathione reductaee indicated two or three bands on 
the alkaline side of haemoglobin. More complex patterris 
may be revealed as the number of samples screened is 
increased. The serum isoenzymes have not been invest~ 
igated. during the current study. 
Electrophoresis of several haemolysates followed 
by staining for ADA revealed the well established poly-
morphism (Harrie 1975). No new variantswere observed 
and our data is incomplete for the anal~·sis of the 
distribution of the various genes controlling this 
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polymorphism amongst our three clinical groups. 
It is noteworthy to recall tnat a mutant HGPRT 
with significant~y reduced activity in erythrocytes 
has been found in a f~w patients with gout (Kelley 
et al 1 969, Yu et al 1 972). A number of s-tudies have 
demonstrated the presence of eleatrophoretic variants 
of normal human HGFRT, a deficiency of which would 
cause impaired purine salvage. Arnold and Kelley (1971) 
have questioned whether the electroFhoretic heterogeneity 
could be due to a nongenetic alteration of the protein 
which may occur during the preparation of the sample. 
The haemolysates used. in the current study received 
identical treatment and eo any variation found ought 
not to be attributed to preparation of sample. It is not 
possible however to eliminate the role, if ariy, assumed 
by drug therap~ in some individuals. However Fox and 
Lacroise (1977) found a different pattern of isoenzymes 
in haemolysates from four patients with partial HGPRT 
deficiency as compared with normal. There was variation 
in .isoenzymes amongst these patients and their observations 
suggest that electrophoretic variations is a common 
occurance in partial aGPRT deficiency and support the 
existence of structural gene mutations with genetic 
heterogeneit~ in this d:i5order.Gulumian ahd Wakid (1975) 
have isol2ted four components from purified human 
erythrocyte HGFRT by isoelectric focusing. Variation 
in electrophoretic migration of HGFRT has certainly 
been observed in the present study but such variation 
is not confined to one clinical group. Until repeat 
specimens and family studies have been persued it is 
not prudent to claim a polymor~hism. 
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Column chromatography of serum on Bio Rad with 
subsequent elution using physiological saline shows 
real potential as the initial step in the identification 
of any unusual metaboli te ,, apart from uric acid, having 
absorbance at 290 nm which may occur in sera from gouty 
patients or individuals with hyperuricaemia. The pre-
liminary investigations reported in this work have shown 
that it is possible to align synthetic markers to a 
definate position irt, the elution profile bsing saline 
as eluant. Although the work has been concentrated 
on purine and pyrimidine bases, nucleosides and 
nucleotides, we can also identify the elution of 
tryptophan and tyrosine. The bases such as adenine and 
guanine are not reeolved by thi's technique but it is 
then relativily easy to recolve them by HPLC or by 
other means. It is also highly probable that ATP or 
GTP are not reeolved using this non specific elution 
method but we are confident that complete resolution 
can be achieved with HPLC following the initial pur-
ification step on Bio Rad which aimed at a broad crude 
separation of purine pyrimidine derivators. The elution 
profiles shown in Figs29&31do indicate that there are 
some different components in the sera of random controls 
and sera from gouty individuals or individuals with 
hyperuricaemia. ThiE crude chromatography could not as yet 
be used as an ancillary aid to the diagnosis of gout. 
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Nature of future work. 
The en~gma of urate binding to plasma proteins 
persists but as more sensiti~e •ssays_for the detection 
of uric acid are developed, a clear cut resolution will 
emerge. The effect of different anticoagulants on ultra-
filtration should· be investigated. It seems worth while 
either to denature plasma proteins using agents such as 
sodium dodecyl sulphate which will disrupt the globular 
proteins into subunit structure or to degrade the proteins 
with enzymes such as neuraminidase., phospholipases or 
proteases which will change the structure of the plasma 
protein molecules. By such techniques it seems probable 
that the uric acid bound to the proteins could be released. 
This free uric acid would then be easy to detect . 
The study of the association of lipidaemia types 
and hyperuricaemia should be extended to patients with 
uncontrolled gout and to other individuals having hyper-
uricaemia without gout. 
The presence of uric acid in leucocytes demands 
confirmation. Disruption of the cells with enzymes such 
as lysozyme or pro-teases would be worthwhile. A rapid 
detection-of uric acid following such treatment would 
be indicative of the presence of uric acid within the 
leucocyte ~hereas a slow appearance of uric acid would 
favour ~he presence of precursors, with subsequent synthesis, 
of uric acid. 
The present study has indicated anomalous results 
for a few individuals and for example one female gout 
patient had an exceptionally high activity of PRFP 
synthetase, It is essential not only to confirm such a 
result with a repeat sample but to check her reported 
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chemotherapy and to extend our investigations to other 
close relatives in her family. 
The preceding discussion has indicated that the 
kinetic st~dies for PRFP synthetase should be repeated 
at pH 8 preferably in Tris buffer, of adequate buffer 
capacity to maintain the pH, with the addition Of a 
fixed amount of inorganic phosphate which is essential 
for enzymic activity. Whenever a linked enzyme assay 
system is used, the linked enzyme must be dialysed in 
order to remove ammonium sulphate which curtails the 
usefulhess of the method by precipitation .of complex 
magnesium salts. 
Any linked enzyme system has limited application 
when studying inhibitors. The current work on PRFP 
synthetase has been frustrated by interference of an 
inhibitor with the coupled reactions .. It is therefore 
desirable to use an alternative assay and the m~t 
promising appears to be the measurement of the rate 
of disappearance of the substrata ATP using the principle 
of chemiluminescence. It would be useful to study the 
effect of some inhibitors such as alcohol and nicotine 
using ~his new assay for PRFF synthetase. 
We should also investigate whether the high activity 
of PRFF synthetase found in gout patients is due to the lack 
of substrata for the purine salvage enzyme HGFRT. 
The current electrophoretic survey was estentially 
a preliminary scan. New staining techniques for the 
detection of the three enzymes studied have been developed 
during the current work and these techniques should be 
used for other gel support &ystems as well as for the 
techniques of isoelectric focusing. 'i'he apparent 
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polymorphisms should be consolidated by fami·ly studies. 
It appears from unreported current work that the isoenzyme, 
pattern for serum ADA is coincidentai with serum lipo-
protein staining. Such an observation demands further 
investigation and it i~ proposed to selectively degrade 
the lipoproteins in serum w.i th enzymes such as cholesterol 
oxidase and phosphol:i:pases prior to electrophoresis and 
subsequent staining for ADA and phospholipide. 
The potenti!al of column chromatography of serum on 
Bio Rad with subsequent elution using physiological 
saline should be fully explored with wider application 
not only to gout patients but to other hyperuricaemic 
individuals. 
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Ta ble 2 Conditions associated with hyperuricaemia 
Decreased renal excretion 
Nephritis 
Urinary obstruction 
Urinary suppress ion 
Destructive renal lesions 
Renal hypogenesis 
Congestive heart failure 
Adrenocortical insufficiency 
Hepatic disease 
Drug t herapy (nicotinic acid) 
Ora l thiazide diuretics 
Myocardia l infarction 
Increased nuc~c acid turnover 
Chronic leukaemia 
Polycythemia 
ACTH or cortisone therapy 
Pernicious anaemia 
Sickle cell anaemia 
Thalassemia 
I.Jmphoblastoma 
Macroglobinaemia 
Starvation 
Gout 
Pneumonia 
•. 
Other causes 
Eclampsia 
Chronic lead poisoning 
Hypertension 
Obesity 
Degenerative vascular disease 
Sarcoidosis 
Chronic beryllium disease 
Psoriasis 
Down's syndrome 
Neoplastic disease 
Multiple myeloma 
Table 3 Drug induced hyperuricaemia 
Drug Mechanism 
Diuretic agents Not fully understood 
(except spironolac- Increased proximal tubular resorption 
tone ) of uric acid and/or impaired tubular 
secretion. 
Alcohol 
Aspirin 
Cytotoxic drugs 
Ethambutol 
Levodopa 
Nicotinic acid 
Pyrazinamide 
Lactic acid inhibits uric acid secretion 
Low doses inhibit uric acid secretion 
Increases nucleic acid turnover and 
excretion 
Decreases uric acid clearance 
Unknown 
Increases purine production, decreases 
uric acid excretion 
Inhibits uric acid s ecretion 
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Table 4 Genetic Aspects of Hyperuricaemia and Gout 
Molecular defects 
Primary hyperuricaemia 
Specific enzyme defects 
" 
Undefined 
" 
Secondary hyperuricaemia 
Increased purine biosynthesis 
de novc 
" 
Type 
PRPP synthetase variants 
HGPRT partial deficiency 
Normal excretion of uric 
acid 
Over excretion of uric acid 
Glucose-6-phosphatase 
deficiency or absence 
HGPRT deficiency 
Metabolic disturbance 
Increased PRPP and Uric Acid 
production 
Increased purine biosynthesis denous 
by surplus PRPP. Increased uric 
acid production 
Over production or retention of 
uric acid 
Increased uric acid formation 
Increased production and decreased 
excretion of uric acid 
Increased uric acid production 
Lesch-Nyhan syndrome 
Inheritance 
Unknown 
X linked 
Polygenic 
Polygenic 
Autosomal 
recessive 
X linked 
Table 5 Reactions of PP-Ribose-P 
Phosphorobosyl 
Acceptor 
Glutamine, NH3 
Adenine 
Guanine, hypoxanthine 
Xanthine 
Orotate 
Uracil 
2,4-Diketopyrimidines, 
2,6-diketopurines 
Nicotinate 
Nicot:mamide 
Qufnolinate 
Imidazoleacetate 
l+ATP) 
Hxstamine 
(+ ATP) 
Anthranilate 
ATP 
Product 
Phosphoribosylamine 
Adenylate 
Guanylate, enosinate 
Xanthylate 
Orotidylate 
Uridylate 
Uridylate, oroticy late, 3-phospho-
ribosyl-uric acid, 
J~phosphoribosyl-xanthine 
Nicotinate ribonucleotide 
Nicotinamide ribonucleotide 
Quinolinate rioonucleotide + co2 
Phosphoribosyl-imidazoleacetate 
(+ADP + Pi) 
Phosphoribosyl-histamine 
(_+ADP + PH 
Phosphoribosyl-anthranilate 
1~(5-Phosphoribosyl)ATP 
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Enzyme Commission 
Number 
• 2.4.2 .14 
2.4.2.7 
2.4.2 .8 
2.4. 2.10 
2.4 . 2 .9 
2.4.2 .11 
2.4.2 .12 
Table 6 Subum~t Analysis of PIWP synthetase 
Electrophoresis 
S D S - Polyacrylamide 
lOM Urea-Polyacrylami'de : 
Amino Acid Analysis: · 
Tryptic Peptide Mapping 
Amino-Terminal Analysis 
Analytical Ultracentrifugation 
In 0 . 01 N HCl: 
Single Protei n Band, MW 33,500 
Single Protein Band , 
18 Arginine + 20 Lysine Residues 
per 33,500 MW Subunit 
37 Peptides Identified 
(Fluorescamine Reagent) 
Threonine Only 
(Dansyl Chloride Method) 
Molecular Weight 33,200 
(Sedimentation Equilibrium) 
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Table 7 Aggregated Forms of PRPP synthetase 
Relative Stokes Molecular No . of Enzyme 
S20, w Radius Weight Subunits Activity 
~ 
4.8 31 65,000 2 .o <3% 
7.1 43 133 ,000 4 . 0 <3% 
9.7 61 258 ,000 7.7 <3% 
15.9 74 513,000 15.4 lOO% 
22.1 108 1,042,000 31.1 lOO% 
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TABLE 8 Enzyme mutations found by Electrophoretic studies in patients with Gout or Hyperuricaemia 
Enzyme Number of Technique Number of Reference 
Variants cases 
PRPP Synthetase 1 Cellulose acetate electrophoresis 3 Becker et al (1973) 
" " " 1 Lebo and Martin (1976) 
HGPR transferase 1 Polyacrylamide gelelectrophoresis 4 Bakay et al ( 1972) 
1 Isoelectric focusing 1 Fox et al (1975) 
1 Isoelectric focusing 1 Gutensohn and John (1979) 
APR transferase 1 Polyacrylamide gel electrophoresis 1 Nyhan and Bakay (1975) 
TablelO Inhibitors studied and range 
of concentrations investigated. 
Inhibitor Concentration 
range 
Ethyl alcohol 0- 22·5% 
Methyl alcohol 0- 22•5% 
Propanol 0- 4·5% 
Butanol 0- 2•7% 
2.3.Diphospho!lycerate 1·i- 7•2 mmol/l 
Nicotinamide 22•5-225•0 mmol/1 
Nicotinic acid 0- 18•0 mmol/1 
Histidine 0- 90•0 mmol/l 
Formaldehyde 0- 0·08mmol/l 
Table 11 Inhibitors studied at a 
fixed concentration 
Inhibitor Concentration 
2.3.Diphospho!lycerate 5•4 mmol/1 
2 Hercaptoethanol 25•0 mmol/1 
Dithiothreitol 25•0 mmol/1 
Histidine 22•5 mmol/1 
Uric acid 112 ·6 mmol/1 
Formaldehyde O·o8% 
Formaldehyde 0•016% 
Lithium carbonate 1·8 mmol/ 1 
Tryptophan 11 • 3mmol/l 
Caffeine 18• Ommol/1 
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Table1 ·2 Urate binding to plasma proteins by occlusion at diasto1ic pressure 
Expt. Time Total Albumin Total Conjugated Alkaline ca2+ PO 111 IgG IgA I gM T4 Temp Uric 4 Number (mins) Protein g/1 bilirUbin bilirubin phosphatase mrriol/1 
mmol/1 g/1 g/1 g/1 nmol/1 
oc Acid 
g/1 )..llllol/1 )Jlno1/l of 1 'fmoVI 
0 75 47.5 11.5 0. 2 64.5 2.58 0 . 975 37 359.5 
1 4 75.5 46.5 11.5 o. 2 62 .o 2.58 0 . 970 37 359 . 5 
10 84.5 52.0 12.0 0. 2 67.5 2.75 0.980 37 358 . 9 
0 77.0 46.0 11.0 4.0 74.0 2.57 1.01 14.13 1. 77 0.60 123 37 345.2 
2 
10 85.0 49.0 12.0 4.0 75.0 2.69 1.05 14.57 1.91 0. 71 138 37 342 . 3 
0 72.0 44.5 85.0 2.41 1.16 37 292 
3 
10 83.5 55.5 96.0 2.66 1.055 37 289 
0 72.0 45.0 80.0 2.385 1.050 4 304 
4 
10 82.0 54.0 92.5 2.595 0.960 4 307 
Table 13 Changes in mean serum levels of total protein, albumin, calcium and 
uric acid induced by venous stasis in different individuals 
Experiment Total Protein Albumin Calcium Uric Acid 
9LI 9/1 m mol/1 f mol/1 
1 12.7 9.4 6.2 -1.7 
2 10.4 6.5 4.7 -0.8 
3 16.0 19.8 10.4 -1.0 
4 13.9 20.0 8.8 +1.0 
5* 14.0 11.0 5.4 N.G. 
* Data of Christiansen et al (1975) - mean values in epileptic patients 
Table L4 Urate binding to plasma proteins as estimated by ultrafiltration 
using Amicon cones 
Sample Total in serum Ultrafiltrate Bound % Bound 
}J m o y1 }J mo y1 fmol/1 
B 309.5 309.5 0 0 
c 708.3 607.1 101. 2 14 .3 
R 169.6 163.7 5.9 3 . 5 
G 261.9 258.9 3 .9 1.1 
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Table 15 Uric acid content (mean and S.D.) in 3 clinical groups of individuals 
Male Female Total 
Clinical Group Number Uric Number 
.uric Number Uric 
of acid S.D. of acid S.D. of acid S.D. 
individuals lJ mol/1 individuals lJ mol/1 individuals lJ mol/1 
(_mean) (_meanl (meanl 
Normal 21 336 67 30 301 80 51 315 76 
Gout 47 492 137 7 404 135 54 481 138 
Hyperuricaemic 24 509 143 12 564 166 36 527 151 
Table 16 PRPP synthetase activities (mean and S.D.) in 3 clinical groups of individuals 
Male Female Total 
Clinical Group Number Enzymic Number Enzymic Number Enzymic 
of acitivity S.D. of activity S.D. of activity S.D. 
individuals (mean) individuals (mean) individuals (mean) t 
Normal 21 106.4 29.6 30 88.3 30.6 51 96 31.2 
Gout 47 120.4 37.6 7 133.7 79.1 54 122 44.2 
Hyperuricaemic 24 121.9 35.3 12 98.8 29.2 36 114 34.8 
Activity Units: ~ moles substrate/mg./ml. protein/hr 
t Average standard error of the difference between meane = 7•74 
Table1 7 Statistical analysis of the regression equation for the Li~~weaver-Burke plots 
velocity of reaction and (s] is the substrate concentration, of the effect of 
l l ,where v is the 
-;; vl~] . 
varying concentrations of R-S-P on the red cell PRPP synthetase activity in six individuals. 
Individual Clinical condition Regression equationt S.D . of Y about R2 Analysis of Variance regression line 
H Gout y = 0 . 0014 + O.OOOlx 0.0004954 99.4 0.000442 
s Control y = 0 . CX)()4 + 0 . CX)()3x 0 . 001870 99 . 2 0.004751 
B Tophaceous gout y = 0 . 0014 + O.OOOlx 0 . 0007220 98.4 0 . 000348 
Du Hyperuricaemia y = 0 . 0010 + O. OOOlx 0.0003019 99 . 5 0 . 000190 
Da Gout y = 0 . 0005 + O. OOOlx 0 . 0009962 98 .0 0 . 000545 
F Control y = 0. 0012 + o.ooo1x 0 . 0003387 99 .6 0.0003198 
t y 
Table. 18 
Mean Michaelis constante and maximum velocitiee for R-5-P, MgCl2 
and ATP determined by Lineweaver Burke plo~s 
for PRPP synthetase activity. 
Substrate Mea& Km Mean Vmax Activity unite 
R-5-P 5•6 X 10- 5 ~6o p mol/mljhr 
MgCl2 7•0 X 10 -4 1092 p mol/ml/hr 
ATP 2•9 X 10-~ 907 p mol/mljhr 
Table 1 9 Effect 0! varying the c0ncentratien 
$f phosphate on PRPP synthetase activity. 
Sample Phesphate concentration m mol/1 
number 0 1 20 60 
1 0 1• 3 13·2 105·8 
2 0 6·2 23·8 59•7 
3 0 0 10·8 97·0 
Mean 0 2•5 15•9 87·5 
14 5 
Table2oMean percentage inhibition of PRPP synthetase with varying 
concentrations of Ethyl alcohol in three groups of individuals. 
% Concentration Mean % Inhibition 
of 
ethyl alcohol Total all Normal Gout Byperuricaemic 
groups 
2 . 25 -o.7 -1.7 -0.4 o. 3 
4.5 -0.1 0.8 -o.5 -0.4 
9.0 3.7 7.0 2.1 2.2 
13.5 16.0 22 . 6 12.5 16.0 
18.0 31.2 27.2 29.2 49.2 
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Table21 Mean percentage inhibition of PRPP synthetase with 
varying cc::mcentrations of Ethyl alcohol showing the 
two di'fferent shape curves observed. 
Mean % Inhibition 
% Concentration 
of Combined Curve Curve 
Ethyl alcohol curves shape 1 shape 2 
2.25 -0. 7 -1.5 1.2 
4.5 -o.l -1.1 2 . 3 
9.0 3.7 -o. 7 11.5 
13.5 16.0 9 . 9 31.7 
18.0 31.2 29 . 6 56.3 
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Table22 Mean percentage inhibition of PRPP synthetase with varying 
n-butanol in three groups of individuals . 
% Concentration l-1ean % Inhibition 
n-butanol All groups Normal Gout Hyperuricaemic 
- -
0.23 -· ~2.4 -3.8 -1.8 -2.4 
0.45 -1.8 -3.3 1.3 -1.8 
0.90 2.2 -0.2 3.8 2.2 
2.30 7.3 6.8 6 . 0 12.9 
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Table. 23 
Percentage inhibition of FRPP synthetase 
act ivity using 5·4 m mol/l 2:3 diphosphoglycerate. 
Group of Mean % Number of 
individuals inhibi ti01 ~.D . individua s 
Normal 40·5 2·6 3 
Gout 41 .o 4·3 6 
Hyperuricaemic 41 . 2 0 -2 2 
All groups 41 · 0 3. 1 11 
149 
<.11 
0 
Table24 Mean percentage inhibition of PRPP synthetase with varying concentrations of 
nicotinamide in three groups of individuals. 
Concentration Clinical condition 
of Normal Gout Hyperuricaemia 
ni co ti nami de 
mmol/R. % Inhibition S.D. % Inhibition S.D. 
' 
Inhibition 
22.5 3.7 o. 7 2.5 1.2 3.95 
90.0 15.2 1.8 12.9 2.4 13.70 
180.0 48.5 6.4 48.3 2.7 47.10 
225.0 64.1 4.6 64.8 2.7 61.25 
S.D. 
0.1 
3.2 
6.8 
0.1 
Table 25 Me an % I nhibition of PRPP s ynt h e tase 
using two fixed concentrations of 
Formal dehyde. 
Concentrat i on of Formaldehyde. 
Group of 0·08% 0 · 016% 
individuals 
me a n % mean % 
inhibitio n S .D . inhibitio ~ S .D . 
Normal 94 · 6 2 · 9 48 · 2 2·9 
Gout 93 ·1 4 · 2 43 · 0 4 · 2 
Hype ruricaemicf 93 · 3 2 · 2 5 6 - 6 3 · 2 
1 5 1 
Table26 Erythrocyte Glutathione reduct~se activities (mean and S.D . in 3 clinical groups of individuals 
Male Fema le Total 
Clinical Group 
Number Enzymic Number Enzymic Number Enzymic 
of activity S.D. of activity S.D. of activity S.D. 
individuals (mean} individuals (mean) individuals (mean) t 
Normal 21 101.55 69.9 30 110 . 98 56 . 70 51 107.1 62 .o 
Gout 47 81.93 43.1 7 87.26 42 . 60 54 82 . 6 42 .7 
Hyperuricaemic 24 128.03 74.8 12 106 . 58 72.9 36 120.9 73.8 
Activity units: ~ moles substrate/mg. protein/ml/hr 
t Average standard error of the difference between means = 12•15 
01 
w 
Table 27Plasma Glutathione reductase activities (mean and S.D.) in 3 clinical groups of individuals 
Male Female 
Clinical Group Number Enzymic Number Enzymic Number 
of activity S.D. of activity S.D . of 
individuals (mean) individuals (mean) individuals 
Normal 21 571 260 30 665 198 51 
-
Gout 47 520 238 7 445 203 54 
Hyperuricaemic 24 648 200 12 648 200 36 
Activity units: ~ moles substrate/ml/hr 
t Average standard error of the difference between means = 46•83 
Total 
Enzymic 
activity S.D. 
(mean) t 
626 228 
511 233 
683 218 
Table.28 Mean a ctivity and standard deviation of 
Adenosine deaminase 
in normal and hyperuricaemics (including gout). 
Group of Mean ADA Standard Number of 
Individuals Activity Deviation Individuals 
u/l 
Normal 2 ·1 0•6 40 
Hyperuricaemic 3·4 1 • 2 43 
1 54 
Table 2 9 Mean and S.D. for HGPRT 
in two clinical groups of individuals 
Mean and S.D. Clinical g'8Up 
Normal Gout 
Mean 143 156 
s.o. 85 74 
Number 0f 
individuals 10 35 
155 
Table. 3 0 · Uric acid content of normal control samples and 
hyperlipidaemia samples classified according to Fredrickson. 
Fredricksons Number of Uric acid umols 11 
classification individuals Mean S.D. Range 
Normal 93 317 95 90-56~ 
Type IV 103 433 1o8 120-700 
Type IIb . 53 4oo 91 84-6.58 
Type IIa 26 331 Bo 120-4~5 
Table 3 1-Total number of ser a analysed for uric acid 
con tent eacli year showmg the number of 
hyperur.tcaexuc samples and tbetr percentage 
of the total 
--
Year Number Number of % hyperuricaemics 
hyperuricaemics 
1970 1270 30 1 23.7 
1971 1270 353 27.8 
1972 1711 538 31.4 
1973 1996 699 35 . 0 
1974 2207 833 40 .0 
1975 2736 977 35.7 
1976 3154 1169 37.1 
1977 3273 1123 34.3 
1978 3451 1276 37 .o 
1979 3314 1199 36 . 2 
1 57 
V\ 
00 
Table32Number of hyperuricaemic samples found in a routine 
clinical laboratory. Distribution of abnormal 
values according to sex during a 2§ year period. 
Number of % hyperuricaemic samples 
Year Individuals 
investigated Male Female Total 
I976 1876 male 46.5 23.2 37.1 1278 female 
1977 1946 male 42.8 21.9 34.3 1327 female 
1978 709 male 42.5 24.0 35.0 (Jan-April) 479 female 
2~ 4531 male 44.2 22.8 35.6 Year 3084 female 
Table33Number of hyperuricaemic samples found in a routine clinical laboratory. Month by month analysis with sex segregation 
over a 2 year period. 
% hyperuricaemic samples 
Year J an . Feb. Mar. Apr . May June July Aug . Sept. Oct. Nov. Dec. 
Total 1976 35 . 5 35.7 37.8 37.1 37.8 41.5 38.0 40.2 38.0 33 . 3 33 .6 34 . 9 
Population 1977 31.0 31.6 31.8 35 . 6 35 .0 35 . 6 38.7 34.6 37.0 36.5 32.0 33 . 2 
Male 1976 43 . 0 48 . 6 43.8 42 . 3 50.7 52.4 45.9 53.5 51.6 45 .0 37 . 2 47 .0 
Population 1977 42.5 35 . 9 38.5 46 . 7 40 . 4 46 .5 46.1 43 . 7 44.5 46.8 39 .4 44.0 
Female 1976 22.0 11.1 26 .0 29 . 6 20 . 4 28 . 4 26.0 21.2 24.5 18.3 27 . 7 17 . 8 
Population 1977 14.8 25.5 22.0 22.0 27 . 1 19 . 6 27 . 9 20 . 5 23 .4 18.9 21.5 17 . 4 
Ta ble 34 Kinetic properties o! PRPP s ynthetase. 
ENZYME SOURCE MICHAELIS CONSTANTS REFERENCE 
R-5-P ATP Mi+ Pi 
Huma n erythrocytes 1·5x10-5M 5•0x10-5M 1·0x10-3M Hersko et al (1969) 
Human erythrocytes 3·3x10-5M 1•4x10-5H -4 2•0x10 M Fox and Kelley (1972) 
Rat liver -4 2•9x10 M -4 2·2x10 M Roth et al (1974) 
Lymphocytes 5•1x10-5M 1•8x10-5M Danks and Scholus ( 1974) 
S • t yphimuri urn 6 -4 1• x10 M 4·6x10-5M 2•0x10-3M Switzer ( 1971) 
4•0x10-3M 
Human erythracytes 1•2x10-5M 7•5x10-5M 5•2x10 -4 (1973) Sperlin~ et al 
• 
Mutant erythrocytes 1•2x10-5M 6·0x10-5M 4•8x10-4 Sperling et al ( 1973) 
-· Huma n erythrocytes 1·4x10-5H 6•0x10-6M Becker et al (1973) 
Human mutant erythrocytes 2•1x10-5M 1•1x10-5M Beck er et al (1973) 
Ehrlich Ascites tumour cells -4 2·0x10 M 3•3x10-3M Hurray and Won~ (1967) 
5·6x10-5M 2•9x10-5M -4 Present study Human erythrocytes 7•0x10 M 
~I 
(}. 
Table. 3 5 Correla tion of red cell Glutathione reductase and plasma glutathione reductase activities in 
three clinical groups. 
Clinical group 
Enzyme Normal Gout Hyperuricaemic 
t t Mean SD corf• significancet Mean SD corf• coe • coe • significance Mean SD corf. significance coe • 
Glut. reductase 107· 1 62 · 0 B2·6 42·7 120·9 73·8 
(Erythrocyte) 
V 0 •512 • • • 0·199 N S 0·247 N S 
. 
Glut. reductase 626·0 228 511•0 233 683·0 218 
(Plasma) 
1 significant at 1 in 1000 • • • 
significant at 1 in 100 • • 
significant at 1 in 20 • 
Not significant N s. 
TableJ6Correlation of Age with Enzymic activities in 3 clinical groups of individuals 
Enzyme Clinical type Number of Correlation Significance t 
individuals coefficients 
PRPP Synthetase Normal 51 0.10 NS 
Gout 5'4 -Q.21 NS 
Hyperuricaemia 36 -0.19 NS 
Glutathione reductase Normal 51 0.53 *** 
(Erythrocyte } Gout 54 0.04 NS 
Hyperuricaemia 36 0.002 NS 
Glutathione reductase Normal 51 0.49 *** 
(Plasma} Gout 54 0.05 NS 
Hyperuricaemia 36 0.27 NS 
t 
significant at 1 in 1000; *** 
significant at 1 in lOO ** 
significant at 1 in 20 * 
Not significant NS 
o-
w 
Table. 3 7 
Enzyme 
Correlation of red cell PRPP synthetase and erythrocyte Glutathione reductase activities in 
three clinical groups of individuals. 
Cliaical group 
Norn.al Gout Hyperuricaemic 
Mean SD corr. significance Mean SD corr. significance Mean SD corr. significance 
coef. coef. coef. 
PRPP synthetase 96·0 31·2 122·0 44·2 114·0 34·8 
V 0•245 • o-445 • • o-430 • 
Glut. reductase 
(Erythrocytes) 107•1 62•0 B2·6 42·7 120·9 73·8 
significant at 1 in 1000 • • • 
significant at 1 in 100 • • 
significant at 1 in 20 • 
Not significant N s 
o-
J:>,.. 
Table. 38 Standard err or of difference between mean enzymic activities (students t test) 
of red cell PRPP synthetase, red cell Glutathione reductase and plasma Glutathione 
reductase in three clinical groups:- normal, gout and hyperuricaemic . 
PRPP s ynthetase Glutathione reductase Glutathione reductase 
Clinical group (Erythrocytes) (Plasma) 
t Degrees of signi!icanc e t t Degrees of significance t t Degrees of significance -t 
freedom freedom freedom 
Normal 
V 
-3·399 103 • • • 2•634 ~4 • • 2•380 104 • 
Gout 
-
Normal 
V 
-2 · 377 75 • -0-848 71 N s - 1· 324 78 N s 
hyperuricaemic 
Gout 
V 1"012 91 N s 
- 3·o65 93 • • • -3·550 93 • • • 
hyperuricaemic 
t significant at 1 in 1000 • • • 
significant at 1 in 100 • • 
significant at 1 in 20 • 
Not significant N s 
Fig. 1 Forma tion of Uric acid by deamination of Adenine and Guanine. 
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Fig. 6 Scan of eluant at 254nm following elution of 
0•2 ml of serum by 0•9 % saline after Sephadex 
G200 gel filtration. 
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Fig. 7 Distribution of serum uric acid concentration 
in individuals with Type IV hyperlipidaemia and in 
individuals with normal lipid profiles. 
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Fig. 9 Distribution and confidence intervals of red cell 
PRPP synthetase in three clinical groups. 
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Fig. 1 0, The effect of varying R-5-P concentration on PRPP synthetas e activity in 
(i) control sample (ii) tophaceous gout 
(i) Control sample (ii) Tophaceous gout 
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Fig. 1 2 The effect of varying concentrations of HgCl2 ion on PRPP synthetase activity in the 
presence of 1•33 m moljl ATP. a) concentration profile 
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Fig. J4 The effect of varying pH on the enzymic activity 
of PRPP synthetase • 
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Fig. 15. The mean % inhibition profile of PRPP 
synthetase activity with ethyl alcohol. 
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Fig. 16 The mean % inhibition of PRPP synthetase activity with ethyl a lcohol 
in two groups of individuals showing two different profiles a) and b). 
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1 7 Inhibition profile of PRPP synthetase 
activity with methyl alcohol 
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Fit;. 1 8 Inhibition profile of (a) tophaceous gout (b) normal,for PRPP synthetase 
activity with 2:3 diphospho~lycerate 
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Fi~. 19 Inhibition profile for PRPP synthetase 
activity with nicotinamide 
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Fig. 20 Effe ct of 25 mmol/l 2 -me r c aptoethano l on 
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Fig. 2 1 Inhibition profile of 
PRPP synthetase with Histidine. 
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Fig. 2 7 Agarose electrophoresis of haemolysates for Adenosine deaminase 
isoenzyme activity: Block diagram indicating detected activity 
positions in the three clinical groups; normals, gouts and 
hyperuricaemics. 
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Fig. 2 8 Agarose electrophoresis of haemolysates from normal, gout and hyperuricaemic samples for 
HGPRT isoenzyme activity. 
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A typical elution pattern of a normal serum on 
Biol - Gel P- 2 , mesh 200-400 using 0 •9% sal ine 
as el uant monitored at 290 nm. 
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Fig. 3 0 
The composite elution pattern of pooled sera 
and markers, added singly, on Bio-Gel P-2 mesh 
200-400 using 0• 9% saline as eluant monitor£d at 290 nm. 
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Fig.3 l Typical elution pat terns for a) hyperuricaemic 
b) gout c) familial primary gout serum on Bio-
Gel P-2, mesh 200-400 using 0•9% saline as 
eluant monitored at 290 nm. 
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Fit;. 3 2 Percentage hyperuricaemic samples 
from 1970-1975 per month 
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Fig. 3 3 Number of uric acid samples 
analysed per year 
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Fig. 34 The effect of varying phosphate 
concentration on PRPP synthetase 
activity. 
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Fig. 3 5 Proposed configuration of the Mg2+ 
ATP o< 5 complex required at the active 
site of PRPP synthetase. 
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APPENDIX 1 
Automated methods of anaiysios for occ~usion experiments-. 
Assays .were performed with the fo~~o.wing equipment. 
Technic on l::l-lA mu~ti channe~ ·biochemica~ · ana~yser. 
Nuc~ear Enterprise NE 1600 gamma counter. 
Hy~and ~aser nepheiometer PDQ. 
Reagents were ob.tained from Tecnnicoh Instruments and the 
Radio.chemica~ Centre, Amersham. 
a) 
b) 
Tot a~ :F'rotein. (Technicon method "SDA-0014 PK 7"). 
Es.timated by e.bsorbance at 550 nm fo~J.:owing the 
reaction of protein .with a biuret reagent. A b~ank 
reagent is necessary to compensate for endogenous 
absorbance of samp~e at 550 nm. 
A~bumin. (Technicon method "SD4-0030 PK 7"). 
A~bumin reacts with bromcreso~ green at .pH 4 • 20 
to form a co~oured comp~ex, the absorbance of which 
is measured at 630 nm. -No b~ank is necessary. 
c) Bi~irubin, · ( ~echnicon method "SD4-0018 FK 7"), 
d) 
The method uses a strong aika~ine buffer and measures 
a~ka~ine azobilir:..bin as the end :t:roduct at 600 nm. A 
o~ank reaction is necessary. 
A~ka~ine phosphatae;e, (Technicon metho.d "SD4-0006 PK ?,") 
The method is based on the enzymic hydroysi s of 
p-nitropheny~ phosphate in 2-amino-1-propano~ at 
pH 1 0• 25 in ti'~e presence of magnesium ions. The 
absorbance of the ana~ytica~ stream is measured at 410 nm 
fo~~owing dialysis which separates the p-nitrophenol from 
bilirubin which absorbs at the same wavelength. 
e) Calcium. (Technicon method "SD4-C003 PLC 7"), 
Calcium is estimated colorimetrically at 570 nm 
by complexing the metal with cresol phthalein complexone 
1 
in the presence of 8-hydroxy quinoline to eliminate 
magnesium interference and potassium cyanide to eJ.:iminate 
heavy metal interference and to stabilise th~ base reag~nt. 
Calcium ion is· dia.l:ysed before complexing with 
the dye. 
f) Inorganic phosphate. (Technicon method "SD4-0004 PK 7") 
Phosphate is estimated after dialysis by conversion 
of acidified ammonium molybdate solution to phospho'-
molybdate followed by reduction of the phosphomoly.bdate 
·by stannous chloride to molybdenum blue" The 
absorbance of the latter is meaeured at 660 run. 
The flow diagrafu~ f6r these systems are shown in Diagrams 
Thyroxine. (T4l by .·radio immuno assay (RIA). The radio 
immuno assay depends on competition for a limited number 
of binding e:ites on a T4 specific antibody between T4 in 
serum and 1.25 I thyroxine. The proportion of l25r thyroxine 
bound to antibody is inversely proportional to the 
concentration of unlabelled T4 pree:ent in serum. This 
proportion is measured by separating free T4 by ade:or.ptioi:l 
on a solid matix and estimat~ng the radioactivity of the 
bound fraction remaining in solution. By meae,uring the 
proportion of 1 25 I thyroxine bound in the presence of 
reference standard serum containing varying amounts of 
T4, that present in other sera can be interpolated. 
Immunoglobulins ( IgG, IgA and I gM ) by laser nephelometr;y. 
The nephelometer ie: de5igned to quantitate specific 
protein concentrations by utilizing. the principle of 
moleculur light scatter. f"lonospecific antiserum reacts 
with a specific antigen to f6rm antigen-antibody complexes 
in solution which scatter an incident light beam. The 
amount of light scattered is proportional to the concentration 
2 
of the antigen. The processing circuits in the instrument ai;J.d 
the selec,ted angle of scattered light are de£'igned to 
optimise the measurement of forward light scatter for 
these reactions and to selectiv'ily min±miee the forward 
light sca.tter produced by potentially interfering substances. 
The camples after dilution and reaction with the appropriate 
antiserum are read in c. laser nephel:ometer and the results 
calculated from a prepared standard cur~e. 
Fredrickson's classification .of abnormal Lipoproteins. 
Fredricksoh (1969) distinguished five different 
. types of hype~lipoproteinaemia by staining the lipoprotein 
separation following electrophoresis of sera from patients 
with lipoprotein abnormalities. This classification 
was modified by the WHO (1970) by subdividing the 
predominant Type II g~oup into Type IIa and Type IIb. 
Stone and Thorp (1966) had separated the lipoproteins 
by size analyses into small (;S), r.1edium (M) and large 
particles(L) and expressed the resulting pattern as a 
S M L profile. This classification has been related to 
the Fredr.ickson types (::tone and Thorp 1 971 ) and the 
characteristics of both are su.."11Ilarised in Diagram 13 
The relationship o·f serum cholesterol snd triglycerides 
occuring in the different Fredrickson types is shown 
in Diagram 1·4 • 
Triglyceride Assay. 
The method (Bucolo and David, 1973) is based on the 
enzymic hydrolysis of triglyceride to glycerol and the 
corresponding fatty acid. The liberated glycerol is 
then asea;yed at 340 nm by the following linked reactions. 
3 
glycerol Glycerol + ATP kinase ) - Phosphoglycerol + ADP 
AD:r h h 1 t pyruvate ATP + pyruvate + p osp oeno pyr.uva e kinase 
lactic + pyruvate + NADH ~ lactate + NAD dehydrogenase 
The change in absorbance at 340 nm is proportional to 
the concentration of glycerol from the triglycerides 
and free glycerol in the serum:. The latter is estimated 
by the link reactions prior to ~ddition of glycerol 
kinase. A blank reaction without serum is run in parallel, 
All measurements were done with Calbiochem Triglyceride 
kits on an MSE Vitatron. 
~erum Cholesterol 
A Technicon AAiwas used to estimate total cholesterol 
by the wethod of Annan and Isherwood (1969). Prior 
extraction of serum is not required and a single colour 
reagent ( sulphoe-.alicylic acid in acetic and sulphuric 
acids) is used. The method is calibrated using standard 
solutions of cholesterol ih propan-2-ol and the absorbance 
measured at 630 nm. 
Lipid t~p~ng by nephelometry. 
Thorp (1969) developed a classification of hyper-
li~idaemia, based on the size of the lipoprotein particles 
in sera,.by measurement of light scattered by the lipoproteins 
using a Thorp microne~helometer. The amount of light 
scattered depends on the difference between the refractive 
index of the sera and that of the particles. Three 
types of low-density lipoprotein particles are designated. 
4 
S =small (1ow density or B-lipopro~eins S·= 0~20) 
M = medium (very low densi.ty or pre-p lipoprotein S=20-400 
L = large (chylomicra, S over 400) 
A sample of fasting serum is analysed for total 
chol:ester.ol content ·(C) . An aliquot ·Of the serum is 
diluted by one tenth and the light scattered by the 
sample measured on a nephelometer(A). The solution 
is filtered through .a membrane of pore size 0•1 Jl• 
which filters off the chyl:omicrons and the light-scattering 
measured againsgt (B). 
Equations relating A,B and C to the quantity of 
S,M and L particles in the serum have been devised 
by Thorp (1969). 
L = constant x (A-B) 
M= 11 (B-5) or if B is greater than 50, M= 5•7 (B+37) 
S = 2•1, C-0·19, M-10·5 
Lipoprotein electrophoresis, 
Buffer Sodium barbital, pH 8·6, 0·05M with 0•035% EDTA 
was used as bridge buffer and for the preparation of 
1% aga.rose electrophoretic plates containing 0·· 04% EDTA, 
Apparatus Coming Black Box electrophoresis equipment. 
Procedure 
1•0 pl aliquots of f~sting sera were applied to 
sample wells on agarose plates. Excess moisture was 
drained from the plates following electrophoresis for 
35 minutes at 90 volts. The agarose was dried at 60° for 
approximately 20 minutes prior to staining in freshly 
prepared 0·02% Fast Red 7B in 84% aqueous methanol 
for 2-3 minutes. The film is washed with gentle agitation 
in 50% aqueous methanol until the background is pale pink. 
5 
The resulting stained bands are examined for !l:ipoprotein 
fractions and the ord'er of bands from cathode to anode 
are chylomicrons, .~ .-, pre fJ - and..,( -lipoprotein. 
Measurement of Creatinine 
The assays were performed on a suitably ·programmed 
Gilford 3500 enzyme rate analyser. 
The reaction.is based on the Jaffa reaction whereby 
creatinine reacts with a saturated solutibn of picric 
acid in sodium hydroxide producing a red colour which 
is moni t.ored .at 51'0 rim and read against a standard 
creatdnine sloution, equivalent to 100 f mol/1. 
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Appendix II 
The results from a routine clinical laboratory 
assay of serum uric acid uEing an autoanalyser over 
a ten year period have been analysed. The samples 
have been crudely separated into abnormal and normals. 
A serum uric acid content was cla~:>sified as "abnormal" 
for all valuee greater than 420 p- moJ.:s/1. These abnormal 
sera are of course hyperuricaemio_. specimens. The dis-
tribution of the abnormal serum uric acid year by year 
during this 10 year period is shown in Fig,JJand the 
percentage of hyperuricaamic sera month ·by month during 
the period 1970-1975 is shown 'in Fig. 32 The total 
number of sera analysed for their uric acid content 
each year is shown in Table32together with the number 
of hyperuricaemic blood samples per year. 
The data for the period from January 1976 to April 
1978 inclusive has been further analysed for the dis-
tribution of the hyperuricaemic samples amongst men 
and women. This data is summarised in Table 3 I 
The month by month distribution of hy.peruricaemia sera 
for men and for women is compared with that found for 
the total population in Table 31 
$'feat,t~bafh ireattttenf fct qoaf 
16 t{\ c~ttt~t~ 
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Appendix III 
The Development of Understanding of Gout. 
Gout in the Earliest times. 
Gout at the Time of. the Renaissance. 
Gout in the Seventeenth Century. 
Gout in the Eighteenth Century. 
Gout in the Nineteenth Century. 
The history of gout is an interesting one., and. it 
has taken many years as well as men of renown to interpret 
the nature of the malady. The word 'gout' was first 
recorded in Roman times and was derived from the Latin 
word gutta, meaning a drop, which r.eferred to the four 
humours, which when in equili-brium ·were said to main-
tain the health of the body, any.excess of one of these 
humours would drop or flow into a joint causing pain. 
This classification of a clinical condition would not 
be restricted to the flow of humours only to joints 
as tne flow could occur to other parts of the .body 
and examples would have been 'gouty' migraine, diarrhoea 
and haemorrhoids. Catarrh and '·rheumatism' were words 
also used to express the conce:.;t of flowing humour, 
It wus a Dominican monk, Randolfus of Bocking 
who used the word 'gout' as we would understand it 
today as a painful .periodical s-.:elling of the big toe, 
In the fifth century B.C. Hippocrates wrote the 
oldest known medical textbook, known as the works of 
Hippocrates, based upon clinical observations. He also 
believed that gout was a result of an excessive accumulation 
of one of the body's humours, probably phlegm, which 
distended the affected joint painfully. He attributed 
the cause to sexual excess or too rich a diet with a 
sedentary :life. Later G'alen added an hereditary factor 
to the Aphorisms, and not_ed that those who inherited 
gou-t suffered the conse~uences more se:verely. 
The three most well known Aphorisms of Hippocrates 
which rei' er to gout are basically as follows.:-
(i) 'Eunuchs do not take the gout nor 
become bald' 
(ii) 'A woman does not take the gout 
unless her menses be stopped" 
(iii) 'A young man does not take the gout 
until he indulges in coitus. ' It. is 
thought that· HiJ>pocrates meant 'before 
the age of puberty. 
Hippocrates also noted that ~ttacks of gout were 
related to the seasons and that 'gouty' afflictions 
were more promins.nt in the. cpring and the Autumn 
as were. arthritic diseases in the ::'pring. CeJ.:sus 
explained tha Autl.i.mn afflictions as nat_ure' s way of 
ex~elling bad humours to the extremities after their 
build up in the body during the heat of the sununer. 
It would appear that Hippocrates was able to 
distinguish between acute gout and acute rheumatism 
which he termed arthritis. In his 'Afflictions of the 
Farts' he .compared the two diseases. He referred to 
gou~ as 'Jodagra' which he described as the most 
violent of all joint afflictions. "It J.:asts long 
and becomes chronic. The p&in may remain fixed in 
the great toes- it is not fatal.'' He also stated 
that 'In arthritis, fever comes on, acute pain affects 
• 
the joints of the body, ~nd the pains which vary 
between mild and severe flit from joint to joint; 
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I. 
it is of short duration, and often very acute, b.ut· riot 
mortal. 
old.' 
It attacks the young. more frequently than the 
The treatment advocated for gout at this time by 
Hippocrates and his Greek followers were diet and in-
cluded types of food' and its preparation, the nature 
of wines and the taking of a barley water. When chronic 
gout was noted, a stronger form of treatment was recommended 
in the form of a purgative, white hellebore, because 
Hipp_ocrates thought that 'an attack of dysentery was 
naturELl relief for the affliction, ' 
The Gr~eks introduced the art of medicine to Rome 
and the Roman, Celsus (25B.C.-A.D.50), although not a 
physician, classified all known human and vetinary 
maladies. He noted one type of joint affliction which 
he termed arthritis but applied more specific terms 
to local sites e.g.- podagra, chiagra etc. Many 
literary Romans e.g. Virgil, Martial arid Avid were 
not impressed by the results of treatments of the. day 
which included bleeding from a vein at the onset of 
an attack and external local treatment to affe·cted 
joints. These w~iters also h~ld a fascination for 
gout and the 'Demon Goddess Podagra' ~as the star of 
Lucian's comic tragedies, Trapopodagra. The remedies 
thc:;.t the Goddess refers to in the play included the 
use of herbs and mineral medications as well as raw 
toads and human excretment. All were used against 
gout in the second century A.D. 
The second century physiGdans Galen .and Arataeus 
subscribed to most of Hippocrates' teachings. Arataeus 
suggested that there was a specific 'toxic substance' 
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in the blood of gouty patients: this hypothesis. wai= 
the. first i:ndi:cation of the existence of uric ac:i!d 
·b.ut was no.t proven until the 19th century. He .also 
left an accurate descri•pti·on of ari initial attack of 
gouty arthritis as follows:- '~he joints begin to be 
affected in this way:- pain seizes the great toe, then 
~he forepart of the heal on which we rest; next it 
comes into the arch of the foot, but the ankle joint 
swells last of all.' All sufferers at first wish to 
blame the wrong cause:- some friction of a new shoe, 
o,thers a long wa.lk. others an ac"cident' or being 
trodden upon ••• but the true cause is seldom believed 
by the patient when he hears it from a physician. 
'The first affected (in gout)are the lig-
aments of the joints, such as have their 
origin in the bones. Now there is a great 
wonder in regard to these; there is not 
the slightest pain in them should you 
cut or squeeze them; but if they become 
spontaneously painful, as in gout, no 
other p~in is more severe than this, 
not iron screws, nor cords, not the 
wound of a dagger, nor burning fire, 
for all these may be had recourse to 
as cures for the still greater pains. 
And if one cut them whilst they are 
painful the smaller pain of the in-
cision is obscured by che greater; and 
if it prevail, they experience pleasure 
in forgetting their former sufferings ..•• 
in a word, any part which is ver~ compact 
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is insensible to touch or to a wound. For 
.pain c.onsists of an irrita"ti'on,- but what_is 
compact cannot be inflamed, and hence is not 
sensible to pain; but a spongy tiscue is 
very sensitive.' 
At the end of the fourth century after the fall of 
the Roman empire many new and exotic cures for gout were 
introduced from the east, but were found to b_e of no use 
although many persisted in the middle ages. Two Bygantine 
physicians contributed to the knowledge of gout: Alex-
ander of Tralles introduced the use of hermodactyl 
(colchicum) as the specific treatment for gout &nd 
Faul of Aegmar thought that gout must be due to some 
congenital weakness. He speculated that sorrow, 
anxiety, or other passions of the mind ~ight pre-
cipitate attack, and also introduced the colchicum 
plant (hermodactyl) ae- the specific .treatment for gout. 
Even in the eigh-th century the teachings of Galen 
still persisted in the Moslem Empire and the use of 
colchicum was advocated for the treatment of gout. 
The great physicians of the Caliphate-rl!esue (d.857), 
Rhages (d.923-924), and Avicenna. (980-1037), 'Frince of 
Ehysicians'- applied the new botanical knowled·e;e which 
was creeping in from India, Eersia, and possibly even 
China, to the materia medica, but for gout, colchicum 
remained the standard remedy. 
Physicians of the Middle Ages merely carried on 
applying many. of the strange cures that were in vogue 
in the Byzantine era. 
su-fferers being:-
One such remedy for gout 
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'Roast a fat old goose and stuff with chopped 
-kit,tens., lard i-ncense, wax and flour of rye. 
This mus·t all be eaten, and the dripping~:; 
aPplied to the painful joints.' 
Even during the per:Lod of the European Renaissance 
of learning no progress was made in man's understanding 
of gout. Two centuries later the humoral hy.pothesis., 
although not in the pure form of humoralism as defined 
by Galen, was questioned. The concept that gout might 
only be attributed to_an alteration in the proportion 
or nature of humours was doubted and it was suggested 
that gout might be caused by some chemical change in 
blood, or even the production in the. body of ~ome 
toxic substance. At this stage interest was_shown in 
the possible nature of such a substance and the site 
of its formation and storage in the body. 
Go.ut had been well. recognised in England since the 
thirteenth century as a clinical enti t,y. The reason 
for this could well. have been due to the almos.t ex-
cl.usiv~ly meat eating habits of the upper classes and 
nobility. The size of the meals were enormous and washed 
down with large quantities of heavy sweet wines; veget&bles 
and fresh fruit were never eaten by this 'class' of person. 
John of Gaddesden, physician to King Henry V of 
England, was responsible for writing the first English 
textbook of medicine, the 'Rosa Angiica' 1280 in which 
some progress in the understanding of 5out was stated. 
This progress was his personal observation that heredity 
in gout seemed to come more importantly through the 
mother's side of the farr.il.y and might often skip a 
generation. 
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The Tudor dy~asty from· Hertry VII were affected by 
gout and King Henry VIII licensed John Gil:bert, the 
first specialist rheumatologist on record, 'to cure 
the goute, the crampe and al1 sore eyes.' 
Ambrose Fare, the French surgeon (1510-1590) 
suffered personally from gout whi.ch he described in 
Book XVIII of his Workes: "The paines of the goute 
a:l'e rightly accounted amongst the most grievous and 
acute; so that through the vehemency of the agony r.~any 
are almost mad, and wish thems.elves dead." He noted 
that. the natural duration of e.n attack was forty days, 
although those who had developed t·ophi were .scarcely 
ever free. He also observed a stricter periodicity 
in attacks of those who suffered with the. inherited 
type of disease; and in some others a purely in-
dividual rhythm. His views on the origin of gout 
were in the Galenic tradition i.e. the humours., he 
pointed out that it was the toxic virulence of the 
peccant matter distilled from the humours and not the 
quantity that was important, 'as it causeth extreme 
paines not by abundance, because it happens to many 
who have no signs of swelling in the jointes.' He 
was convinced that the disease was caused by dietary 
and sexual overindulgence. He recommended frequent 
copious bloodletting, vomiting, sweating, diurasis, 
and purging, particularly with hermodactyl. 
Thomas Sydenham ( 1 624-1,689) was named by his 
countrymen the 'English Hippocrates'. He studied 
and wrote extensively about being. a sufferer, which 
was probably why he wrote a classical description of 
the disease. His description, differentiating finally 
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·between gout and rheumatism, has never be.en surpassed. 
In fact he wrote more about gout than any other physician 
in the 17th century.- He did not adv:oca:te the use of 
violent purges which was rather unfortunate for fellow 
sufferers since seammony and coloajrth, together with 
a small dose of colchicum, formed the basis for most 
purgative prescriptions and this resulted in the use 
of colchicum being banished throughout Europe for the 
.next hundred and fifty years-. :':ydenham suffered' his 
first gouty attack at the age of thirty, seven years 
later he developed haematuria from a ''renal calculus' 
and was rarely out of pain. Hi£ Treaise on the Gout 
(1683) is prefaced with an account of his own .suffer-
ings: 'my health prevents me from troubling the world 
much more with medical treatises ...• I am at a loss 
to know whether the stone or the gout be most ,severe. ' 
Af.ter the writing ·Of this treatise he retired permanently 
to the country. His treatment comprised dietetic 
restric-tion, simple cooking, few drugs, and an ample, 
non-alcoholic fluid intake, a tranquil life devoid 
of excesses with regular horse-back e~~rcise. Opium 
was- his favourite medicament during the acute attack, 
and he introduced a liquid tincture of laudanum which 
brought him early fame throughout the continent of 
Europe. Jesuits' bark (quinine) ~as used by him as 
a prophylactic between attacks although he did not 
believe in the use of analgesics judging their effect 
to be non-significant. 
The contents of Sydenham's treatise describe the 
symptoms of gout and some of the complexities which 
still exist today. 
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'There is no doubt but that men will conc:lude 
either that the nature of the diseaEe,, which 
is my present subject, is incomprehensible, or 
that I who have been afflic~ed with it for these 
thirty-four years past am a person of very slender 
abilities -insomuch as my observations concerning 
this distember and the cure thereof fall short 
of their expectations. But no:t withstanding this 
I will faithfully deliver my remarks concerning 
the difficulties and intricacies occuring in 
the history of the diseaEe and the method of 
cure, leaving the illustration thereof to time, 
thst discoverer of the truth.' 
He continues that the disease, is common among 
elderly people living lives of luxury, particularly 
those that have been athletic in their youth but have 
given up exercise completely. 'The gout, however, does 
not only seize the gross arid corpulent, but sometimes, 
though less frequently, attacks lean and slender persons ..•• 
sometimes in the prime of life, when they have received 
the seeds of it from gouty parents, or have o.therwise 
occasioned it by an over-early use of venery.' 
'The regular gcut general~y seizes in the following 
manner.: it comes on a sudden towards the close 
of January or the beginning of February, giving 
scare any sign of its approach except that the 
patient has been afflicted for some weeks before 
with a bad digestion .... and the day preceeding 
the fit the appetite is sharp but preternatural. 
The patient goes to bed and sleeps quietly till 
about two in the morning, when he is awakened 
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by a pain which usually seizes the great toe, but 
sometimes the he~li the calf of the l~g or the 
ankle. The pain resembles that of a dislocated 
bone •..• and this is immediately succeeded by a 
chil.lness, shivering and a slight fever. The 
chi.llness and shivering abate in proportion 
as the pain increases, which is mild in the 
beginning but grows gradually more violent every 
hour, and comes to its height towards evening, 
adapting itself to the numerous bones of the 
Tarsus and Metatarsus, the ligaments where it 
affects; sometimes resembling a tension or 
laceration of those ligaments, sometimes the 
gnawing of a dog, and sometimes a weight and 
constriction of the parts affected, which 
become so exquisitely painful as not to endure 
the weight of the clothes nor the Ehaking of 
the room from a person's walking briskly therein. 
And hence the night is not only passed in pain, 
but likewise with numberless endeavours to ease 
the pain by continua.lly changing the situation 
of.the body and part affected, which notwithstanding 
abates not till two or three in the morning: that 
is till after twenty-four hours from the first 
approach of the fit, when the patient is suddenly 
relieved •...• and being now in a breathing sweat 
he falls asleep, and upon waking finds the pain 
much abated, and the part affected to be swollen; 
whereas before only a remarkable swelling of the 
veins thereof appeared, as is usual in all gouty fits, 
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The next day, and perhaps two or three days 
afterwards, if the gouty matter be copious, the 
part affected will be somewhat paines, and the 
pain increa·ses to.wards evening and remits about 
the break of day. In a few .days it seizes the 
oth~r foot in the same manner, and if the p~in 
be violent in this, and that which was first 
seized -be quite easy, the we·akness of this soon 
vanishes and it becomes as strong and healthy 
as if i" had never been indisposed: nevertheless 
the gout affects the foot just seized as it did 
the former both in respect of the vehem~nce and 
duration of the pain; and sometimes ...• it affects 
both at the· same time with equal violence.' 
He points out that an attack of gout is always 
comprised of a number of these recurrences or exacer-
bations, and will often last two months, although those 
who possess "strong constitutions, and such as seldom 
have the gout" may recover in fourteen days. In patients 
who suffer frequent attacks or who are debilitated from 
age or disease, the attack may last until the end of 
the following summer, when it usually disappears. 
'During the·first fourteen days the urine is high 
coloured, and after separation lets fall a kind 
of red gravelly sediment and not above a third 
part of the liquids taken in is voided by urine, 
and the body is generally costive during this 
time. The fit is accompanied throughout with 
loss of appetite, chillness of the 1vhole body 
towards eventide, and a heaviness and uneasiness 
even of those parte that are not affected by the 
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dis.ease, jben the fit is going off a violent 
itching seizes the foot·, especially between 
the toes, ·whence· the 'skin peels off, as if 
the patient had taken poisort. The disease. 
being over, the appetite and strength return 
sooner or later, according as the immediately 
precedirtg fit bath been more or lees severe, 
and irt consequence of this the following fit 
comes on in a sho~ter or longer space of time; 
for if the last fit proved very violent the next 
will not attack the patient till the same season 
of the year returns again. 
In this manner does the regulae gout, accompanied 
with its genuine and proper symptoms appear; but 
when it is exacerbated either by wrong management 
or long continuance,,,,, and Nature is unabZLe to 
expel it according to her usual way, the symptoms 
vary considerably from those just described above, 
For whereas the pain hith~rto only affected the 
feet ..... it now ~eizes the hands, wrists, elbows, 
knees and other parts. no less,, severely that it 
did the feet before .... and at length forms stony 
concretions in the ligaments of the joints, which 
destroying the skin of the joints, stones not unlike 
chalk or crab's eyes, come in sight and may be 
picked out with a needle.' 
These tophi he considered to be due to "undigested 
gouty matter thrown out around joints in li~uid form, 
and changed to their peculiar hardness by the heat and 
p~in of the jpint." 
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Later he describes tne chronic phase: 
•·rn the ~ast p~ace, before the disease came· to 
such a height:, the patient not onJ y enjoyed ~ong 
interva~s ·between the fits, but ~ike.wise had no pain 
in the ~imbs and ihe other parts .of the body, a~~ 
the bo:li~y functions being du~y performed. \·ihereas 
now his ~imbs, during the intermission of the disease, 
are eo contracted and disab~ed that though he can 
stand, and perhaps wa~k a ~i tt~e, J'et it is very 
s~ow~y and with great and ~ameness, so that he 
scarse seems to move at a~~ •.••. the feet in this 
state of the disease are never quite free from pain, 
But besides the above mentioned symptoms, viz. 
pain, ~ameness, inabi~ity to motion of the parts 
affected ...•. the gout breeds the stone in the 
kidneys in many subjects, either 
(1)because the patient is ob~iged to ~ie ~ong on 
his back, or 
(2)because the secretary organs have ceased performing 
their proper functions, or e~se 
(3)because the stone is formed from a part of the same 
morbific matter; which, however, I do not pretend 
to determine. And sometimes a suppression of urine, 
caused by the stones sticking in the urin~ry paseages, 
destroys him. 
He then states his much quoted and famous passage: 
'But what is a conso~ation to me, and may be so 
to other gouty pe~sons of sma~~ fortunes and 
s~ender abi~ities, is that kings, great princes, 
generals, admira~e, phi~osophers and severa~ 
other great men ha~e thus ~ived and died .. 
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Inshort i.t may, in a more especial mc-.nner, be 
affirmed of th.i:s disease that it destroys more 
rich than poor persons, and' more wise men than 
fools, which seems to demonstrate to the justice 
and strict imparti:ali t;y of Fro.vidence, who 
abundantly supplied these that want some of 
the convenience of life with other advantages, 
and tempers its profusion io others with equal 
mixture of evil. ~o it appears to me universally 
and absolutely decreed that no man shall enjoy 
unmixed happiness or misery, but experience; both. 
Since those whom ~he favours in one way she afflicts 
in another- a mixture of good and evil. pre-eminently 
adapted to our fra:il moriality - Nihil est ab omni 
parte beatum.' 
At the end of his Treatise he states:-
'The gout seldom atiacks women, and then only the 
aged, or such as are of a masculine habit of body ..•.. 
nor have I hitherto found children or very young 
persons affected with the true ~out. Yet I have 
~nown some who have felt some ~lig~t touches of 
it before they came to that age, but they were 
such as begot by gouty parents. And let this 
suffice for the history of this disease.' 
Robert Boyle (1627-1691 ), the discoverer of Boyles' 
lhw, hypothesizes th~t gout could not be cured psychologically 
by frightening the victim. He told of a peasant who, 
while his hands and feet were wrapped in poultices, 
was fightened by a sow entering his house through the 
open door. ~he sow was attracted by the smell of the 
poultice and proceeded to devour it, ...... "whereupon 
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the man was put into such a fright that his pains 
decrease.d that very day •..•. and never returned." 
Another remedy for gout was that advocated by Dr. 
Thomas JJover (1660-1742), a follower of 2ydenham, who 
prescribed 'Diaphoretic Compound Ipecacuanha :Powder. ' 
The patients receiving this treatment were advised by 
the apothecaries to make a will, the doses being so 
large. 
In the 18th century the age of the S:pa Therapy began 
and saw the end of the draEtic treatments mainly iue to 
the work of ilrs. jilliam Cadogan (1711-1797) and George 
Cheyne (1671-1743). George Ch~yne was known as the 
Gout Doctor and himself was a sufferer of the gout. 
In his own words he was born of healthy parents in the 
prime of their days. He became a tutor in a gentleman's 
family until persuaded by Professor Archibald :Pitcairne 
to study medicine under him. Not only was Pitcairne 
professor of medicine at Edinburgh he was involved in 
the mathematical school of medical science, and Cheyne 
being a good mathematician soon adopted the teachings 
of hi.s master. After the ~ublication of one of his 
books he obtained his Aberdeen M.D. and moved to London 
and in 1701-1702 was elected F.R.S. 
Until Cheyne came to London he ha~ always been 'of 
sedentary and temperate habits,' but when he started 
in practice in London he changed his whole manner of 
living. He became a frequenter of Taverns and made 
friends among the younger gentry and free-livers, not 
only was this way o£ life enjoyable to him but was useful 
in bringin,g; him profes>:ion~cl busine~:l<. 
As this pace of life told on his health he lost 
... 
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his friends and his prosperous career. He was persuaded 
by his friends to 'take the Waters of Bath.' After a 
few years he established a fashionable practice in Bath 
and wrote his ,bo.ok 'An Ese:a;y on the Nature and Due 
Method of Treating the Gout (1120). Dr. George Cheyne 
was the first to advocate completely mi~k and vegetarian 
regime for certain cases of gout and thus became the 
advent of a more rational and civilised attitude towards 
the treatment of gout. 
Horace Walpole and many others during the 18th century 
supported the hypothesis that gout was a remedy and not 
a disease and that by having the gout they would be 
free fro~ more serious diseases. 
~ir Alfred Garrod (1819-1907) used the interest irt 
chemistry of the day to rationalise scientific inquiries 
into the nature of gout. 
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